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I. Biological Role of the Id3 Protein  
I.1 Introduction 
The family of the Id proteins [1, 2], inhibitors of DNA binding and cell differentiation 
(Id1-4), represents the class V of the large group of the helix-loop-helix (HLH) transcription 
factors [3], and is characterized by the fact that its members do not display a basic region 
N-terminal to the HLH domain. By contrast, the related bHLH proteins contain not only the 
HLH domain which is required for protein-protein interactions, but also the basic Lys-/Arg-
rich sequence (indicated by the letter “b”) which is important for protein-DNA interactions. 
Both regions are essential for their activity as DNA transcription regulators. Indeed, the 
bHLH proteins bind to DNA as homo- or heterodimers folded into a parallel four-helix bundle 
with the two basic extensions correctly juxtaposed to allow the recognition and binding to the 
so-called DNA E box (CANNTG), N box (CACNAG) or Ets site (GGAA/T) [4] present in 
promoter regions of the target genes (Scheme I.1, left) 
Scheme I.1. Effects of the Id proteins on bHLH-mediated DNA transcription. Activation of transcription by 
formation of the DNA-bHLH dimer complex (left), and inhibition of transcription by sequestering the bHLH 
factors in inactive dimers with the Id proteins (right). 
 
In developing cells, the bHLH proteins mostly regulate the expression of genes which are 
required for terminal cell differentiation and cell cycle arrest in the G1 phase. As the Id 
proteins only possess the HLH domain, but not the basic DNA-binding region, the dimers 
formed with bHLH proteins are unable to bind to DNA (Scheme I.1, right). This leads to an 
inhibition of the bHLH-mediated DNA transcription by the Id proteins. Dimerization partners 
of the Id proteins among the bHLH family are the ubiquitously expressed E-proteins (E12, 
E47, E2-2 and HEB) and the tissue-specific myogenin-regulating factors MyoD and 
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myogenin [5, 6]. Norton and co-workers have proposed the following mechanism to explain 
how the Id proteins can override the high energy of the bHLH-DNA complexes to sequester 
the bHLH factors: the nuclear Id proteins interact with the transiently free bHLH proteins and 
not with the chromatin-associated ones, and prevent the reassociation of the free-ones with the 
chromatin domains [7].  
It is believed that the bHLH fold is stabilized only upon dimerization and binding to the 
DNA. In the dimeric form, the structure of the bHLH domain is very similar among all the 
HLH family members, as shown by a comparative study based on known crystal structures 
and homology models [8]. In the case of the HLH domain of Id3, a three-dimensional homo-
logy model based on the crystal structure of the DNA-bound homodimers of E47, MyoD and 
Max has shown that the highly favored packing of the hydrophobic core together with the 
absence of repulsive interactions within the N-termini explains the formation of an Id3 
homodimer [9]. 
A splice variant of human and rat Id3 has been detected, which is characterized by 
different dimerization properties [10]. In both species, the isoform contains a modified C-
terminal region [11] where the last 19 C-terminal residues are replaced by a new sequence of 
60 (human, Id3L) or 29 (rat, Id3a) residues. These isoforms have different expression patterns 
and effects on cell growth and death control with respect to the shorter variant of Id3. For 
example, expression level of Id3 is low in normal blood vessels, whereas Id3a is totally 
absent. However, expression of both is induced upon injury [12]. Moreover, Id3L has been 
found in advanced human atherosclerotic plaques [13] and has impaired ability to form 
heterodimers with E47 [10]. Interestingly, gene delivery of Id3a was found to induce 
apoptosis and inhibit Id3 expression in vascular smooth muscle cells (VSMCs) [14].  
I.2 Id3 Protein Expression 
In general, Id proteins are overexpressed in proliferating, undifferentiated normal and 
cancer cells, while their expression level is low or absent in non-proliferating cells [15]. 
The expression pattern of Id3 overlaps with that of Id1 during embryogenesis [16]. Both 
proteins are required for neurogenesis, angiogenesis and vascularization of tumors [17]. The 
Id3 gene was identified as an immediate early response gene induced in the early phase after 
mitogen stimulation by serum growth factors or forskolin, or after stimulation of protein 
kinase C by tumor-promoting phorbol esters [18]. In contrast, Id3 gene silencing might be 
controlled by DNA methyltransferases, histone acetyl transferases and histone deacetyl- 
ases [2]. Homologues of the Id3 protein were found in a range of non-mammalian animals, 
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such as in Drosophila melanogaster extramacrochaetae [19, 20], Xenopus [21], zebrafish [22] 
and chick [23]. Unlike Id1 and Id2, the Id3 protein in mammals and its non-mammalian 
homologues exhibit a highly conserved organization of the coding gene, which indicates that 
they all evolved from a common ancestor.  
The human Id3 gene is mapped to chromosome 1p36 [24-26]. Deletions of the latter are 
often present in neuroblastoma and other tumors derived from the neural crest. Accordingly, 
tumor cell lines with N-myc protein overexpression have generally low Id3 gene expression, 
whereas cell lines with high Id3 gene levels do not overexpress N-myc. Mutually exclusive 
expression of these two genes, Id3 and N-myc, has also been found in developing mouse 
tissues, suggesting an inverse correlation between the two genes in human neuroblastomas 
and during normal development [24].  
Id3 protein level and function can be regulated during transcription (alternative splicing), by 
modification of the protein stability (ubiquitination), by posttranslational modifications 
(phosphorylation), and also by the presence of binding partners. These aspects are discussed 
below.  
I.3 The Role of the N- and C-Terminal Regions on the Id3 Protein Function 
With 119 amino acid residues (13 kDa), Id3 is the smallest member of the Id protein 
family. The 41-residue long HLH motif is responsible for the interaction with the bHLH 
proteins. However, the N- and C-termini are also important for the Id3 function. The N-
terminus contains a consensus site for cyclin-dependent kinase 2 (CDK2), in which serine at 
position 5 (Ser-5) is phosphorylated by cyclin-CDK2 complexes, with consequent modulation 
of the Id3 affinity to the E-proteins. The N-terminal amino group is important for ubiquiti-
nation. Deletion studies on the Id3 C-terminus have indicated that the 15 C-terminal residues 
are critical for the full inhibitory activity of Id3 on the muscle-specific creatine kinase (MCK) 
reporter gene, suggesting that the C-terminus of Id3 also mediates important biological 
functions [27, 28]. C-terminal mutants of Id3 and a chimeric protein containing the N-
terminal part of Id3 and the C-terminus of Id2 did not inhibit the MyoD function; however, 
they could interact with E47. This suggests that the biological action of Id3 might require 
additional functions that depend on its C-terminal residues. Both the C-terminal region and 
HLH domain of Id3 are required for full inhibition of MCK reporter gene activity and for 
growth-suppressive activity in immature B lymphoma cells [29]. Id3 is probably not only 
a passive transcription repressor but also an active one. As in all active transcription 
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repressors, a high amount of  proline, glutamine and alanine residues can be found in the C-
terminal domain of Id3, particularly proline (29 % in the C-terminus) [27]. 
I.4 Id3 Protein Stability 
Id3 is a short-lived protein with a half-life of 20 min [30]. It is difficult to express 
a large amount of Id proteins because of their low stability inside the cells. Their degradation 
is mediated by several regulation pathways: for example, Id3 is N-terminally degraded 
through the ubiquitin-proteasome pathway [31], similarly to Id1 and Id2. Constitutive photo-
morphogenesis 9 signalosome (CSN), which is thought to cooperate with the ubiquitin-
proteasome system in the regulation of protein stability in all eukaryotes [32], is also involved 
in the Id3 protein stability pathways. Unlike Id2 and Id4, Id1 and Id3 bind to the CSN subunit 
CSN5 (and/or CSN7 for Id3) [33]. The kinases associated to CSN phosphorylate CSN-bound 
proteins, leading to inhibition of Id1 and Id3 ubiquitination, as supported by the fact that 
inhibitors of CSN-associated kinases significantly induce Id ubiquitination and proteasome-
dependent degradation [33].  
The stability of Id3 can also be affected by its dimerization partners. Protein p204, 
a member of the interferon-inducible p200 protein family, is a growth inhibitory factor and is 
involved in the differentiation of skeletal [34] and cardiac muscle myoblasts [35]. It induces 
differentiation by binding to the Id proteins (Id1, Id2 and Id3) and by accelerating their ubi-
quitination and proteasome degradation. Additionally, protein p204 has the ability to decrease 
the Id protein level in the nucleus, where Id enforces its inhibitory function, by driving its 
translocation from the nucleus to the cytoplasm. In contrast, the degradation of Id3 is slowed 
down when bound to the Gata4 protein [35] or to E47 [36]. After separation from Gata4, Id3 
is translocated to the cytoplasm and degraded via the ubiquitin-proteasome pathway. Also the 
heterodimer Id3/E47 is less sensitive to degradation by the proteasome and the half-life of Id3 
is thus extended. 
I.5 Id3 Protein Localization and Phosphorylation 
The Id proteins functions depend on their distribution between the nucleus and the 
cytoplasm; although their small size allows them to enter and exit the nucleus by passive 
diffusion, there is an indication that their subcellular localization is regulated also by other 
pathways. Id1 and Id2 proteins are predominantly localized in the cytoplasm, whereas Id3 and 
Id4 have a nucleo-cytoplasmic distribution [37]. In contrast to Id1 [38] and Id2 [37], Id3 
possesses neither a nuclear export signal (NES) essential for cytoplasmic localization nor 
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a nuclear localization signal (NLS). Upon coexpression with E47, which contains a NLS 
region, Id3 accumulates in the nucleus. E47 acts as a nuclear chaperone for Id3 [36].  
The subcellular localization of many proteins is regulated by protein modifications such as 
phosphorylation. Id2, Id3 and Id4 possess a conserved consensus CDK2 phosphorylation site 
at Ser-5 [39, 40]: phosphorylation at this position occurs at the late G1 state of the cell cycle, 
which corresponds to the time both for activation of cyclin A and cyclin E dependent CDK2 
and for the formation of a specific E-box-DNA-binding complex. Phosphorylation of Id3 
changes its specificity for abrogating E-box-dependent homo- or heterodimer complexes. 
Unphosphorylated Id3 inhibits an E12 homodimer complex but not the E12-MyoD hetero-
dimer. Phosphorylated Id3 has greater ability to abolish the E12-MyoD complex but nullifies 
the inhibition of the E12 homodimer.  
Phosphorylation of Id3 by CDK2 also negatively affects its ability to inhibit DNA binding of 
ternary complex factors (TCFs) with Ets-domain. Phosphorylation of Id3 decreases protein-
protein interactions between the Id protein and TCFs and thereby reduces the DNA-binding 
inhibitory activity of the Id3 protein [41]. 
The Id proteins are required for the entry of the cells into the S phase; however, a CDK-
dependent phosphorylation alters the ability of Id3 to promote the S phase entry in fibroblast 
cells (phosphorylated Id3 cannot promote cell growth), suggesting a G1 into S phase cell 
cycle regulatory function of the Id proteins [40]. The situation is, however, different in 
VSMCs [42]. 
Overexpression of the Id proteins leads to apoptosis or cell proliferation, depending on the 
cell line. For example, overexpressed Id3 protein does not promote apoptosis in muscle cells 
(myoblasts) [43, 44], but leads to apoptosis in serum-deprived rat embryo fibroblasts. Id3 
protein-induced apoptosis is mediated at least in part through p53-independent mechanisms 
and could be efficiently rescued by coexpression with E47 and antiapoptotic Bcl2 and 
BclXL [45]. Induction of apoptosis is correlated with the ability of Id3 to promote the cell 
cycle S phase entry. The close association between apoptosis and the pathways, through 
which Id3 promotes the G1 to S phase cell cycle transition, is based on functional properties 
of phosphorylated and unphosphorylated Id3 forms. Unphosphorylated Id3 (present 
throughout early G1), but not the phosphorylated form (persisting from late G1 throughout the 
S phase) drives apoptosis. A lowering of functional CDK2 activity and consequent 
hypophosphorylated Id protein in serum-deprived fibroblasts might therefore trigger apoptosis 
induced by overexpression of the Id gene.  
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In conclusion, phosphorylation plays an important role in regulating the activity (negative 
effect in fibroblasts), dimerization specificity and stability (inhibition of ubiquitin-mediated 
proteasomal degradation) of the Id3 protein. 
I.6 Id3 in the Cell Cycle Control  
The Id proteins tune the balance between cell growth and differentiation by negatively 
regulating the function of bHLH transcription factors. In mammals, the pocket proteins of the 
retinoblastoma (Rb) family control a crucial proliferation checkpoint [46]. The Rb pathway is 
negatively influenced either by direct interaction with Id2 or indirectly by inhibition of Ets-
mediated transcription of p16INK4a [41] and Id protein heterodimerization with bHLH proteins 
(Scheme I.2).  
Scheme I.2. Id proteins and cell cycle control. 
 
The E-proteins and MyoD block G1 into S phase cell cycle transition mediated by Id 
proteins through the transcriptional activation of the p21Cip1 and consequent inactivation of  
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CDKs, thus enhancing the activity of the Rb protein (pRb) [15]. CDKs in complex with 
cyclins sequentially phosphorylate pRb, thus releasing it from its transcriptionally repressive 
complex with E2F and facilitating the S phase progression. The Id proteins disturb the activity 
of the bHLH factors and thereby downregulate CDK inhibitors (CDKI: p21Cip1, p16INK4a) [44] 
and activate the CDKs for pRb phosphorylation and cell cycle progression into the S phase.  
I.7 Id3 and its Cellular Pathways 
I.7.1 Interaction with bHLH Proteins [47] 
The Id3 protein is a general negative regulator of the bHLH transcription factors, 
especially the E-proteins and MyoD. It binds to the bHLH proteins, prevents DNA binding 
and thereby blocks transcription activation. Id3 interacts with both spliced forms of the E2A 
gene, E47 and E12, as well as with the related protein E2-2. E47 and E12 preferentially 
associate with Id3 rather than with any other Id protein in vitro and in vivo [48].  
I.7.2 Ras-ERK-MAP Kinase Pathway, Ets Proteins  
There is a link between extracellular signal-regulated kinase (ERK) and mitogen-
activated protein kinase (MAPK) signaling, and the HLH transcriptional regulators E2A, 
HEB and Id3 during thymocyte maturation [49]. Id3 protein expression is regulated by the 
Ras-ERK-MAP kinase pathway which is activated by T-cell receptor (TCR) signaling, result-
ing in a significant reduction in E2A/HEB DNA binding activity. ERK in turn activates the 
Ets domain-containing transcription factor SAP-1. Activated SAP-1 then induces expression 
of the zinc finger-containing protein Egr-1 [50], which causes a direct activation of Id3 
protein expression and a subsequent decrease in E-protein DNA binding activity, and, ultimat-
ely, promotion of thymocyte maturation (Scheme I.3).  
Id3 together with Id1 shuts down the upstream Ets transcription factors by direct physical 
interaction. Inhibition of Ets1, a non-bHLH protein, by Id1 and Id3 proteins leads to 
inhibition of p16INK4a expression and, consequently, allows cyclin D-CDK4-mediated 
phosphorylation of pRb and the liberation of the Id2 protein from a hypophosphorylated pRb-
Id2 complex [41, 51].  
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Scheme I.3. Id proteins pathways: Ras-ERK-MAPK kinase pathway. 
 
I.7.3 The Pax Pathway 
Id1-3 also bind and repress Pax transcription factors (Pax-2/5/8) which play important 
roles in cellular differentiation and organism development [52]. Binding occurs through the 
paired-DNA-domain of the Pax proteins and results in the disruption of DNA-bound 
complexes. Interaction of the Id proteins with the Pax proteins leads to the inhibition of 
promoters regulated by Pax complexes, such as the B-cell-specific mb-1 promoter. A subset 
of Ets-domain transcription factors, including Elk-1, can also form ternary complexes with the 
paired-domain transcription factor Pax-5. The Id proteins cause dissociation of both Pax and 
Ets-domain proteins from DNA in a manner similar to their effect on bHLH proteins [53]. 
Nevertheless, both Pax and Ets-domain proteins bind DNA as monomers. Thus, removal of an 
obligatory dimerization partner, as it is necessary for the inhibition of the bHLH protein 
heterodimers, is not a universal mode of action for the Id proteins.  
I.7.4 TGFβ and BMP Regulation of Id Expression [54, 55] 
The transforming growth factor (TGF) β family possesses a broad biological potential, 
such as the regulation of cell growth, differentiation and fate determination in various cell 
types including epithelial cells, endothelial cells, hematopoietic cells and mesenchymal cell 
types including fibroblasts, chondrocytes and osteoblasts. Members of the TGFβ family, 
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including TGFβs, activins, bone morphogenic proteins (BMPs) and growth/differentiation 
factors transmit their pleiotropic effects through transmembrane serine/threonine kinase type I 
and type II receptors. Upon ligand-induced heteromeric complex formation between type I 
and type II receptors, the type I receptor becomes phosphorylated and activated by the type II 
receptor kinase, and mediates specific intracellular signals. Smad proteins are the central 
signal mediators of the TGFβ superfamily activated by type I receptor kinases. Smad proteins 
are subdivided into three subtypes: receptor-regulated Smads (R-Smads), common-mediator 
Smad (Smad4) and inhibitory Smads (Smad6/7). R-Smads are further subdivided into two 
subtypes: Smad2/3 for TGF-β and activin signaling pathways, Smad1/5/8 for BMP signaling 
pathways. Inhibitory Smad proteins repress the action of BMPs by inhibiting the receptor-
mediated phosphorylation of Smad1/5/8 or by competing with Smad4 for the binding to 
Smad1/5/8. Among the three different classes of Smads, only R-Smads interact directly with 
activated type I receptors and become activated through phosphorylation. R-Smads then form 
heteromeric complexes with Smad4, followed by nuclear translocation and regulation of gene 
transcription in collaboration with other transcription factors and transcription regulators 
(Scheme I.4).  
Scheme I.4. Regulation of Id3 expression by TGFβ and BMP proteins. 
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There are two pathways in the signaling cascade of the BMP family: the first is Smad-
dependent via Smad phosphorylation, and the other is a Smad-independent pathway involving 
MAPK. Stimulation of epithelial or endothelial cells with BMP factors upregulates the 
expression of the Id genes via phosphorylation of BMP-responsive Smad1/5 which binds to 
Smad-responsive elements in the Id promoter and thus activates its transcription. In contrast, 
TGFβ inhibits the expression of the Id genes, as TGFβ-responsive Smad3 activates the 
transcription repressor ATF3 which inhibits the Smad-initiated transcription. ATF3 co-
operates with TGFβ-responsive Smad3, but not with BMP-specific Smad1, which allows cells 
to distinguish between TGFβ and BMP inputs. Unlike in epithelial cells, TGFβ is able to 
induce the synthesis of the Id proteins in endothelial cells by binding the type I receptor 
serine-threonine kinase ALK-1 that then activates the BMP R-Smads [56]. Also in immune 
cells, TGFβ upregulates Id2 and Id3 protein expression leading to the sequestration of the 
E2A gene products [51].  
I.7.5 The VEGF Pathway 
Vascular endothelial growth factor (VEGF), a homodimeric heparin-binding glyco-
protein, exerts its biological effects by binding to the tyrosine kinase receptors VEGFR1 and 
VEGFR2. VEGF is produced by almost every cell type, and is required for the angiogenic 
switch. VEGFR1 is important for vascular modeling and regulation of endothelial cell-matrix 
interactions. VEGFR2 is the critical receptor which controls proliferation, differentiation and 
migration of endothelial cells and is expressed in some non-endothelial cells, too. Pituitary 
tumor transforming gene (PTTG) is an oncogene known to promote thyroid cell proliferation. 
High PTTG expression observed in thyroid cancers upregulates VEGFR2 expression and 
VEGF secretion, and there is evidence that PTTG takes part in thyroid tumorigenesis by 
promoting a VEGF-VEGFR2-Id3 mitogenic autocrine mechanism in human thyroid cells. 
VEGF is involved in VEGF-VEGFR2-Id3 pathway by activating VEGFR2 which in turn 
upregulates Id3 expression. Id3 is an important gene in VEGF-dependent angiogenesis. 
Expression of VEGFR2 and/or VEGFR1 in non-endothelial cells including ovarian, prostate 
and pancreatic carcinoma cells suggests the existence of a potential autocrine stimulatory 
pathway. VEGF and VEGFR inhibitors have been used against cancer progression and 
metastasis in the last decade [57].  
VEGF leads to a pronounced upregulation of Id1 and Id3 in the bone marrow, presum-
ably in the to-be-mobilized progenitor cells. Activation of protein kinase (MAPK) pathway by 
VEGFR stimulation could concern the Id1 and Id3 promoters at the Egr-1 site, as demonstr-
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ated for other cell types [54, 58, 59]. In the bone marrow, the Id proteins are required for the 
mobilization and proliferation of endothelial progenitor cells which enter the bloodstream as 
circulating endothelial progenitors and migrate to the tumor site.  
VEGF and TGFβ induce the expression of Id1 and Id3 through the MAPK cascade in human 
umbilical vein endothelial cells. Forced expression of the Id proteins induces proliferative 
activity (angiogenesis) accompanied by downregulation of p16INK4a caused by direct 
inhibition of Ets1/2 transcription factors [41]. Overexpression of the Id proteins induces pro-
angiogenic processes such as transmigration and expression of the matrix metalloproteinases 
MMP-2 and MMP-9.  
Inhibition of expression and/or function of Id1 and Id3 has a therapeutic value for conditions 
associated with pathological angiogenesis, not only of cancer but also of rheumatoid arthritis. 
Indeed, Id1 and Id3 are overexpressed in the endothelial cells of the synovial tissue 
in rheumatoid arthritis, a chronic inflammatory disease characterized by aggressive pro-
liferation [60].  
I.8 Id Proteins as Targets in Cancer 
The Id proteins are potential targets in cancer therapy [61], because they are heavily 
involved in pathways regulating proliferation, differentiation, angiogenesis, migration, 
invasion and cell-cell interaction [4, 62-64]. They are mainly overexpressed during embryo-
genesis and development as well as in tumor cells, whereas their expression significantly 
decreases in normal mature adult tissues [17, 63].  
Id1 and Id3 are important for tumor angiogenesis, and their loss causes vascular defects in 
both xenografts and the more physiologically relevant genetic tumor models. The angiogenic 
defect in Id-deficient mice may be attributed to combined downregulation of MMP-2 and 
fibroblast growth factor receptor 1 and α6β4 integrin. A partial decrease of Id levels 
significantly inhibits tumor invasion and metastasis because of reduced expression of 
MMPs and vascularization with consequent reduction of oxygen and nutrients supply to the 
tumor cells [57]. 
There are at least four essential hallmarks for malignancy (anaplasia, uncontrolled 
proliferation, sustained neoangiogenesis and invasion of neighboring tissues) that are con-
nected by dysregulated Id expression during tumorigenesis [46]. The Id proteins are required 
for vascularization of tumors. Nevertheless, some tumors, e.g. the Lewis lung carcinoma, can 
grow despite the lack of Id expression and of a functional vasculature [50]. 
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Tumor progression depends on a multistage angiogenic process; the initial quiet phase is con-
nected with quiescent endothelial cells. The second stage is associated with an angiogenic 
switch, including increased tumor growth and significantly increased endothelial 
proliferation, migration, vascular dilation and microhemorrhages. Id gene expression 
stimulates angiogenesis of endothelial cells through the inhibition of the angiogenesis 
inhibitor thrombospondin-1 and through the activation of VEGFR-mediated functions [4]. 
Although Id1 and Id3 are not expressed in adult bone marrow, VEGF-upregulated Id 
expression in bone marrow cells suggests that VEGF-activated Id1 and Id3 protein expression 
is essential for the mobilization and recruitment of circulating endothelial precursor cells 
(CEPs) and VEGFR1+ hematopoietic cells to the tumor vasculature. Therefore, new therapies 
target Id1+/+Id3+/+VEGFR2+ CEPs and VEGFR1+ hematopoietic precursor cells to inhibit 
tumor angiogenesis [65]. 
I.9 Conclusion and Perspectives 
The Id proteins subtly, but decisively determine the cell fate by a complex interplay of 
regulatory pathways, as seen with Id3 protein which is required for neurogenesis, angio-
genesis and vascularization.  
Id3 activity is regulated at different levels, e.g. by gene expression or at the protein level. Id3 
phosphorylation and ubiquitination, alternative longer spliced variants and expression of Id3 
binding partners may also play a role: for example, a modulation of Id3 activity is provided 
by a switch from the expression of Id3 to that of Id3L, as the latter cannot bind to E-proteins, 
or by overexpression of E47 which sequesters Id3 and thus inhibits its function. Phosphorylat-
ion of Id3 also affects its role in the cell cycle progression and proliferation. Additionally, 
transfer of Id3 from the nucleus to the cytoplasm represents another mechanism to control the 
Id functions. 
Thus far, the interest in Id proteins mainly focused on their biological role in physiological 
and pathological conditions, while information on their biophysical and structural features 
was scarce. Purpose of the presented PhD thesis was the investigation of the smallest of the Id 
proteins, Id3, from a structural point of view, using a chemical and spectroscopic approach. 
The major challenge was the total chemical synthesis of the full-length Id3 protein and of 
related analogues whose conformation has been successively examined.  
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II. Full-Length Id3 Protein: A Target for Peptide Chemists [1] 
II.1 Introduction 
The synthesis of small proteins by the chemical approach is an attractive alternative to 
the expression in bacteria as well as cell-free systems, as it allows to carry out a variety of 
chemical manipulations to the native target by the use of backbone surrogates, unnatural 
amino acids, conformational constraints or site-specific labels. All these synthetic tools are 
helpful for the analysis of the protein structure and folding. This chapter describes the total 
chemical synthesis and conformational study of the Id3 protein, and shows that the product 
obtained by chemical methods spontaneously undergoes self-association and forms disulfide-
bonded dimers. 
II.2 Solid-Phase Synthesis of the Id3 Protein  
Stepwise solid-phase methodology is widely applied for the synthesis of peptides 
with chain length of up to ca. 50 residues. Above this limit, the accumulation of byproducts 
related to the lack of quantitative coupling/deprotection reactions represents the major 
problem [2]. Nevertheless, since the introduction of the solid-phase peptide synthesis (SPPS) 
by Merrifield [3], a number of stepwise syntheses of polypeptides and small proteins both 
with the Boc (tert-butyloxycarbonyl) and the Fmoc (9-fluorenylmethoxycarbonyl) strategies 
have been reported [4-14]. Thus, we decided to investigate whether the latter approach could 
be applied to the Id3 protein, too. The polypeptide chain was automatically synthesized on 
Wang resin which had been manually preloaded by treatment with Fmoc-His(trityl)-OH, 
HOBt (N-hydroxybenzotriazole), DIC (N,N’-diisopropylcarbodiimide), and DIPEA (N,N-
diisopropylethylamine); the resulting loading was 0.6 mmol/g. Double couplings of Nα-Fmoc-
protected amino acids were accomplished with in situ activation by HBTU (O-(1-
benzotriazolyl)-1,1,3,3-tetramethyluronium hexafluorophosphate), HOBt and DIPEA in 
DMF/NMP (N,N-dimethylformamide/1-methyl-2-pyrrolidinone); the Fmoc group was 
removed by piperidine/DMF/NMP. Neither capping nor monitoring of the acylation yields 
was carried out. However, to control the quality of the growing chain, small amounts of 
peptide were detached from the resin after the coupling of Gln-66, Gly-57, Leu-41 and 
Ser-21. The cleavage mixture consisted of trifluoroacetic acid (TFA) containing 10% (v/v) 
scavengers: water, triisopropylsilane (TIS) and ethanedithiol (EDT). The good homogeneity 
of the four intermediate products (II.1-4) allowed us to continue the synthesis until Met-1 was 
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coupled (II.5). All five crude sequences, corresponding to the C-terminus 82-119 elongated 
with helix-2 (II.1), helix-2 and the loop (II.2), the entire HLH motif (II.3), the HLH motif 
and part of the N-terminus (II.4) and, finally, the entire Id3 protein (II.5) were then purified 
and characterized by mass spectrometry (Table II.1) and analytical HPLC (Figure II.1). 
Table II.1. Amino acid sequence of the human Id3 protein and analytical data of the synthetic Id3 
polypeptides II.1-6. 
Human Id3a 
M1KALSPVRGCYEAVCCLSERSLAIARGRGKGPAAEEPLSL40 
LDDMNHCYSRLRELVP56GVPRGTQLS65QVEILQRVIDYILDLQ81 
VVLAEPAPGPPDGPHLPIQTAELAPELVISNDKRSFCH119 
Synthetic Id3 polypeptides 
Product Sequence MWcalcd. (Da) MWfound (Da) tR (min)b 
II.1 Ac-(66-119)-OH 5999.0 5999.8 23.3 
II.2 Ac-(57-119)-OH 6895.0 6895.4 21.4 
II.3 Ac-(41-119)-OH 8838.2 8838.5 21.1 
II.4 Ac-(21-119)-OH 10813.5 10813.4 19.8 
II.5 H-(1-119)-OH 12969.1 12972.3 22.4 
II.6 H-[Q-59, P-63]-(1-119)-OH 12969.1 12971.6 21.3 
a Underlined sequences: helix-1 (41-56) and helix-2 (66-81); double underlined sequence: loop (57-65).  
b Gradient: 10% ACN for 3 min, 10-70% ACN in 40 min. 
 
 
The pure product II.5 was subjected to tryptic digestion which cleaved the peptide bonds 
formed by the carboxyl groups of Lys and Arg. Additional molecular masses could be 
detected and assigned to disulfide-bonded fragments. This indicates that some oxidation 
processes of the five cysteine thiol groups (at positions 10, 15, 16, 47 and 118) occurred 
spontaneously. 
The above-described synthetic procedure was further applied to the preparation of the 
full-length Id3 analogue II.6. This analogue contains two amino acid substitutions in the loop 
region: Pro-59→Gln and Gln-63→Pro. Previous site-directed mutagenesis studies of the Id1 
protein carried out by Pesce and Benezra [15] showed that the loop of Id1 is critical for the 
protein function. Replacement of the loop regions of the four Id HLH motifs by the 6-amino-
hexanoyl moiety also compromised the helical character [16], suggesting that the Id loops 
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play a role in the folding of the Id dimerization domains. One of the fully-conserved positions 
in the loops is occupied by proline, a residue which is known to influence the secondary 
structure of peptides and proteins and to induce a kink in the backbone due to the geometric 
constraints imposed by the five-membered ring. Therefore, we wanted to see whether shifting 
the position of proline within the loop would affect the protein folding. We chose to invert the 
native residues Pro-59 and Gln-63 located exactly two positions after the N-terminus and 
before the C-terminus of the loop, respectively. Synthetically, these two exchanges were not 
significant, as the analytical HPLC profiles of the crude products of II.5 and II.6 were 
comparable (Figure IX.8 in the Experimental Part). The product was confirmed by mass 
spectrometry with and without tryptic digestion after purification by preparative RP-HPLC.  
 
Figure II.1. Analytical RP-HPLC profiles of the Id3 polypeptides II.1-5 before (top) and after (bottom) 
purification by preparative RP-HPLC. 
II.3 Homodimerization of the Id3 Protein 
Expressed Id3 protein has been shown to form homodimers [17]. Therefore, we in-
vestigated the self-association properties of the chemically synthesized protein. A solution of 
protein II.5 (200 µM in 50 mM Tris buffer, pH 6, or in 50 mM phosphate buffer, pH 7.25) 
was flushed with nitrogen and incubated overnight to allow the association process. Then, one 
aliquot was exposed to air to allow the formation of disulfide bridges, whereas another aliquot 
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was crosslinked by glutaraldehyde. Finally, the untreated (fresh or overnight incubated), oxi-
dized and crosslinked samples were analyzed by SDS-PAGE under reducing (in the presence 
of dithiothreitol, DTT) and non-reducing conditions. In the absence of DTT, the untreated Id3 
samples showed one band for the monomer and one band for the dimer (Figure II.2, lanes c 
and e), whereas only the monomer was present upon treatment with DTT (Figure II.2, lanes b 
and d). These results suggest that the Id3 protein II.5 spontaneously forms homodimers which 
can be stabilized by disulfide bridges. The presence of Id3 homodimers was also confirmed in 
samples oxidized by air (Figure II.2, lane f) and chemical crosslinking (Figure IX.18 in the 
Experimental Part). Mutant II.6 also forms homodimers in non-reducing conditions (Figure 
II.2, lane h). This suggests that the two substitutions in the loop region do not influence the 
self-association process. 
 
Figure II.2. SDS-PAGE characterization of the homodimers formed by the Id3 protein II.5 or mutant II.6. The 
loaded samples correspond to protein II.5, freshly prepared (lanes b and c) or incubated overnight (lanes d and e) 
which was denatured in the presence (lanes b and d) or absence (lanes c and e) of DTT, and to protein II.5 
incubated overnight, oxidized by air and denatured in the absence of DTT (lane f). Lanes g and h correspond to 
a fresh sample of mutant II.6 in the presence or absence of DTT, respectively. The molecular weight marker was 
loaded twice (lanes a). 
II.4 Conformation of the Id3 Protein 
The conformation of the synthetic Id3 protein II.5 was studied by circular dichroism 
(CD) spectroscopy. The spectrum of the sample in phosphate buffer (0.1 M, pH 7.25) dis-
played an intensive negative band close to 206 nm (attributed to the π→π* amide transition), 
a negative shoulder near 222 nm (attributed to the n→π* amide transition) and a positive band 
below 200 nm (Figure II.3, right).  
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Figure II.3. CD spectra of the N-terminally truncated Id3 analogues II.1-4 (left) and of the synthetic full-length 
Id3 protein II.5 and its double mutant II.6 (right). All samples (30 µM) were dissolved in phosphate buffer 
(0.1 M, pH 7.25). 
Such a CD shape is similar to the one attributed to the α-helix conformation. However, the 
π→π* band is blue-shifted (by about 2 nm) and remarkably more intense than the n→π* 
band. A different type of helix, the 310-helix, is characterized by a strong negative 
Cotton effect in the region 202-206 nm and by a weak one near 222 nm, with a ratio 
[ ] [ ]RRR 206202222 −ΘΘ=  equal to 0.3-0.4 [18]. This value was ~ 0.6 for the Id3 protein, an 
intermediate value between the typical values found for α-helices (R ~ 1) and 310-helices. 
This might suggest that both helix types coexist. However, the R value alone is not sufficient 
to assess the presence of a 310-helix [19], as other structural elements could play a role in de-
termining the CD shape below 210 nm. In particular, unordered and extended conformations 
should be considered, because they both show a strong negative band close to 200 nm [20]. 
Moreover, we know from a previous study that the N- and C-terminal regions of the Id3 
protein adopt no preferred conformation, at least as isolated domains [16], and it is probable 
that they remain partly flexible even in the entire protein. Accordingly, secondary structure 
analysis of the CD spectrum of Id3 using the CONTIN algorithm [21, 22] indicated that at 
least 30% of the sequence is unstructured (Table II.2). A similar overall conformation was 
observed for the double mutant II.6 (Figure II.3, right panel, and Table II.2), which suggests 
that altering the position of a potential proline-induced kink of the backbone within the loop 
does not cause significant structural changes and that this region of the Id3 protein is flexible 
enough to tolerate such amino acid substitutions. 
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The CD properties of the full-length Id3 analogues were further compared to those of 
the N-terminally truncated Id3 fragments II.1-3 (Figure II.3, left panel), which were obtained 
as intermediates during the synthesis of the full-length protein II.5. It was observed that the 
number of helical residues increased with the number of residues belonging to the HLH motif 
(Table II.2). As the C-terminal domain 82-119 is likely to be mainly unstructured [16], the 
helical fraction found for the peptides II.1-3 (ca. 40% each) should be mostly attributed to the 
complete HLH motif (peptide II.3) or portions of it (peptides II.1 and II.2). Moreover, the 
fact that the full-length protein II.5 and the analogue II.3 lacking the N-terminus (residues 
1-40) displayed a similar number of helical residues indicates that the N-terminal part of the 
protein does not significantly contribute to the helix content of the whole protein. 
Table II.2. Conformational properties of the synthetic Id3 polypeptides II.1-4, full-length Id3 protein II.5 and its 
double mutant II.6 at 30 µM in phosphate buffer (0.1 M, pH 7.25). 
 
 
Surprisingly, the analogue II.4 lacking the segment 1-20 was characterized by a moderate 
amount of β-strand structure and reduced helix character in comparison to the shorter ana-
logue II.3 and the full-length sequence II.5. Indeed, the ratio between the helix and the β-
strand fractions was < 1 for the N-terminally truncated analogue II.4, and ~ 3 for the full-
length protein II.5. However, in the presence of 2,2,2-trifluoroethanol (TFE, 40%, v/v, in 
phosphate buffer), the ratio α/β increased to ~ 3 also for the analogue II.4 (Figure II.4). These 
% Secondary structure elements by CONTINb 
(no. of residues) 
Product No. of 
residues 
% Helix (no. of 
residues)a 
helix β-strand turns unordered 
II.1 54 39 (21) 40 (22) 5 (3) 23 (12) 32 (17) 
II.2 63 39 (25) 43 (27) 5 (3) 22 (14) 30 (19) 
II.3 79 38 (30) 44 (35) 5 (4) 21 (16) 30 (24) 
II.4 99 24 (23) 20 (20) 24 (24) 20 (20) 36 (36) 
II.5 119 29 (35) 34 (40) 12 (14) 24 (29) 30 (36) 
II.6 119 31 (37) 38 (45) 7 (8) 24 (29) 31 (37) 
a The helix percentage was estimated by the ellipticity value at 222 nm using the procedure of Chen and
Yang [23] (for details see paragraph IX.7 in the Experimental Part).  
b The CD spectra were analyzed by the CONTIN algorithm.  
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results indicate that a hydrophobic environment stabilized the helix structure, whereas 
a hydrophilic environment favored self-assembly and β-strand structure.  
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Figure II.4. Effect of TFE on the conformation of II.4. The solid line corresponds to the CD spectrum of 
a 91 µM sample in phosphate buffer (0.1 M, pH 7.25), whereas the dashed line to that of a 83 µM sample in 
phosphate buffer mixed with 40% TFE. The secondary structure element composition of peptide II.4 in 
40% TFE was estimated by the CONTIN algorithm and turned out to be as follows: 36% helix, 13% β-strand, 
20% turn and 31% unordered structure. 
The fact that increased β-strand content was not related to the presence (II.5 and II.6) or 
absence (II.3) of the complete N-terminus (residues 1-40), but rather to the shortening of the 
N-terminus suggests that in the latter case the flanking region N-terminal to the HLH motif is 
crucial for secondary structure formation and/or aggregation. One possible explanation might 
be that residues 21-40 exert a destabilizing effect on the HLH fold – for example by pointing 
toward it – upon formation of a loop induced by the proline residues just proximal to the N-
terminus of helix-1. This does not probably occur in the full-length protein due to the larger 
N-terminus. Moreover, as three out of the five cysteine residues of Id3 are located within the 
last 20 residues of the N-terminus, this region might be involved in additional intra-/inter-
molecular interactions. Further studies will be necessary to understand the importance of the 
N-terminus in stabilizing the Id3 structure better. 
II.5 Folding Stability of the Id3 Protein 
The full-length Id3 protein II.5 and its double-mutant II.6 were subjected to chemical 
denaturation by guanidinium chloride. The titration curve, obtained by recording the change 
in the CD intensity at 222 nm of a solution of II.5 in phosphate buffer (0.1 M, pH 7.25) at 
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room temperature upon denaturant addition, is shown in Figure II.5. High concentrations of 
the chaotropic agent prevented recording of the spectra at wavelengths below 210 nm; 
however, the change of the band at 222 nm could be observed, and exhibited a sigmoidal 
decrease in intensity with increasing concentration of the denaturant.  
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Figure II.5. Effect of increasing guanidinium chloride concentration on the helix content of protein II.5 
(100 µM in 0.1 M phosphate buffer, pH 7.25) at room temperature: CD spectra (left) and curve of the value 
of [Θ]R222 as a function of the guanidinium chloride concentration (right). 
In order to compare the stability of the full-length proteins with those of the N-terminally 
truncated analogues II.3 and II.4, the denaturation curves were expressed as the folded 
fraction (%) versus denaturant concentration (Figure II.6). The native and double-mutated 
full-length protein behaved similarly to the polypeptide II.3, lacking the N-terminus. They 
displayed a pre-unfolding phase characterized by a linear reduction of the folded fraction 
upon denaturant concentrations below 3.5 M, followed by a sharp decrease between 4 M and 
5.5 M concentration of the denaturant. Assuming a two-state model transition that involves 
only the native (N) state and unfolded (U) state, all data sets but those of II.4 were fitted using 
a non-linear least-square regression [24], which yielded the Gibbs free energy change for 
unfolding in aqueous solution in the absence of denaturant, ∆G0H2O (for details see Equation 
IX.6 in the Experimental Part). This value was 28 kJ/mol and 26 kJ/mol for the full-length 
products II.5 and II.6, respectively, whereas the values corresponding to the unfolding of the 
analogue II.3 lacking the complete N-terminus and of the isolated Id3 HLH motif turned out 
to be of 17 kJ/mol and 22 kJ/mol, respectively. This suggests that the full-length protein was 
more stable than the shorter analogues lacking the N-terminal domain or both the N- and C-
terminal domains, and therefore that both flanking regions play a stabilizing role in the Id3 
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fold. The ∆G0H2O value found for the Id3 HLH domain was smaller than the one reported in 
the literature for the bHLH motifs of the Id3 dimerization partners E47 ∆G0H2O = 44 kJ/mol) 
and MyoD (∆G0H2O = 33 kJ/mol) [25]: this is in agreement with the observation that the Id3 
protein forms less stable homodimers than the corresponding binding partners [17].  
In contrast, the polypeptide II.4 lacking only the N-terminal segment 1-20 and containing a 
significant amount of β-strand structure exhibited a different behavior: there was an immedi-
ate loss of folded fraction already in 0.5 M denaturant, which, however, slowed down until 
the denaturant concentration reached 3.5 M. After that point, a sharp decrease of the curve 
was observed. More than one transition probably occurred, the first at submolar denaturant 
concentration, another one at ~ 3 M denaturant concentration and the last one above 4 M 
denaturant concentration.  
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Figure II.6. Denaturation curves of II.3-6 and of the Id3 HLH peptide (residues 41-81) obtained by titration of 
the peptide solutions in phosphate buffer (0.1 M, pH 7.25) by guanidinium chloride (left). The peptide 
concentration was in the range of 50-100 µM.  
II.6 Conclusion 
The Id3 protein has been shown to be a valuable target for solid-phase synthesis. This 
encourages the preparation of further chemically modified analogues of Id3 which will enable 
the investigation of its biophysical features. The results presented above have already shown 
that the synthetic Id3 protein adopts a stable α-helical conformation in the core region, and 
self-associates to form disulfide-bonded dimers. 
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III. Conformational Studies of the Id3 Helix-Loop-Helix Motif 
III.1 Introduction 
The Id3 protein forms heterodimers with bHLH transcription factors, in particular with 
the ubiquitously expressed members of the E family (E2A, E2-2, HEB), and thus inhibits the 
formation of DNA-binding bHLH homo- or heterodimers [1, 2]. The HLH motif spanning the 
Id3 residues 41-81 (peptide III.1) is required for dimerization. The latter, its analogues, and 
sequences corresponding to some of its binding partners were prepared by standard SPPS 
using the Fmoc strategy (Table III.1). Peptides III.2 and III.3 containing the substitution 
Phe→Tyr at positions 48 and 76, respectively, were prepared to see whether the hydroxyl 
group is involved in potential hydrogen bonding and consequent conformational stability. 
The importance of the cysteine residue within the first helix was evaluated using peptide 
III.4, which contains the replacement Gly→Cys. The secondary structure of all these HLH 
analogues was analyzed by CD spectroscopy and compared to that of the native Id3 HLH 
motif III.1. The HLH motifs of the bHLH proteins E47, E12, and MyoD (III.5, III.6 and 
III.7) were prepared to compare their helical properties to those of the Id3 HLH peptide. 
Both helical segments of the Id3 HLH domain (III.8 and III.9) were also synthesized 
separately, and their conformation in solution was studied 
III.2 Solid-Phase Synthesis of the HLH Motifs of Id3, E47, E12, and MyoD 
The peptides were synthesized on Rink amide resin using a double coupling of Nα-
Fmoc-protected amino acids and activation in situ by HBTU/HOBt/DIPEA. Once the syn-
thesis was complete, the N-terminus was acetylated and the peptides were cleaved from the 
resin, purified by preparative RP-HPLC, and characterized by analytical RP-HPLC and 
MALDI-TOF mass spectrometry (Figure IX.4 and IX.5 in the Experimental Part). The amino 
acid sequences of the native HLH motifs of human Id3, E47, E12 and MyoD are reported in 
Table III.1, and correspond to the results of sequence alignment studies [3]. Unlike the helical 
parts, the loops are completely non-conserved. 
The HLH motif of Id3 (peptide III.1) contains two tyrosine residues at positions 48 and 
76, which are conserved within the Id family, but not in the HLH family. Indeed, the Id3 
Tyr-48 is replaced by a phenylalanine residue in E47 (III.5), E12 (III.6) and MyoD (III.7), 
whereas the Id3 Tyr-76 is replaced by a valine residue in E47 and E12, but conserved in 
MyoD. To see whether the presence of the tyrosine residues in Id3 is critical or not, the two 
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analogues III.2 and III.3, in which either position was modified with phenylalanine, were 
prepared. 
The Id3 cysteine residue is also conserved within the Id family, whereas it is replaced 
by an alanine residue in E47, E12 and MyoD. Again, to study the role of this position, the Id3 
Cys-47 residue was replaced by a glycine residue in peptide III.4. 
The peptides III.5-7 were found to be much more difficult sequences than peptide III.1. In 
fact, analysis of the aggregation potential of the four sequences by using the program Peptide 
Companion predicted that the aggregation risk was high for the chains corresponding to E47, 
E12 and MyoD, and medium for the chain corresponding to Id3. After TFA cleavage, pep-
tides III.5-6 had to be additionally treated with trimethylsilylbromide (TMSBr)/EDT/TFA to 
reduce the oxidized methionine residues. This treatment was not necessary for peptide III.1.  
Table III.1. Analytical data of the HLH motifs III.1-7 and of helix-1 (III.8) and helix-2 (III.9) of Id3. 
HLH sequencesa 
Ac-LDDMNHCYSRLRELVP GVPRGTQLS  QVEILQRVIDYILDLQ-NH2 hId3 
Ac-VRDINEAFRELGRMCQ MHLKSDKAQT KLLILQQAVQVILGL-NH2  hE47 
Ac-VRDINEAFKELGRMCQ LHLNSEKPQT KLLILHQAVSVILNL-NH2  hE12 
Ac-LSKVNEAFETLKRCTS SNPNQRLP   KVEILRNAIRYIEGL-NH2  hMyoD 
Synthesized peptides 
Product Sequenceb MWcalcd.(Da) MWfound (Da) tR (min)c 
III.1 Ac-(41-81)-NH2 4838.6 4839.6 22.1 
III.2 Ac-[F-48]-(41-81)-NH2 4822.6 4822.4 21.9 
III.3 Ac-[F-76]-(41-81)-NH2 4822.6 4829.0 22.6 
III.4 Ac-[G-47]-(41-81)-NH2 4792.5 4788.6 21.3 
III.5 Ac-(559-599)-NH2 4749.7 4751.0 21.2 
III.6 Ac-(562-602)-NH2 4754.7 4753.0 21.5 
III.7 Ac-(122-160)-NH2 4545.3 4541.4 19.0 
III.8 Ac-(41-57)-NH2 2058.4 2058.4 15.2 
III.9 Ac-(65-81)-NH2 2086.4 2085.5 26.6 
a The underlined sequence corresponds to the loop region.  
b Id3 peptides, with the exception of peptide III.5 (hE47), peptide III.6 (hE12) and peptide III.7 (hMyoD). 
c Gradient: 10% ACN for 3 min, 10-70% ACN in 40 min. 
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III.3 CD Spectroscopy   
Secondary structure investigations of the synthetic peptides reported in Table III.1 were 
carried out by CD spectroscopy in phosphate buffer (0.1 M, pH 7.25), with and without 30% 
TFE, which stabilizes secondary structure elements by promoting the formation of intramo-
lecular hydrogen bonds. As peptides III.5 and III.6 were not soluble in pure phosphate buffer, 
30% TFE was added to increase their solubility. For comparison, a solution of peptide III.1 in 
buffer with and without TFE was examined as well. The following stock solutions were pre-
pared: 100 µM for III.1, III.5-9, 83 µM for III.2, 96 µM for III.3 and 108 µM for III.4.  
In phosphate buffer, the CD spectrum of III.1 was characterized by a negative band close to 
208 nm, attributed to the π→π* transition, followed by a second negative band located near 
222 nm, attributed to the n→π* transition. A positive band was present below 200 nm (Figure 
III.1). This CD spectrum is typical for an α-helix, including the ratio R of ~ 1 between two 
minima ( [ ] [ ]RRR 206202222 −ΘΘ= ). Composition of secondary structure elements of peptide 
III.1 was extrapolated by the dichroic data using the CONTIN algorithm [4, 5]. Beside a high 
helical fraction (65%), β-strand (6%), turn (7%) and unordered (21%) elements have been 
found (Table III.2). Interestingly, the R value decreased from ~ 1 to 0.77 in the presence of 
TFE, and a significant blue shift of the whole CD spectrum was observed (Figure III.1). Such 
dichroic differences were interpreted by the CONTIN algorithm as an increase in turn and 
unordered structure at the expense of the helical content (Table III.2). This was unexpected, 
due to the well-known ability of TFE to induce ordered conformations; however, it is also 
known that TFE tends to stabilize single helices rather than packed helices or coiled coils. 
This is also supported by the decrease in the R value, as values close to and higher than 1 
usually indicate helix packing or coiled coils [6]. Therefore, it is likely that TFE disturbs the 
highly compact helical packing of the Id3 HLH motif, and weakens its helical character. 
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Figure III.1. CD spectra of the synthetic HLH motif of Id3 (III.1, 100 µM) in phosphate buffer (0.1 M, pH 
7.25) (solid line) and in the presence of 30% TFE (dashed line). 
The importance of the helix packing for a stable conformation of the Id3 HLH motif is 
supported by the observation that the isolated Id3 helix-1 and helix-2, peptides III.8 and III.9, 
respectively, showed a different propensity to adopt helical conformation, with helix-1 being 
much less helical than helix-2 (Figure III.2). This suggests that helix-2 possesses intrinsic 
helicity, whereas the conformation of helix-1 may depend on the environment. Accordingly, 
the presence of 30% TFE stabilized helix-1, and a significant transition from unordered to 
helical conformation was observed: the negative band at 199.8 nm shifted to 206.4 nm, 
whereas a positive band below 198 nm appeared. The number of helical residues rose up 
to 10. Helix-2 was further stabilized by the presence of 30% TFE, too, and the number of 
helical residues increased from 10 up to 16 (Table III.2).  
 
Figure III.2. CD spectra of helix-1 (III.8) and helix-2 (III.9) at 100 µM concentration in phosphate buffer 
(0.1 M, pH 7.25) (left) and in the presence of 30% TFE (right). 
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The analogues of the Id3 HLH motif III.2, III.3 and III.4 are helical in phosphate buffer, too 
(Figure III.3). However, unlike peptide III.2 (Phe→Tyr-48), peptide III.3 (Phe→Tyr-76) 
contains less helical residues than peptide III.1 (17 vs. 27, Table III.2). This indicates that the 
Tyr-76 is more strongly involved in hydrogen bonding than Tyr-48, stabilizing the helical 
conformation. 
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Figure III.3. CD spectra of the native Id3 HLH motif III.1 and its analogues III.2-4 at ~ 100 µM concentration 
in phosphate buffer (0.1 M, pH 7.25). 
Peptide III.4 (Gly→Cys-47), measured in phosphate buffer, also contains less helical residues 
than peptide III.1, which suggests that Cys-47 plays a role in the stabilization of the HLH 
folding.  
Peptides III.5-7, representing the HLH motifs of the bHLH proteins E47, E12 and 
MyoD, were generally less helical than the Id3 HLH motif. Peptide III.7 was the only one 
which was soluble in phosphate buffer (0.1 M, pH 7.25), whereas the others required the 
presence of 30% TFE (Figure III.4). The latter peptides have strong tendency to aggregate and 
the α-helical contribution to the CD spectra was low. Accordingly, a significant amount of β-
strand fraction was estimated by the CONTIN algorithm, while the number of helical residues 
was only 7 or 8 (for peptides III.5 or III.6, respectively) vs. 21 for peptide III.1 (Table III.2). 
In contrast, peptide III.7, which could be measured in pure phosphate buffer, showed a differ-
ent CD shape characterized by a blue-shifted π→π* band at 202 nm, followed by the n→π* 
band near 222 nm, with R value of 0.43. These dichroic properties resemble the ones of 310-
helix. Obviously, peptide III.7 also contains less helical residues than peptide III.1 (5 vs. 27), 
and the composition of secondary structure elements is comparable to that of the peptides 
III.5-6; however, the ratio between regular and irregular α-helical elements was 1 for III.5-6 
and 0.5 for III.7, which would might reflect the presence of 310-helical turns in III.7. 
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Figure III.4. CD spectra of the native Id3 HLH motif III.1 and its bHLH binding partners III.5-7. The samples 
(100 µM) were dissolved in phosphate buffer (0.1 M, pH 7.25; peptides III.1 and III.7) or in a mixture of 
phosphate buffer (0.1 M, pH 7.25) and TFE (70:30, v/v, peptides III.5 and III.6). 
Peptide III.1 was characterized by a ratio α/β much higher than 1 (7 in the presence of TFE 
and 11 in pure phosphate buffer), whereas peptides III.5-7 showed a α/β ratio smaller than 1 
(0.6 for peptide III.5, 0.7 for peptide III.6, and 0.4 for peptide III.7). Interestingly, peptide 
III.5 underwent a significant β→α transition upon incubation at 10 °C for 7 days (Figure III.5 
and Table III.2). The α/β ratio increased from 0.6 to 2.7. This phenomenon was observed only 
for the HLH motif of E47, but not for E12 and MyoD, which suggests that the HLH motif of 
E47 has a superior helix propensity allowing for a slow conformational change towards the 
helix formation. 
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Figure III.5. CD spectra of a 100 µM solution of the HLH motif of E47 (peptide III.5) in a mixture of 
phosphate buffer (0.1 M, pH 7.25) and TFE (70:30, v/v), recorded immediately after preparation (solid line) and 
after incubation at 10 °C for 7 days (dashed line). 
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Table III.2. Conformational properties of the synthetic peptides III.1-9 in phosphate buffer (0.1 M, pH 7.25) 
and/or in the presence of 30% TFE. 
% Secondary structure elements by CONTINb 
(no. of residues) 
Product Concentration 
(µM) 
% Helix  
(no. of 
residues)a helix β-strand turns unordered 
III.1 100 46 (19) 65 (27) 6 (2) 7 (3) 21 (9) 
III.1c 100 46 (19) 52 (21) 7 (3) 16 (6) 26 (11) 
III.2 83 51 (21) 60 (25) 4 (2) 15 (6) 21 (8) 
III.3 96 34 (14) 42 (17) 12 (5) 17 (7) 29 (12) 
III.4 108 49 (20) 54 (22) 6 (2) 16 (7) 24 (10) 
100 15 (6) 17 (7) 29 (12) 20 (8) 34 (14) 
III.5c 
100d 32 (13) 39 (16) 14 (6) 18 (7) 29 (12) 
100 20 (8) 19 (8) 26 (11) 20 (8) 35 (14) 
III.6c 
100d 15 (6) 17 (7) 29 (12) 20 (8) 35 (14) 
100 13 (5) 12 (5) 31 (12) 21 (8) 36 (14) 
III.7 
100d 15 (6) 15 (6) 29 (11) 22 (9) 34 (13) 
III.8 100 29 (5) 9 (2) 7 (1) 30 (5) 54 (9) 
III.8c 100 65 (11) 60 (10) 4 (1) 26 (4) 10 (2) 
III.9 100 76 (13) 59 (10) 3 (1) 14 (2) 24 (4) 
III.9c 100 100 (17) 95 (16) 0 (0) 0 (0) 5 (1) 
a The helix percentage was estimated by the ellipticity value at 222 nm using the procedure of Chen and
Yang [7]. The peptide length was the same for all samples (41 residues), with the exception of peptides
III.7 (39 residues), III.8 and III.9 (both 17 residues). 
b The CD spectra were analyzed by the CONTIN algorithm. 
c The peptide was measured in the presence of 30% TFE. 
d The sample was incubated at 10 °C for 7 days. 
 
III.4 Discussion and Conclusion 
The Id3 helix-2 is intrinsically helical, whereas the conformation of the Id3 helix-1 may 
depend on the environment: indeed, it becomes helical after connection to helix-2 through the 
loop region, as observed for the HLH peptide III.1, or upon addition of TFE. This behavior 
is in agreement with the results reported in Chapter II, where the helical content of the Id3 
sequence 57-119 (peptide II.2) increased after elongation with helix-1 (peptide II.3).  
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The hydroxyl group of the tyrosine residue in the helix-1 does not seem to be important 
for the conformation, as the Phe-48 mutant did not show any changes in the secondary 
structure composition. Tyr-48 is probably participating in the π-π interactions and not in 
the hydrogen bonding. In contrast, Tyr-76 must be involved in the hydrogen bonding which 
stabilizes the Id3 HLH motif, because after its replacement with the phenylalanine residue, 
there was a significant decrease in the number of helical residues. Accordingly, a homology 
model of the Id3 HLH dimer proposed by Norton and co-workers [8] shows an interchain 
contact between the side chain of Tyr-76 and the side chain of Gln-81 (Figure III.6). There-
fore, the role of Tyr-76 seems to be important for the stabilization of the dimer.  
 
Figure III.6. The crystal structure of the DNA-bound dimer of the MyoD bHLH motif can serve as a model for 
the Id3 HLH motif because of the highest sequence identity and conserved residue similarity to the Id3 sequence 
over helix-1 and helix-2 [8]. The side chains of Tyr-76 and Gln-81 are indicated in green and orange, 
respectively. The crystal structure of MyoD was taken from the PDB data bank (PDB ID: 1MDY) [9], the 
sequence substitutions were done by using the spdbv program and the model structure was created with the 
VMD program. 
Cys-47 is also important for the conformation: indeed, the glycine mutation negatively 
affected the helix character leading to an increase in the number of turn elements. 
The HLH motifs of the bHLH proteins E47, E12 and MyoD were generally less helical than 
the Id3 HLH motif; this suggests that the HLH domains of the bHLH transcription factors 
require the binding to DNA or at least the presence of the N-terminal DNA binding domain 
to fold in a stable manner [10].  
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IV. Conformational Fragment Analysis of the Id3 Protein 
IV.1 Introduction 
Previous chapter showed that the Id3 helix-1 is helical either in the presence of TFE or 
when connected to helix-2 which possesses intrinsic helicity. Accordingly, the entire HLH 
motif of Id3 is highly helical. In contrast, the regions preceding and following it do not prefer 
any conformation as isolated fragments [1]. In order to have some insights into the conforma-
tional interplay of the single subdomains, conformation of a series of peptides which span 
adjacent subdomains was analyzed (peptides IV.2-5 and IV.7-14 in Figure IV.1). For exam-
ple, peptide IV.2 reproduces the C-terminal part of the N-terminus and helix-1, and peptide 
IV.3 reproduces helix-2 preceded by the loop and followed by the N-terminal part of the C-
terminus. Comparison of these two peptides with the ones spanning only helix-1 (III.8) or 
helix-2 (III.9) gives an idea about the role of the adjacent regions on the conformation of the 
two helices. Similarly, peptides IV.5 and IV.7 suggest the influence of the N- and/or C-
terminal elongations on the central HLH motif 
Beside the Id3 fragments containing the native amino acid sequence, additional ana-
logues displaying some amino acid substitutions have been synthesized. For example, peptide 
IV.4 represents a mutant of peptide IV.3, in which four natural amino acids within helix-2 
have been replaced with the achiral α-aminoisobutyryl (Aib) moieties, Cα-tetrasubstituted 
residues, which should change the helical character of the peptide segment. It is known that 
peptide sequences rich in Aib residues tend to fold into a 310-helical conformation which is 
stabilized by i, i+3 interactions [2-7]. 310-Helices are usually very short and often located at 
the termini of α-helical segments and have been proposed as intermediates in the folding-
unfolding process of α-helices. The entropic penalty for the necessary loop closure for the 
formation of i, i+3 versus i, i+4 hydrogen bonds is lower.  
A phosphorylation site corresponding to Ser-5 of Id3—also present in Id2 and Id4— 
modulates the protein activity during the cell cycle and alters the bHLH protein binding speci-
ficity [8-11]. Thus, the phosphorylated peptide IV.10 has been prepared and compared to the 
unphosphorylated peptide IV.9 to see the effect of the posttranslational modification. More-
over, peptide IV.11, in which the consensus sequence for phosphorylation has been modified 
by replacing Pro-6 with glutamine residue, should suggest whether the N-end of the protein 
is sensitive to point mutations. Similarly, peptide IV.8 representing the N-terminally truncated 
analogue of peptide IV.9 should suggest the role of the flanking region 1-20. The latter 
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contains three cysteine residues (Cys-10, Cys-15 and Cys-16) which might form intra- and 
intermolecular disulfide bridges involving also Cys-47 of helix-1. The importance of the latter 
residue was evaluated by using the corresponding Gly-47 mutant of peptide IV.9 (IV.12) or 
of peptide II.3 (IV.14). Also, a double mutant of the native sequence 57-119 (peptide IV.13) 
containing two substitutions in the loop region was prepared, in which Pro-59 was replaced 
by glutamine residue and Gln-63 by proline residue to see if the presence of the cyclic amino 
acid preceding the N-end of helix-2 might influence the latter. The proline residue is a fre-
quent helix terminator due to its rigid conformation and the inability of the Nα-atom to partici-
pate in a hydrogen bond, but it can also precede the beginning of a α-helix; therefore, shifting 
the proline position from 59 to 63 might potentially change the length of the helix-2. 
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Figure IV.1. Sequence and schematic representation of the Id3 protein domains (N-terminus, HLH motif and C-
terminus) and of the Id3 peptide sequences used for the conformational fragment analysis (the mutated positions 
are indicated in bold, X = Aib, Y = PO3H2). 
Finally, peptide IV.6 has been prepared to study an interesting region of the Id3 C-terminus 
which is particularly rich in proline residues. In proline-rich polypeptides, the constraints of 
the pyrrolidine ring stabilize a left-handed polyproline II (PPII) helical conformation which 
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plays an important role in many vital processes [12-14]. Thus far, nothing is known about the 
proline-rich region of Id3; with peptide IV.6 it should be possible to evaluate the tendency of 
this Id3 segment towards a PPII structure. 
IV.2 Solid-Phase Synthesis of the N-Terminal and C-Terminal Id3 Fragments 
and Related Analogues 
Peptides IV.1-12 were synthesized on Rink amide resin and cleaved as C-terminal 
peptide amides, whereas peptides IV.13-15 were synthesized on Fmoc-His(trityl)-Wang 
resin and cleaved as free peptide acids. Peptide chain assembly was performed under stan-
dard conditions using double coupling of the Nα-Fmoc-protected amino acids and activation 
in situ by HBTU/HOBt/DIPEA. Fmoc-Aib-OH was inserted at positions 67, 70, 73 and 77 of 
the native Id3 sequence in peptide IV.4 (in place of the hydrophobic residues Val, Leu, Val, 
and Ile) (Table IV.1). In peptide IV.10, the Fmoc-O-benzylphosphoserine was introduced 
at position 5 by standard procedure with activation in situ by HBTU/HOBt/DIPEA. After 
peptide removal from the resin, cleavage of the benzyl protecting group and reduction of the 
oxidized Met residues were accomplished simultaneously by treatment with a TFA mixture 
containing 5% (v/v) of TMSBr/EDT (2:3, v/v) for 1 hour. 
Once the synthesis was completed, the N-terminus of peptides IV.1-8 and IV.13-14 was 
acetylated and the peptides were cleaved from the resin by TFA with 10% (v/v) scavengers. 
Peptides IV.2 and IV.7-12 were treated with TFA/TMSBr/EDT, as described above. The 
crude peptides were purified by preparative RP-HPLC and then characterized by analytical 
RP-HPLC (Figures IX.6-7 in the Experimental Part) and MALDI-TOF mass spectrometry. 
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 Table IV.1. Analytical data of the synthetic Id3 fragments IV.1-15. 
Synthetic Id3 fragments 
Product Sequence MWcalcd. (Da) MWfound (Da) tR (min)a 
IV.1 Ac-(1-40)-NH2 4189.9 4188.8 23.5 
IV.2 Ac-(21-58)-NH2 4133.8 4130.9 17.8 
IV.3 Ac-(57-101)-NH2 4882.7 4878.9 23.5 
IV.4 Ac-[Aib-67,70,73,77]-(57-101)-NH2 4798.5 4799.5 21.0 
IV.5 Ac-(41-101)-NH2 6825.9 6824.2 21.3 
IV.6 Ac-(85-100)-NH2 1633.8 1634.9 10.8 
IV.7 Ac-(17-101)-NH2 9286.8 9291.7 22.5 
IV.8 Ac-(21-81)-NH2 6813.9 6814.8 21.3 
IV.9 H-(1-81)-NH2 8969.6 8969.1 20.5 
IV.10 H-[S(PO3H2)-5]-(1-81)-NH2 9049.5 9071.8b 21.4 
IV.11 H-[Q-6]-(1-81)-NH2 9000.6 9002.3 21.3 
IV.12 H-[G-47]-(1-81)-NH2 8923.5 8925.3 20.3 
IV.13 Ac-[Q-59, P-63]-(57-119)-OH 6895.0 6892.6 21.5 
IV.14 Ac-[G-47]-(41-119)-OH 8792.1 8791.4 22.0 
IV.15 H-(82-119)-OH 4016.6 4017.7 11.5 
a Gradient: 10% ACN for 3 min, 10-70% ACN in 40 min for all peptides, with the exception of peptide IV.15 
(10-95% ACN in 40 min). 
b (M+Na)+. 
 
IV.3 CD Spectroscopy   
The secondary structure of the Id3 fragments and their analogues was investigated by 
CD spectroscopy in phosphate buffer (0.1 M, pH 7.25) or, in the case of the N-terminal Id3 
peptides (IV.9, IV.11 and IV.12), both in phosphate buffer and water, as their solubility in the 
buffer was limited. All peptides, with the exception of peptide IV.15, were measured at two 
different concentrations, ~ 100 µM and ~ 30 µM; however, no difference was observed.  
Whereas the Id3 HLH motif was helical (peptide III.1), both the N-terminal (peptide IV.1) 
and C-terminal (peptide IV.15) domains were mostly unordered, as shown by the CD spectra 
characterized by an intense negative band around 199 nm (Figure IV.2).  
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Figure IV.2. CD spectra of the Id3 HLH motif (III.1, 30 µM), N-terminus (IV.1, 30 µM) and C-terminus 
(IV.15, 43 µM) in phosphate buffer (0.1 M, pH 7.25). 
Peptide IV.2, which contains part of the N-terminus (21-40) and helix-1, was also found to 
be mostly unordered (Figure IV.3, left). However, in contrast to the single helix-1 (peptide 
III.8), a moderate fraction of β-strand structure (28% vs. 7% of III.8) was estimated by the 
CONTIN algorithm. This suggests that the 20 N-terminal residues preceding helix-1 are not 
important for the helicity of helix-1, but rather favor a β-strand conformation (Table IV.2). 
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Figure IV.3. CD spectra of peptide IV.2 and helix-1 (III.8) in phosphate buffer (0.1 M, pH 7.25) at 100 µM 
concentration (left). CD spectra of peptide IV.8 and of the HLH motif (III.1) in phosphate buffer (0.1 M, pH 
7.25) at 30 µM concentration (right).  
The CD spectrum of peptide IV.8, which contains the N-terminal tail 21-40, similar to peptide 
IV.2, and the entire HLH motif, was characterized by two negative bands at 207.4 nm, attrib-
uted to the π→π* transition, and 222 nm, attributed to the n→π* transition, and by a positive 
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one below 200 nm (Figure IV.3, right). Comparison of the dichroic properties of this peptide 
and of the HLH motif alone (III.1) reveals a reduced helix stability for IV.8 (decreased in-
tensity of the bands at 222 nm and below 200 nm), probably due to a different helix packing 
(the ratio R was 0.80 for IV.8 and 1.26 for III.1). In fact, the number of α-helical residues 
decreased from 24 for III.1 to 18 for IV.8 (Table IV.2). In contrast, the number of β-strand 
residues increased, thus leading to a α/β ratio of ~ 1 for IV.8 against the value of ~ 5 for III.1. 
These observations have been already reported for the larger polypeptide II.4 reproducing 
the Id3 residues 21-119 which contains an increased amount of β-strands with respect to the 
peptide II.3 reproducing the Id3 residues 41-119. It can be therefore concluded that in all 
three cases studied (peptides IV.2, IV.8 and II.4), the N-terminal tail 21-40 favored the form-
ation of β-strand elements while disfavoring the helix conformation. 
Peptides IV.5 and IV.7 contain the HLH motif, the proline-rich region of the C-terminus, 
and, in the case of IV.7, the N-terminal tail 17-40. Both peptides are characterized by a negative 
CD band around 206 nm, attributed to the π→π* transition, followed by a less intense one 
centered near 222 nm, attributed to the n→π* transition, and a positive band below 195 nm 
(Figure IV.4, left). However, the CD curve of peptide IV.7 is less intense than that of peptide 
IV.5. The ratio R was 0.58 for peptide IV.5 and 0.50 for peptide IV.7. Peptide IV.5 was char-
acterized by a much higher α/β ratio (10) than peptide IV.7 (0.7), which suggests that the 
presence of the N-terminal tail in the latter peptide favored a β-strand at the expense of α-
helical conformation. Accordingly, the difference spectrum between IV.7 and IV.5 shows 
a positive component with a maximum near 205 nm and a shoulder near 222 nm, and a negat-
ive band below 200 nm, a shape which has been reported for distorted β-strands [15] (Figure 
IV.4, right). Such β-strand-inducing effect of the N-terminus has been already observed for 
the peptides IV.2, IV.8 and II.4, as described above.  
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Figure IV.4. Comparison of the CD spectra of peptides IV.5 and IV.7 with the HLH motif III.1 (all samples 
were at 30 µM concentration in 0.1 M phosphate buffer, pH 7.25) (left). CD spectra differences underlying the 
impact of the N-terminal part (residues 17-40) on IV.5 (solid line), of the C-terminal part (residues 82-101) on 
III.1 (dashed line) and of both terminal parts (dotted line) on III.1 (right). 
The HLH motif III.1 was compared to peptide IV.5 (displaying 20 additional C-terminal 
residues) and to peptide IV.8 (displaying 20 additional N-terminal residues). Although the C-
terminus is mostly unordered, it stabilizes and elongates helix-2 in its direction: indeed, the 
number of the helical residues increased from 24 to 30 upon connection the C-terminal part 
to the HLH motif. This result is in agreement with finding described in Chapter II, which 
concerned the comparison of the HLH motif with peptide II.3 (residues 41-119): accord-
ingly, in the presence of the entire C-terminus, the number of helical residues increased from 
24 to 35. In contrast, the 20 N-terminal residues induce a transition from helical to β-strand 
structure, and the number of helical residues decreases from 24 to 18 upon connection the N-
terminal part to the HLH motif, while the number of β-strand residues increased from 5 to 13. 
As already reported in Chapter II, these 20 residues could even abrogate the helicity gained by 
addition of the C-terminal part in peptide II.4 which contains only 20 helical residues against 
the 35 ones of peptide II.3 and the 24 ones of the HLH motif III.1. 
Peptide IV.3 contains the loop sequence and helix-2 with a portion of the C-terminus. 
Its CD spectrum is characterized by a negative band around 207 nm, attributed to the π→π* 
transition, followed by a less intense one centered near 222 nm, attributed to the n→π* trans-
ition. A positive band is present below 200 nm (Figure IV.5). Compared to peptide II.2 
(residues 57-119) a lower number of helical residues was found in peptide IV.3. The number 
was however larger than that of helix-2 alone. Thus, the entire C-terminus seems to stabilize 
the helix-2 in a more efficient manner than only the residues 82-101, which would support a 
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close spatial arrangement between helix-2 and the C-end. The number of helical residues 
significantly increased (from 17 to 30) when helix-1 was connected to the peptide IV.3 to 
yield peptide IV.5. The same tendency was already observed in the presence of the entire C-
terminus (comparison of peptides II.2 and II.3, residues 57-119 and 41-119, respectively).  
Peptide IV.4, containing four Aib residues within helix-2, is an analogue of peptide IV.3. Its 
CD spectrum shows a negative band at 201.2 nm and a second less intense negative band 
around 220 nm. No positive band below 200 nm was found (Figure IV.5). A dichroic para-
meter that is used to distinguish a 310-helix from a α-helix is the ratio R which is in the range 
of 0.3-0.4 for the 310-helix and close to 1 for the α-helix [3, 16]. In addition, the positive band 
near 195 nm is much less intense for a 310-helix than for a α-helix. The CD spectrum of pep-
tide IV.4 can be assigned to a 310-helix, with a ratio R of 0.26. This confirms the ability of the 
Aib residues to induce a 310- over a α-helix type.  
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Figure IV.5. CD spectra of peptides IV.3 and IV.4 at 30 µM concentration in phosphate buffer (0.1 M, pH 
7.25). 
Peptide IV.6 represents the proline-rich region in the Id3 C-terminus, also present in 
peptides IV.3-5 and IV.7. Its CD spectrum is characterized by a single negative band centered 
at 199 nm (Figure IV.6). A typical CD curve for the polyproline helix II (PPII) in aqueous 
solution shows a weak positive band at 218-228 nm, attributed to the n→π* transition, and 
a strong negative band below 205 nm [14, 17, 18]. The PPII helix is the only known 
secondary structure which has a positive band in the wavelength range 218-228 nm. However, 
the absence of a positive band does not necessarily indicate the absence of PPII content [18], 
because other local structures which negatively contribute to the CD signal in this region 
might be included as well.  
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Figure IV.6. CD spectrum of peptide IV.6 at 100 µM concentration in phosphate buffer (0.1 M, pH 7.25).  
Proline residues can occur exclusively at the initial two or three positions of 310- and α- 
helices. Any following proline residue would act as a helix breaker, or at least to a kink of the 
helix backbone. PPII helices are a major component of unordered polypeptides [19, 20]. The 
PPII conformation is favored at low temperatures or upon addition of denaturants, such as 
urea or guanidinium chloride [14]. These denaturation agents interact with the backbone and 
force the polypeptide to extend. This can favor the formation of a PPII helix, which is indic-
ated by an increase in the intensity of the positive band over 218-228 nm in the CD spectra. 
Denaturants clearly disfavor a compact native structure, but it is not yet clear whether the 
resulting backbone conformations are disordered. The denatured states probably possess 
significant amounts of locally ordered backbone structures [18]. Protein denaturation using 
urea and guanidinium chloride can be considered as a transition from a globally structured 
state to a dynamic ensemble of locally structured states. The fraction of PPII helix can be 
calculated from the CD band intensity of the local maximum, [Θ]max, using the following 
equation [14, 21]: 
 
%100
13700
6100max ×+Θ=PPII Eq. IV.1
 
Temperature- and urea-dependent CD measurements of peptide IV.6 have been carried out 
in order to see whether the PPII helix could be stabilized. The CD region of 218-228 nm has 
been monitored, as the intensity of the positive band in this region is considered to be pro-
portional to the PPII helical content. For the temperature-scan experiment, peptide IV.6 was 
cooled to a minimum of 5 °C and heated to a maximum of 45 °C; a positive band around 
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224 nm was observed at 5, 10 and 15 °C, whereas at higher temperatures, the CD signal 
became negative (Figure IV.7). Using the aforementioned Eq. IV.1, peptide IV.6 was found 
to contain 59% PPII helix at 5 °C. 
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Figure IV.7. Effect of the temperature on peptide IV.6 (100 µM) in 0.1 M phosphate buffer (pH 7.25). 
Further, peptide IV.6 was subjected to urea-titration. Increasing intensity of the positive band 
around 224 nm with increasing urea concentration is shown in Figure IV.8. Peptide IV.6 was 
found to adopt a 63% PPII helix in the presence of 6 M urea. The ellipticity at 224 nm was 
plotted as a function of the urea concentration (Figure IV.8, right). The CD intensity increased 
in a linear manner over the concentration range of 0-3 M urea. At higher urea concentrations, 
the increment abruptly lowered. At low denaturant concentrations, a transition from a broad 
ensemble of conformations to an ensemble dominated by the PPII conformation probably 
occurs, whereas at higher denaturant concentrations, the ensemble is further restricted to the 
PPII conformation. 
IV.3 CD Spectroscopy 51 
 
210 220 230 240 250 260
-4
-2
0
2
4
λ  [nm]
[Θ
] R
 x
 1
0-
3   
  [
de
g 
cm
2 d
m
ol
-1
]
  0M urea
  1M urea
  2M urea
  3M urea
  6M urea
0 1 2 3 4 5 6
0.0
0.5
1.0
1.5
2.0
2.5
[urea] [M]
[Θ
] 22
4 x
 1
0-
3   
  [
de
g 
cm
2 d
m
ol
-1
]
 
Figure IV.8. Effect of increasing urea concentration on peptide IV.6 (100 µM) in phosphate buffer (0.1 M, 
pH 7.25). CD spectra (left) (at high concentrations of urea the CD spectra could be recorded only above 210 nm). 
The value of [Θ]224 is plotted as a function of the urea concentration (right). 
The CD spectra of the N-terminal Id3 analogues IV.9-12 are shown in Figure IV.9. The native 
sequence 1-81 (peptide IV.9) adopted a helical conformation both in phosphate buffer (0.1 M, 
pH 7.25) and in water. However, the CD intensity at 200-230 nm was higher in water, sug-
gesting a superior helix character. Accordingly, the CONTIN analysis of the CD curves 
in buffer and in water indicated α/β ratio of 2 and 9, respectively (Table IV.2). The CD 
spectrum of the native sequence 1-81 phosphorylated at position 5 (peptide IV.10) was less 
intense than the unphosphorylated analogue, which was attributed to a decrease in helicity 
and an increase in β-strand structure (Table IV.2). Thus, the phosphorylation of Ser-5 seems 
to have a significant impact on the conformation of the Id3 sequence 1-81, which is likely to 
hold true for the full-length Id3 protein. In contrast, the CD spectrum of the mutant IV.11, in 
which the consensus sequence for the Cdk-2-dependent phosphorylation of Ser-5 was modi-
fied by substitution of Pro-6 by glutamine, was almost super-imposable to that of the unmodi-
fied sequence, suggesting that the mutation had no effect on the conformation. A deleterious 
mutation was that of Cys-47 with glycine (peptide IV.12), which dramatically decreased 
the helical content while favoring the formation of distorted β-strands under physiologic 
conditions (Figure IV.9). In water, the helical character could be only partially restored; 
accordingly, the difference CD spectrum between the Gly→Cys-47 mutant and the native 
sequence, which shows a positive component near 222 nm and a negative one below 200 nm 
(inset in Figure IV.9), indicates the presence of additional disordered elements and distorted 
β-strands [15]. Therefore, the sulfhydryl group of Cys-47 seems to be important for the 
stabilization of the conformation, probably by participating in hydrogen bonds.  
52 IV. CONFORMATIONAL FRAGMENT ANALYSIS OF THE ID3 PROTEIN 
 
Figure IV.9. CD spectra of the N-terminal fragments IV.9-12 at ~ 30 µM concentration in phosphate buffer 
(0.1 M, pH 7.25) (left) and in water (right, inset: difference CD spectrum between IV.12 and IV.9). 
One possible helix-stabilizing interaction might be an i, i+4 hydrogen bond between the 
β-carboxylic group of Asp-43 and the sulfhydryl group of Cys-47. Further stabilization of 
the helix at pH below 7 could result from the formation of the ion pair between His-46 and 
Asp-42 or Asp-43. The presence of an electrostatic interaction would explain why also the 
native peptide IV.9 was more helical in water than in phosphate buffer. In water, both pep-
tides may be in fact stabilized by a salt bridge involving His-46, whereas in phosphate buffer, 
where the imidazole ring is mostly not ionized, only the native peptide may be stabilized by 
hydrogen bonds involving Cys-47. 
Comparison of peptide IV.9 with peptide II.3 allows to evaluate the effect of the N- or 
C-terminal truncation of the Id3 protein (Figure IV.10). In fact, the analogue lacking the 
entire C-terminus was characterized by a reduced α/β ratio with respect to the analogue 
lacking the entire N-terminus, which suggests that the N- and C-domains of Id3 contribute 
to the folding in a different manner, with the N-domain favoring β-strand elements while the 
C-domain stabilizing helix elements.  
The double mutant IV.13 in which the loop residues Pro-59 and Gln-63 were exchanged 
showed a conformation similar to the corresponding native sequence (Figure IV.11, left). This 
suggests that the loop region is flexible enough to tolerate the shift of the proline residue from 
the N-end to the C-end. Moreover, the beginning of helix-2 must be located after residue 63, 
which confirms the results of the sequence alignment studies. 
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Figure IV.10. Comparison of the CD spectra of the Id3 polypeptides II.3 (residues 41-119, 30 µM) and IV.9 
(residues 1-81, 23 µM) lacking the N-terminus and C-terminus, respectively. 
Surprisingly, the mutation of Cys-47 in helix-1, which was found to be deleterious for the N-
terminal peptide IV.12, was well tolerated in the C-terminal peptide IV.14: indeed, the CD 
spectra of the mutant IV.14 and of the unmodified sequence II.3 were almost superimposable 
(Figure IV.11, right). This different behavior might be explained by the fact that the local 
environment of the residue at position 47 is not the same in the Id3 sequences 1-81 and 
41-119.  
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Figure IV.11. CD spectrum of the C-terminal double mutant IV.13 in comparison with the native sequence II.2 
in phosphate buffer (0.1 M, pH 7.25) (left). CD spectrum of the C-terminal Cys-47 mutant IV.14 in comparison 
with the native sequence II.3 in phosphate buffer (0.1 M, pH 7.25) (right). The peptide concentration was 
30 µM.  
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Table IV.2. Conformational properties of the N- and C-terminally truncated Id3 sequences and their analogues 
in phosphate buffer (0.1 M, pH 7.25) and in water. 
% Secondary structure elements by CONTINb 
(no. of residues) 
Product No. of 
residues 
Concen-
tration 
(µM) 
% Helix 
(no. of 
residues)a helix β-strand turns unordered 
IV.1 40 30 15 (6) 14 (6) 18 (7) 27 (11) 40 (16) 
IV.2 38 100 5 (2) 8 (3) 28 (11) 23 (9) 41 (16) 
IV.3 45 30 31 (14) 38 (17) 15 (7) 18 (8) 29 (13) 
IV.4 45 30 13 (6) 16 (7) 24 (11) 24 (11) 36 (16) 
IV.5 61 30 43 (26) 49 (30) 5 (3) 18 (11) 29 (18) 
IV.6 16 100 13 (2) 10 (2) 5 (1) 32 (5) 53 (8) 
IV.7 85 30 15 (13) 18 (15) 27 (23) 21 (18) 34 (29) 
IV.8 61 30 21 (13) 29 (18) 21 (13) 19 (11) 31 (19) 
IV.9 81 23 27 (22) 34 (28) 15 (12) 22 (18) 29 (23) 
IV.9c 81 30 42 (34) 45 (36) 5 (4) 22 (18) 28 (23) 
IV.10 81 35 11 (9) 21 (17) 28 (23) 18 (15) 33 (27) 
IV.11 81 23 28 (23) 34 (28) 14 (11) 22 (18) 30 (24) 
IV.11c 81 30 41 (33) 44 (36) 6 (5) 21 (17) 29 (23) 
IV.12 81 32 7 (6) 8 (6) 35 (28) 22 (18) 35 (28) 
IV.12c 81 30 30 (24) 24 (19) 20 (16) 19 (15) 37 (30) 
IV.13 63 30 43 (27) 49 (31) 4 (3) 21 (13) 26 (16) 
IV.14 79 30 35 (28) 41 (32) 4 (3) 23 (18) 32 (25) 
IV.15 38 43 13 (5) 8 (3) 10 (4) 32 (12) 50 (19) 
III.1 41 30 37 (15) 59 (24) 12 (5) 18 (7) 11 (5) 
III.8 17 100 29 (5) 9 (2) 7 (1) 30 (5) 54 (9) 
a The helix percentage was estimated by the ellipticity value at 222 nm using the procedure of Chen and Yang [22].  
b The CD spectra were analyzed by the CONTIN algorithm. 
c The peptide was measured in water. 
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IV.4 Discussion and Conclusion 
The conformational Id3 fragment analysis has revealed some interesting properties of 
the N- and C-terminal domains: (i) the presence of the N-terminal region seems to reduce the 
α/β ratio (peptides IV.2, IV.7 and IV.8), as does the removal of the C-terminal tail (peptide 
IV.9). (ii) In contrast, the C-terminus or part of it stabilize the helix character (e.g., peptide 
IV.5), even in the case of helix-1 destabilization by Cys-47 mutation (peptide IV.14). (iii) 
Phosphorylation of the N-terminus at position 5 enhanced the β-strand propensity of the N-
terminal fragment 1-81 (peptide IV.10). (iv) The C-terminal proline-rich motif is capable to 
adopt a PPII helix stabilized by low temperature or urea addition. 
Altogether, these results suggest that the N- and C-domains of the Id3 protein can be critical 
for the folding of the central HLH motif and for its dimerization behavior, the intrinsic 
flexibility of the N- and C-tails is probably a structural prerequisite for the modulation of the 
protein fold during the dimerization processes with different bHLH transcription factors. 
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V. Fluorescence Resonance Energy Transfer (FRET) Studies of Labeled 
Id3 Fragments 
V.1 Introduction
The conformational studies described in previous chapters have shown that the Id3 
HLH peptide has high intrinsic helix propensity, whereas the N- and C-flanking regions do 
not adopt any preferred conformation as isolated domains. However, the N- [1, 2] and C-
terminal domains [3, 4] of the Id3 protein are important for the control of the protein di-
merization events mediated by the HLH domain, thus regulating the Id3 inhibitory activity. 
Accordingly, the conformation of larger Id3 fragments suggests that the regions preceding 
and following the HLH sequence are not completely flexible or extended, but are rather part 
of a compact fold. For example, the Id3 fragment 41-119 reproducing the HLH domain 
connected to the C-terminus displayed superior helical character with respect to the isolated 
HLH domain (~ 35 vs. ~ 24 helical residues, as estimated by the analysis of the CD spectra 
with the CONTIN algorithm), but comparable to that of the synthetic full-length protein 
(~ 40 helical residues) [5]. Thus, the C-terminal flanking region seems to exert a stabilizing 
effect on the Id3 HLH helicity. In contrast, the N-terminus seems to disfavor the helicity: an 
Id3 analogue lacking the first 20 N-terminal residues was found to form a significant amount 
of β-strands at the expense of α-helix, which was assumed to be caused by a probable fold-
ing back of the shortened N-terminus onto the HLH domain [5]. Large Id3 protein fragments 
fluorescently labeled by tryptophan/dansyl (Trp/Dns) donor/acceptor pair [6] at different 
positions along the sequence were prepared to further investigate how the Id3 HLH motif and 
its flanking regions are spatially arranged in solution. The efficiency of the FRET which is 
according to the Förster’s theory [7] related to the distance between the two fluorophores 
was examined. The effect of the FRET pair introduction on the conformation of the native 
sequence was also investigated by CD spectroscopy. Altogether, the fluorescence and CD 
data confirm that the regions in proximity of the N- and C-termini of the HLH domain are not 
completely flexible and extended, but rather point toward the HLH core sequence, thus 
generating a compact fold. Interestingly, deletion of the C-terminus was found to increase 
the β-strand structure amount while reducing the helix content, as it was previously observed 
in the absence of the N-terminal residues 1-20 [5]. Even though the regions preceding and 
following the Id3 HLH domain have no secondary structure propensity as isolated fragments, 
they seem to influence the folding, in particular the α/β ratio, of the Id3 protein. 
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V.2 Design and Solid-Phase Synthesis of the Fluorescently Labeled Id3 Protein 
Fragments 
A FRET active probe containing a donor/acceptor pair is characterized by the decrease 
in emission intensity of the donor in the presence of the acceptor, and can be quantified on 
the basis of the emission intensities of the donor in the presence and in the absence of the 
acceptor. The Id3 peptides containing the donor/acceptor pair Trp/Dns used in this study are 
summarized in Figure V.1. For each FRET peptide, two more analogues were synthesized, the 
first containing the donor (Trp) but not the acceptor (Dns) to measure the fluorescence of the 
donor in the absence of the acceptor, and the other reproducing the native Id3 sequence to 
examine the effect of the donor/acceptor pair on the conformation (Table V.1). The HLH 
domain (residues 41-81) adopts a stable helical conformation which should include about 
24 residues, as estimated from the CD spectrum. We have however shown that the N-terminal 
helix-1 and the C-terminal helix-2 have different intrinsic helix propensity, the former being 
unordered and the latter helical in solution (Chapter III). Thus, it is probable that helix-1 
becomes stable only upon interhelical contacts with helix-2, which leads to the HLH fold. To 
investigate such helix fold, the HLH peptide was labeled with a FRET pair (peptide V.1). We 
chose the Trp/Dns pair because of the relatively small size of the two fluorophores and the 
facile selective introduction during the solid-phase peptide synthesis. Indeed, if not naturally 
occurring, Trp can be added as a terminal residue or inserted in place of another naturally 
occurring hydrophobic amino acid (e.g. Tyr, Phe, Leu, Ile, Val), whereas the Dns group can 
be conjugated to the free N-terminus as well as to the side chain of a naturally occurring or 
properly introduced lysine residue. In our case, it was synthetically convenient to introduce 
Trp at the C-terminal position 82, which is naturally occupied by valine, whereas the Dns 
group was attached to the α-amino group of the N-terminal Gly-40, which was introduced as 
a short spacer between the fluorophore and the N-end of helix-1. Thus, while the native HLH 
sequence was not modified, the N- and C-ends became sterically more demanding and more 
hydrophobic than in the corresponding unlabeled peptide. 
To further investigate the HLH folding in the presence of the regions proximal to its N- and 
C-termini, we designed peptides V.2 and V.3, which contain the HLH motif, a 20-residue 
long N-tail or a 24-residue long N-tail together with a 20-residue long C-tail, respectively. 
In both peptides, Trp replaced the natural Tyr-76. The Dns group in peptide V.2 was intro-
duced as Lys(Nε-Dns) in place of the natural Ile-24. Lys-24 was first introduced as Lys(Nε-
Mtt), which allows the selective on-resin deprotection of the side chain by treatment with 
1% TFA in dichloromethane (DCM) in the presence of 1% TIS. Subsequent treatment of 
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the peptidyl-resin with Dns-Cl yielded the selectively labeled product. In case of peptide V.3, 
the Dns group was directly attached to the N-terminal residue Leu-17. The observation of 
FRET activity of these two analogues would suggest a close spatial arrangement between 
helix-2 and the N-terminal flanking region. 
Instead, peptides V.4-6 were designed to examine the HLH folding in the presence of the 
C-terminal domain. Similar to in peptide V.1, the Dns group was introduced at the N-terminal 
Gly-40, whereas the position of Trp varied: in peptide V.4 it was introduced as an additional 
C-terminal residue, whereas in peptides V.5 and V.6 it replaced Leu-84 and Tyr-76, 
respectively. 
82-11966-8157-6541-561-40
MKALSPVRGCYEAVCCLSERSLAIARGRGKGPAAEEPLSL40
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Figure V.1. Sequence and schematic representation of the Id3 protein domains (N-terminus, HLH motif and 
C-terminus) and of the fluorescently labeled fragments used in this study (the mutated positions are indicated in 
bold). 
Peptide chain assembly was performed under standard Fmoc solid-phase conditions, includ-
ing an initial loading of 0.6 mmol/g for Fmoc-His(trityl)-Wang resin (peptides V.5 and V.6) 
as well as for Rink amide MBHA resin (peptides V.1-4), double coupling of the Nα-Fmoc-
protected amino acids and activation in situ by HBTU/HOBt/DIPEA. The introduction of the 
Dns group was accomplished using its sulfonyl chloride derivative in the presence of DIPEA. 
After the synthesis was completed, cleavage from the solid support and removal of the side 
chain protecting groups were accomplished simultaneously by treatment with TFA in the 
presence of 10% scavengers. Crude products were purified by preparative RP-HPLC and 
characterized by analytical RP-HPLC and MALDI-TOF mass spectrometry (Table V.1). 
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Table V.1. Analytical data of the fluorescently labeled Id3 polypeptides V.1-6. 
Fluorescently labeled Id3 polypeptides 
Product Sequence MWcalcd. (Da) MWfound (Da) tR (min)a 
V.1 Dns-[G-40, W-82]-(40-82)-NH2 5273.2 5270.4 24.1 
V.1a Ac-[G-40, W-82]-(40-82)-NH2 5081.9 5085.3 22.6 
V.1b Dns-[G-40]-(40-81)-NH2 5086.9 5089.3 23.4 
V.2 Ac-[K(Dns)-24, W-76]-(21-81)-NH2 7062.2 7098.5b 23.6 
V.2a Ac-[K-24, W-76]-(21-81)-NH2 6828.9 6831.3 21.8 
V.3 Dns-[W-76]-(17-101)-NH2 9501.1 9502.6 22.2 
V.3a Ac-[W-76]-(17-101)-NH2 9309.8 9307.1 21.5 
V.4 Dns-[G-40, W-120]-(40-119)-NH2 9271.8 9273.5 23.1 
V.4a Ac-[G-40, W-120]-(40-119)-NH2 9080.5 9080.4 23.0 
V.5 Dns-[G-40, W-84]-(40-119)-OH 9159.6 9159.5 22.9 
V.5a Ac-[G-40, W-84]-(40-119)-OH 8968.3 8966.1 21.7 
V.6 Dns-[G-40, W-76]-(40-119)-OH 9109.6 9112.5 24.5 
V.6a Ac-[G-40, W-76]-(40-119)-OH 8918.3 8919.3 23.7 
a Gradient: 10% ACN for 3 min, 10-70% ACN in 40 min. 
b (M+K)+. 
 
V.3 CD Spectroscopy 
Secondary structure investigation of the synthesized Id3 peptides was performed by CD 
spectroscopy in phosphate buffer (0.1 M, pH 7.25). The impact of the fluorescence labeling 
on the conformation of the native sequence was examined by comparing the CD spectra of the 
mono-labeled (only Trp), double-labeled (both Dns and Trp) and unlabeled peptides. Athough 
flexibility of the N- and C-termini of the HLH peptide III.1 was assumed, their labeling to 
yield peptides V.1, V.1a and V.1b unexpectedly affected their properties. The double-labeled 
peptide V.1 was poorly soluble in phosphate buffer and required the addition of at least 15% 
TFE to be dissolved. Despite the presence of TFE, peptide V.1 gave a α-helix-like CD spec-
trum with very weak intensity in comparison to that of the native sequence III.1. Even the 
mono-labeled analogues V.1a and V.1b showed CD spectra with reduced intensity with re-
spect to the unlabeled peptide: especially the N-terminal labeling was found to significantly 
affect the helix stability, leading to a conformational transition from helix to β-strands and 
turns, whereas the presence of the aromatic residue at the C-end caused a more moderate helix 
destabilization (Figure V.2). The fact that the HLH peptide is sensitive to the modification of 
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its N- and C-ends supports the presence of a compact fold which includes also the peripheral 
residues. Indeed, it should be pointed out that the Id HLH motif exists in solution mostly as an 
oligomer (dimer), similarly to all bHLH domains [8, 9], in which the helix bundle requires an 
ideal juxtaposition of the helices. Taking this into account, the behavior of the N- and/or C-
terminally labeled Id3 HLH domain is likely to reflect an unfavorable helix packing as a con-
sequence of the increased steric hindrance at the periphery, leading to a misfolded state. 
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Figure V.2. CD spectra of the unlabeled (III.1) and fluorescence-labeled (V.1, V.1a and V.1b) Id3 HLH motif 
in phosphate buffer/TFE 85:15 (v/v). 
The conformation of the fluorescence-labeled analogues of peptide IV.8 (residues 21-81) and 
peptide IV.7 (residues 17-101) was examined. Peptides V.2 and V.2a gave CD curves similar 
to that of the unlabeled fragment 21-81, but were more intense and a slight blue-shift of the 
minimum close to 205 nm was observed, which was accompanied by a decrease in the 
intensity of the maximum (Figure V.3, left). This might be due to a negative effect of the 
substitution of Ile-24 with lysine in V.2a and lysine(Dns) in V.2, and/or to the substitution of 
Tyr-76 with Trp. However, despite the small differences in the dichroic data, the composition 
of secondary structure elements estimated with the CONTIN algorithm did not dramatically 
change within the peptides IV.8, V.2 and V.2a (Table V.2). 
In contrast, the mono- and double-labeled analogues of peptide IV.7 (residues 17-101) were 
both found to be much more helical than the unlabeled form (Figure V.3, right). The helix 
fraction increased at the expense of the β-strand fraction, which must be attributed exclusively 
to the substitution of Tyr-76 with Trp in helix-2, as the CD curves of the mono- and double-
labeled peptides were comparable in shape and intensity. It is interesting to note that Trp-76 
does not have such a significant influence on the conformation of the peptide V.2a, which 
suggests that the local environment around position 76 is different in peptides IV.7 and IV.8. 
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However, more striking is that the presence of the hydrophobic Trp residue not only increased 
the helicity of the Id3 fragment 17-101 (IV.7), but also allowed recovery of the helicity lost 
upon N-elongation of the sequence 41-101 (IV.5) to residue 17. Moreover, peptide V.3a 
tolerated the N-terminal dansylation, which just slightly enhanced the β-strand content 
(peptide V.3). Therefore, these last two peptides can be reasonably considered models of the 
Id3 HLH fold, whereas peptides V.2 and V.2a are rather models for a misfolded state. 
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Figure V.3. CD spectra of the unlabeled and fluorescence-labeled forms of the Id3 fragments 21-81 (IV.8, left) 
and 17-101 (IV.7, right) in phosphate buffer (0.1 M, pH 7.25). 
The conformation of the Id3 protein lacking the complete N-terminal domain (peptide 
II.3) has been described in Chapter II [5]. Here, we present fluorescence-labeled analogues of 
peptide II.3, which have been prepared to investigate the spatial arrangement of the long 
C-terminus with respect to the HLH motif. All peptides bear a Dns moiety at the N-end, 
whereas the position of the Trp residue has been moved along the sequence: peptides V.6 and 
V.6a contain the donor in place of Tyr-76, peptides V.5 and V.5a in place of Leu-84, and 
peptides V.4 and V.4a at the C-end as an additional residue. Surprisingly, the presence of Trp 
at the C-end induced a significant conformational transition at the expense of the helix 
structure, as indicated by the appearance of a broad negative CD band centered near 203 nm 
which characterized both the mono-labeled and double-labeled analogues V.4a and V.4 
(Figure V.4, top-left). This behavior suggests that the C-terminal tail is not completely flex-
ible or extended, but probably folds into a compact structure. It should be mentioned that with 
the introduction of the C-terminal Trp-amide, not only the ionizable carboxy-terminus was 
lost, but a bulky hydrophobic side chain was also present in a region otherwise rich in polar, 
acidic and basic side chains (S111NDKRSFCH119). Consequently, decreasing the polar 
character of the C-terminal tail might have compromised its stabilizing role. The C-terminal 
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residues 102-119 play a role in the folding as previously shown by comparing peptide IV.3 
(residues 57-101) with peptide II.2 (residues 57-119), and the latter was found to be much 
more helical than the former. 
When Trp was introduced in place of Leu-84, the double-labeled peptide V.5 exhibited a CD 
spectrum similar to that of the unlabeled peptide II.3, whereas the curve of the mono-labeled 
peptide V.5a was more intensive (Figure V.4, top-right). These observations are interesting, 
because they suggest that a fold with superior helicity as the one induced by the bulky hydro-
phobic Trp side chain at position 84 is not compatible with the presence of an as much bulky 
hydrophobic Dns group at the N-end. One explanation might be that Trp-84 allowed the 
helix-2 to be C-terminally prolonged, which led both helix-1 and helix-2 to rearrange in a way 
that was incompatible with the presence of bulky N-terminal groups.  
Unlike the Trp-84 containing peptides V.5 and V.5a, the corresponding Trp-76 containing 
analogues V.6 and V.6a were comparable with the unlabeled sequence II.3 (Figure V.4, 
bottom), thus providing a valuable fluorescent model for the Id3 HLH fold in the presence 
of the C-terminal domain. 
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Figure V.4. CD spectra of the N-terminally truncated Id3 protein II.3 and of its fluorescence-labeled analogues 
at ~ 30 µM concentration in phosphate buffer (0.1 M, pH 7.25). 
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Table V.2. Conformational properties of the fluorescence-labeled Id3 polypeptides V.1-6 and comparison with 
the corresponding unlabeled polypeptides III.1, IV.7-8 and II.3. 
% Secondary structure elements by CONTINb  
(no. of residues) 
Product No. of 
residues 
Concentration 
(µM) 
% Helix 
(no. of 
residues)a helix β-strand turns unordered 
V.1 43 12 9 (4) 11 (5) 35 (15) 21 (9) 33 (14) 
V.1a 43 16 28 (12) 35 (15) 18 (8) 17 (7) 30 (13) 
III.1 41 30 44 (18) 60 (25) 6 (2) 11 (5) 23 (9) 
V.1b 42 30 14 (16) 16 (7) 28 (12) 25 (10) 30 (13) 
V.2 61 11 18 (11) 21 (13) 25 (15) 22 (13) 32 (20) 
V.2a 61 12 23 (14) 26 (16) 20 (12) 22 (13) 32 (20) 
IV.8 61 30 21 (13) 29 (18) 21 (13) 19 (11) 31 (19) 
V.3 85 36 22 (19) 36 (31) 16 (13) 15 (13) 33 (28) 
V.3a 85 36 31 (26) 39 (33) 10 (9) 19 (16) 32 (27) 
IV.7 85 30 15 (13) 18 (15) 27 (23) 21 (18) 34 (29) 
V.4 81 26 15 (12) 14 (11) 24 (19) 24 (19) 38 (31) 
V.4a 81 31 28 (23) 12 (10) 4 (3) 30 (24) 54 (44) 
II.3 79 30 38 (30) 44 (35) 5 (4) 21 (17) 30 (24) 
V.5 80 30 35 (28) 38 (31) 9 (7) 20 (16) 33 (26) 
V.5a 80 30 50 (40) 59 (47) 3 (2) 16 (13) 22 (18) 
V.6 80 30 31 (25) 35 (28) 11 (9) 22 (17) 32 (26) 
V.6a 80 30 41 (33) 41 (33) 5 (4) 23 (18) 31 (25) 
a The helix percentage was estimated by the ellipticity value at 222 nm using the procedure of Chen and Yang [10].
b The CD spectra were analyzed by the CONTIN algorithm. 
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V.4 Fluorescence Spectroscopy 
The labeled peptides were studied by fluorescence spectroscopy in phosphate buffer 
(0.1 M, pH 7.25) at 5 µM concentration. The emission spectra were collected upon excitation 
of the Trp side chain at 295 nm at 25 °C. The emission peak of Trp was centered at 350 nm, 
whereas that of the Dns moiety was observed around 500 nm when FRET occurred. 
The fluorescence intensities of Trp in the mono-labeled analogue (in the absence of the 
Dns group), FD, and in the corresponding double-labeled analogue (in the presence of the Dns 
group), FDA, were used to calculate the FRET efficiency E, applying the following formula: 
 
%1001 ×⎟⎟⎠
⎞
⎜⎜⎝
⎛ −=
D
DA
F
FE Eq. V.1
 
Obviously, the E values are reliable only if the difference in the Trp emission observed be-
tween the mono- and double-labeled analogues exclusively depends on the proximity of the 
acceptor and not on other factors, such as changes in the local environment of the Trp side 
chain. To gain further insight in the conformation of the Id3 fragments, it is necessary that 
the introduction of the fluorescent labels is not accompanied by dramatic structural changes. 
Based on the CD data discussed above, this did not unfortunately hold true for all fluores-
cence-labeled peptides synthesized: for example, the chemical and structural properties of the 
mono- and, particularly, of the double-labeled analogues of the HLH fold (V.1, V.1a and 
V.1b) were completely different from those of the unlabeled form (III.1), which makes them 
useless as Id3 HLH models. Moreover, the mono- and double-labeled peptides were not 
structurally similar, which prevents the estimation of the FRET efficiency observed in the 
double-labeled peptide V.1 (Figure V.5, left). Indeed, the reduced emission of Trp in the 
presence of Dns (indicated by the red arrow) might reflect either FRET or a different local 
environment of Trp, as the composition of secondary structure elements of the mono- and 
double-labeled sequences vary significantly. However, the double-labeled peptide is obvi-
ously FRET active, as the emission of Dns could be clearly detected (indicated by the green 
arrow). Interestingly, an equimolar mixture of the two peptides labeled only with the donor 
(V.1a) or acceptor (V.1b) did not show any intermolecular FRET (Figure V.5, right); this 
suggests not only that the FRET observed for peptide V.1 occurred intramolecularly, but also 
that the mono-labeled species were not able to dimerize, thus supporting the idea that the 
presence of sterically demanding N- and C-ends is incompatible with the formation of a stable 
HLH dimer.  
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Figure V.5. Fluorescence spectra of the peptides V.1a, V.1b and V.1 (each 5 µM, left) and of the equimolar 
mixture of V.1a and V.1b (each 5 µM) compared to the arithmetic sum of the two single spectra (right). Spectra 
were recorded in phosphate buffer/TFE 85:15 with an excitation wavelength of 295 nm at 25 °C. 
As discussed above, peptide IV.8 can be considered a misfolded state of the Id3 HLH 
motif, in which the number of α-helical and β-strand residues was comparable. Analysis of 
the corresponding fluorescent analogues V.2a and V.2 revealed no FRET between Trp-76 
and Lys(Dns)-24 (Figure V.6, left). However, the presence of a non-negligible Dns emission 
might reflect an energy transfer involving Tyr-48. These data suggest that the N-terminal tail 
and helix-2 are far away from each other in peptide V.2, as a consequence of the loss of the 
HLH fold. 
In contrast to the unlabeled Id3 fragment 17-101 (peptide IV.7) which displayed a mis-
folded state rich in β-strands, the corresponding mono- and double-labeled peptides V.3a and 
V.3 were characterized by a number of helical residues similar to that found for the Id3 frag-
ments 41-101 (IV.5), 41-119 (II.3) and even the full-length Id3 protein, this indicates that the 
HLH fold is present again. Therefore, they can be used as fluorescent tools for the study of 
a “miniaturized” Id3 protein shortened at its N- and C-tails. Emission of  Trp in the double-
labeled peptide V.3 turned out to be much lower than in the mono-labeled peptide V.3a, and 
a pronounced emission band was detected in the Dns region (Figure V.6, right). This indicates 
that peptide V.3 is FRET active, with an efficiency of 49% which would correspond to 
a donor-acceptor distance RDA of ~ 25 Å, as calculated by the following equation: 
 
6
0 1
1 −×=
E
RRDA Eq. V.2
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where R0 is the Förster radius that is equal to 24.5 Å for the FRET pair Dns-Trp in phosphate 
buffer (0.1 M, pH 7.25) at 25 °C [11]. 
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Figure V.6. Fluorescence spectra of the peptides V.2a and V.2 (left) and V.3a and V.3 (right) (each 5 µM). 
Spectra were recorded upon excitation at 295 nm in 0.1 M phosphate buffer (pH 7.25) at 25 °C. 
Among the fluorescence-labeled analogues of the Id3 fragment 41-119 (II.3), those 
having Trp at position 76 in the presence and in the absence of the Dns group (peptides V.6 
and V.6a) were the only ones which maintained a conformation similar to that of the un-
labeled peptide. In contrast, among analogues containing Trp-84, only the double- 
labeled one (peptide V.5) was comparable to the unlabeled form, whereas the mono-labeled 
one (peptide V.5a) showed increased helicity. This means that peptide V.5 can be used as 
a fluorescent model for the unmodified sequence, but even if FRET occurs, it is not possible 
to estimate its efficiency, as the Trp environment is probably different in the mono- and 
double-labeled species. The two peptides V.4 and V.4a bearing Trp-amide at the C-end were 
useless for further studies on the Id3 fragment 41-119, as they were mostly disordered. 
Both double-labeled peptides V.5 and V.6 showed a pronounced emission maximum in 
the Dns region, accompanied by a reduction of the emission maximum in the Trp region 
(Figure V.7). Using equations V.1 and V.2, a FRET efficiency of 77% and a distance of 
~ 20 Å between the N-terminal Dns group and Trp-76 were calculated. No estimation of the 
distance between the N-terminal Dns group and Trp-84 could be done, due to the reason 
discussed above. 
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Figure V.7. Fluorescence spectra of the peptides V.5 and V.5a (left, each 5 µM), and V.6 and V.6a (right, each 
5 µM). Spectra were recorded upon excitation at 295 nm in 0.1 M phosphate buffer (pH 7.25) at 25 °C. 
V.5 Discussion and Conclusion 
The Id3 HLH motif (residues 41-81) represents a highly compact structure which can 
apparently be disturbed by the insertion of a Trp residue at the C-end (corresponding to posit-
ion 82, in which a valine residue is naturally present). The impact of a sterically demanding 
aromatic moiety located at the very end of the helix-2 was actually unexpected, as the tails of 
peptide helices display in general high flexibility, which should allow the accommodation 
of large groups. In Chapter III we have discussed the intrinsic helix propensity of helix-2. 
Helical wheel projection of the Id3 fragment 66-81 (corresponding to helix-2) predicts an 
amphipathic character with a wide and continuous hydrophobic surface (the only polar 
residues are located at the margins of the surface, being Gln-66 and Gln-81), and by the 
hydrophilic face including Glu-68, Gln-71, Arg-72, Asp-75 and Asp-79 (Figure V.8). The 
length and angle of the hydrophobic moment µ of the helix are 5.33 and 10.4. The length of 
µ can be related to the helix stability: the higher the length of µ, the more stable is the helix. 
Orientation of µ can reveal information about the helix packing. Elongation of the helix-2 by 
the residue 82 has not much influence on µ in the case of the natural Val-82, but it has 
a dramatic effect in the case of Trp-82, which leads to a decrease in the length of µ and 
change of the angle. Thus, peptides V.1 and V.1a likely contain not only a less stable helix-2 
due to its lowered amphipathic character, but also a different packing between helix-1 and 
helix-2, which is apparently less favorable than that in peptide III.1. 
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Figure V.8. Helical wheel projections of the Id3 fragments reproducing helix-2, residues 66-81 (left), and its 
elongation by residue 82 (indicated by underlined residue) as the natural Val (middle) or Trp (right). The 
projections have been created with the program available online [12] (hydrophilic residues as red circles, 
hydrophobic residues as diamonds, potentially negatively charged as triangles, and potentially positively charged 
as pentagons. Hydrophobicity is color coded as well: the most hydrophobic residue is green, and the amount of 
green is decreasing proportionally to the hydrophobicity, with zero hydrophobicity coded as yellow. Hydrophilic 
residues are coded red with pure red being the most hydrophilic (uncharged) residue, and the amount of red 
decreasing proportionally to the hydrophilicity. The potentially charged residues are light blue). The arrow inside 
the wheel represents the hydrophobic moment of the helix, µ (the numbers refer to the length/angle of µ). 
Even more surprising than the impact of Trp-82 on the conformation of the Id3 HLH fold was 
that of the N-terminal Dns group (cf. peptide V.1b). In Chapter III we have already described 
poor intrinsic helix propensity of helix-1, which is actually disordered in solution. Labeling of 
its N-end through a glycine residue as a short spacer should have therefore been tolerated. In-
stead, the effect of the N-terminal Dns group was significantly more deleterious than that of 
the C-terminal Trp residue, leading to an almost complete loss of helicity (cf. peptides V.1 
and V.1b in Table V.2). The high sensitivity of the N- and C-ends of the Id3 HLH peptide to 
primary structure mutations suggests that they are not flexible tails of a compact core, but 
rather stabilize the folding. 
Interestingly, the labeling of the N-end of the Id3 HLH motif was tolerated in the case of 
the larger fragment reproducing the HLH region and the complete C-terminus (peptides V.5 
and V.6). This different behavior between the short HLH peptide and the C-terminally elong-
ated analogues might be explained by the fact that the latter folded into a less compact struc-
ture, in which the N-terminal Dns groups can be easily located. These analogues displayed 
FRET activity between the Trp residue at position 76 or 84, and the N-terminal Dns group. 
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The distance calculated by the measured FRET efficiency and the Förster radius was ~ 20 Å 
between the N-end and Trp-76. Considering the crystal structure of the DNA-bound MyoD 
dimer, this distance is slightly shorter than those measured intra- and intermolecularly 
between the N-end of the MyoD helix-1 (Arg-121, corresponding to Id3 Leu-40) and Tyr-156 
of the helix-2 (corresponding to Id3 Tyr-76), which are ~ 26 Å and ~ 22 Å, respectively 
(Figure V.9). The Id3 HLH dimer probably adopts more compact structure than the DNA-
binding MyoD dimer. 
 
Figure V.9. View of the four-helix bundle of the MyoD bHLH motif bound to the DNA (PDB ID: 1MDY) [13]. 
Each subunit corresponds to the MyoD residues 121-161. The side chain of Tyr-156, which corresponds to 
Tyr-76 of the Id3 HLH motif, is shown. The distances have been measured by using the α-carbon atom of 
Arg-121 (Id3 Leu-40) and the β-carbon of Tyr-156 (Id3 Tyr-76). 
The modification of C-terminus by amidation with Trp-amide caused a dramatic effect 
on spatial arrangement, which indicates that the C-end of the Id3 protein is important. The 
design and synthesis of other fluorescent analogues of the Id3 fragment 41-119 are necessary 
to analyze the structural role of this flanking region. 
FRET properties of the Id3 fragment 17-101, which reproduces the HLH motif preceded 
and followed by two flanking regions (peptide V.3), suggest that the flanking region N-terminal 
to the HLH motif is not extended but rather folded toward the HLH core, as the distance 
between positions 17 and 76 in peptide V.3 was only ~ 5 Å longer than the distance between 
positions 40 and 76 in peptide V.6. 
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Summarizing the results presented above, it can be concluded that the Id3 HLH fold 
adopts a compact structure in which the helix packing should be similar to that found for the 
MyoD HLH fold. Moreover, the region N-terminal to the HLH domain is likely to build an 
inverse loop that brings position 17 in proximity of the beginning of helix-1 (Figure V.10). 
 
Figure V.10. Proposed model of the Id3 dimer based on the FRET analogues. 
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VI. Synthetic Studies on Id3 Peptide Thioesters as Tools for Native 
Chemical Ligation 
VI.1 Introduction 
The solid-phase methodology is widely applied for the chemical synthesis of peptides 
and protein fragments. In general, the number of amino acid residues that can be assembled in 
a stepwise manner is around 50, but there are also examples of larger polypeptides, including 
the 119-residue long Id3 protein shown in Chapter II. The success of a solid-phase synthesis 
is strongly related to the amino acid sequence which can be classified as “good” or “difficult”, 
depending on the degree of homogeneity of the crude product. The most critical problem in 
stepwise SPPS is the incompleteness of coupling and deprotection reactions, which are very 
often caused by the formation of aggregates of the growing peptide chains. Accordingly, se-
quences predicted to form β-sheets are usually difficult to prepare. The amino acid compos-
ition also plays a role: the presence of a considerable number of β-branched amino acids like 
Val, Ile, Leu, Thr, as well as of Arg and Lys can compromise the synthesis. 
When the desired peptide chain length can not be reached by stepwise SPPS, an alternative is 
the use of the peptide fragment condensation in solution. However, one disadvantage of this 
approach is the fact that the two fragments must be fully-protected to allow a regioselective 
reaction between the C-end of one fragment and the N-end of the second fragment. As the 
purification of fully-protected peptides by preparative RP-HPLC is not easily practicable, the 
solution condensation is mostly limited to those cases, where the crude fully-protected species 
are obtained with good homogeneity. Another problem in the condensation of peptide frag-
ments is the high risk of epimerization of the α-carbon of the activated C-end. An alternative 
to the latter method is represented by the so-called native chemical ligation (NCL) of un- 
protected peptides [1-3]. This procedure does not require coupling reagents or protection 
schemes, but is achieved through a reversible chemoselective capture step followed by an 
irreversible intramolecular acyl transfer. NCL involves the reaction of two unprotected pep-
tides, the first in form of a C-terminal thioester and the other one having an N-terminal Cys, 
which eventually leads to a naturally occurring amide bond at the ligation site [4]. The peptide 
segments react by means of a reversible thiol/thioester exchange to give the initial thioester-
linked product. The latter spontaneously undergoes an irreversible nucleophilic rearrangement 
by a highly favored intramolecular mechanism which results into the final amide-linked prod-
uct (Scheme VI.1). The reaction is performed in aqueous solution at neutral or lightly basic 
76 VI. SYNTHETIC STUDIES ON ID3 PEPTIDE THIOESTERS AS TOOLS FOR NCL 
 
pH, and generally under denaturing conditions. Folding-assisted NCL has been used in special 
cases to accelerate the ligation step [5]. Although the ligation step is usually accomplished in 
solution, some examples are reported in the literature, in which one of the two segments is 
bound to a water-compatible resin (e.g. cellulose), while the other is applied in aqueous 
solution [6].  
Scheme VI.1. NCL between a C-terminal polypeptide thioester and an N-terminal Cys-containing polypeptide. 
 
Expressed protein ligation (EPL), also called intein-mediated protein ligation, is a vari-
ant of NCL [7-9]. The difference arises from the preparation of the C-terminal thioester: in the 
NCL, it is obtained by chemical methods, whereas in the EPL it is first expressed as a protein 
fused to a mutated intein which is then subjected to an intramolecular N→S acyl shift and an 
intermolecular transthioesterification.  
One disadvantage of the NCL and EPL methods is the necessity of a Cys residue at the liga-
tion site [10]. The occurrence of this amino acid in globular proteins is very low and the inser-
tion of additional Cys residues can alter the protein structure and function by the formation of 
unnatural disulfide bridges. Thus, a lot of efforts have been made to develop strategies which 
do not require an N-terminal Cys residue at the ligation point, including the use of removable 
N-terminal thiol auxiliaries, such as the mercaptoethoxy- [11] and the mono- or dimethoxy-
substituted 2-mercaptobenzyl group [2, 12] (Scheme VI.2.).  
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Scheme VI.2. Thiol auxiliary ligation (HS-X: mercaptoethoxy-, mono- or dimethoxy-substituted benzyl thiol 
auxiliary). 
 
Another elegant ligation method has been inspired by the Staudinger reaction, in which 
a phosphine is used to reduce an azide to an amine [13-15]. In this method a peptide bearing 
a C-terminal phosphinothioester is coupled to another peptide with an N-terminal α-azido 
group to form an intermediate iminophosphorane that possesses a nucleophilic nitrogen cap-
able of intramolecular reaction with an acyl donor and give the desired amide bond (Scheme 
VI.3). This method may also be combined with the classic NCL for tandem ligation re- 
actions [16, 17].  
Scheme VI.3. The Staudinger ligation. 
 
The principle of classical Cys ligation has been successfully extended to obtain an 
Ala [18] or a Met residue at the ligation site [2, 19]. The Ala residue, which is highly frequent 
in peptides and proteins, is chosen for the ligation site and substituted with a Cys residue. 
After classical NCL, the Cys side chain is converted to a methyl group by desulfurization 
using palladium or Raney-nickel and hydrogen. In the Met ligation, homo-Cys instead of Cys 
78 VI. SYNTHETIC STUDIES ON ID3 PEPTIDE THIOESTERS AS TOOLS FOR NCL 
 
is used for the transthioesterification step. After the S→N-acyl migration through a favorable 
six-membered ring transition state to form the homo-cysteinyl product, an additional S-
methylation step follows.  
The His ligation has been also proposed, as the imidazole group of the His side chain 
can be an alternative nucleophile to the thiol group [2, 20]. In this strategy, the acyl segment 
which bears the thioacid is activated by a thiophilic promoter (e.g. Ellman’s reagent) and then 
captured by the imidazole of an N-terminal His, subsequently leading to the Nim→Nα-acyl 
transfer to form a peptide bond (Scheme VI.4).  
Scheme VI.4. The His ligation.  
 
The folding-assisted protein ligation using C-terminal peptide thioesters is another ex-
ample of Cys-free ligation [5]. In this case, the protein conformation determines the regio-
selective coupling reaction, provided that the protein is able to correctly fold in a noncovalent 
manner.  
VI.2 Chemical Synthesis of C-Terminal Peptide Thioesters 
C-terminal peptide thioesters are essential intermediates for chemical ligation [21]. 
They are typically prepared either by SPPS [22] or biosynthetically, especially in the case 
of large thioesters, by the intein technology [23]. To avoid the uncomfortable Boc chemistry 
which requires the use of strong acids like HF to remove the peptide from the solid support, 
several research groups have recently explored the possibility of applying the Fmoc chemistry 
for the preparation of thioesters. One problem that must be solved is the lability of the 
thioester bond toward bases; this means that the repetitive treatment with piperidine to cleave 
the Fmoc protecting group [24] is not compatible with the presence of a C-terminal thioester 
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bond. Nonetheless, the Fmoc/t-Bu strategy would offer some advantages with respect to the 
Boc/benzyl one, including the possibility to achieve milder overall reaction and cleavage con-
ditions, the compatibility with a variety of solvents and solid supports, and the real-time UV 
monitoring of the reactions. In contrast to the Boc methodology, the Fmoc methodology also 
provides the synthesis of phospho- and glycopeptides in good yields [25]. Fmoc-chemistry-
based protocols for the preparation of peptide thioesters are now available, which include the 
use of new cleavage cocktails and different types of resin-linkers [21]. For example, the non-
nucleophilic but strongly basic diazabicyclo[5,4,0]-undec-7-ene (DBU) in conjunction with 
N-hydroxybenzotriazole (HOBt) has been shown to be able to remove efficiently the Fmoc 
group without causing aminolysis of the thioester bond [26, 27].  
Solid-phase synthesis using a backbone amide linker (BAL) strategy relies on the an-
choring of the first amino acid protected at the α-carboxylic group as allyl ester to the linker 
by reductive amination [28, 29]. After peptide chain assembly, the orthogonal allylic protect-
ion is removed and the free carboxylic acid is coupled to an amino acid thioester. The final 
cleavage/deprotection step releases the peptide thioester in solution. However, this procedure 
has the disadvantage that a diketopiperazine (DKP) can be formed at the dipeptide stage and 
that the C-terminal residue can epimerize upon coupling with the thioester. To prevent the 
formation of DKP, an amino trithioorthoester derived from Gly can be first anchored to the 
linker by reductive amination [30]. As the trithioorthoester is not susceptible to nucleophilic 
attack, the formation of DKP is avoided. After standard Fmoc-based assembly of the peptide, 
treatment of the peptidyl-resin with TFA leads directly to the corresponding peptide thioester. 
One limitation of this procedure is the fact that only C-terminal Gly thioesters can be synthe-
sized.  
Similarly to the BAL strategy, the side chain anchoring of Fmoc-Glu-allyl or Fmoc-Asp-allyl 
to hydroxyl or amine linkers has also been used for the solid-phase synthesis of thioesters as 
well as of circular peptides [31-34]. Deprotection of the allyl group is achieved by treatment 
of the peptidyl-resin with tetrakis(triphenylphosphine)palladium in the presence of N-methyl-
morpholine or phenylsilane (Scheme VI.5) [34].  
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Scheme VI.5. Side chain anchoring strategy combined to thioesterification on the solid support (PG: protecting 
group). 
 
C-terminal peptide esters anchored to Wang or PAM resins have been converted into thio-
esters by treatment with an excess of Me2AlCl/RSH before TFA cleavage [35]. In this way, 
the use of special linkers is not required; however, epimerization of the C-terminal amino acid 
currently limits this application to the preparation of peptide thioesters having a C-terminal 
Gly [36]. 
Sophisticated linkers have been also developed for the synthesis of peptide thioesters using 
Fmoc chemistry. One example is the aryl hydrazine safety-catch linker which, at the end of 
the peptide chain assembly, can be activated by mild oxidation with N-bromosuccinimide in 
the presence of pyridine in DCM [37]. The reactive acyl diazene is then efficiently cleaved 
with an amino acid S-alkyl thioester to yield the corresponding fully-protected peptide thio-
ester. Subsequent side chain deprotection with TFA provides the desired peptide thioester.  
In the case of the Kenner’s sulfonamide safety-catch linker [38], the C-terminus of the 
growing peptide chain is anchored to the resin via an N-acyl-sulfonamide which is stable both 
in basic and strongly nucleophilic reaction conditions. The first Fmoc-amino acid is attached 
to the sulfonamide resin using PyBOP/DIPEA at low temperatures to avoid racemization [39], 
or using the acyl fluoride that has been shown to give high loading in short times [40]. The N-
acyl-sulfonamide is preactivated after peptide synthesis by N-alkylation with trimethylsilyldi-
azomethane or iodoacetonitrile [25, 41], followed by thiolysis (Scheme VI.6). 
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Scheme VI.6. The sulfamylbutyryl (SAB) safety-catch resin and its application to the synthesis of C-terminal 
peptide thioesters (PG: protecting group). 
 
C-terminal peptide thioesters can be prepared also in solution using protected peptides [42]. 
The peptide is first assembled on the highly acid-labile 2-chlorotrityl chloride resin. After 
cleavage with diluted acid, the free C-terminal carboxylic group of the otherwise fully-
protected peptide undergoes thioesterification with the appropriate thiol using DIC and 
HOBt as activating reagents [43]. Final treatment of the product with concentrated TFA 
provides the fully-unprotected peptide thioester (Scheme VI.7).  
Scheme VI.7. Thioesterification of protected peptides in solution. (PG: protecting group, TIS: triisopropyl-
silane). 
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Before the stepwise solid-phase synthesis of the Id3 protein was achieved, we also con-
sidered the possibility of using the NCL approach, if the assembly of large fragments or of the 
entire Id3 sequence had been prevented by incomplete acylation/deprotection reactions during 
the chain growth. Here, we present the results of a synthetic study of peptide thioesters related 
to Id3 fragments.  
VI.3 Synthesis of Id3 Polypeptide Thioesters 
The Id3 protein contains five natural Cys residues at positions 10, 15, 16, 47 and 118; 
however, the only Cys residue that may be suitable for a NCL procedure is Cys-47, as pos-
itions 10, 15, 16 and 118 are too close to the termini, thus providing no benefit. Alternatively, 
beside the Cys-mediated ligation, also the thiol auxiliary- or His-mediated ligations may be 
considered. To evaluate the synthetic accessibility of peptide thioesters for their use in NCL 
experiments, we decided to prepare a number of Id3 fragments to be converted into thioesters 
either in solution (method a) or on the solid support (methods b and c). The Id3 peptide thio-
esters which have been prepared in this study are reported in Table VI.1. We took short (up to 
16 residues), medium (up to 29 residues) or large portions (up to 46 residues) of three Id3 
subdomains (the HLH motif and the N- and C-termini), in order to test sequences which 
exhibit various difficulties. We also analyzed the influence of the thiol on the thioesterifi-
cation reaction and on the stability of the final thioester: 3-mercapto-propionic acid ethyl ester 
(HSPAE), benzylmercaptane (HSBn) and p-acetamidothiophenol (HSPAA) were used. 
VI.3.1 Thioester Formation in Solution (Method a) 
Three different Id3 sequences were used to accomplish the synthesis of the correspond-
ing thioesters in solution: 1-46, 41-56 and 48-56. The sequences were first assembled on a 2-
chlorotrityl resin, from which they were cleaved as fully-protected C-terminal peptide acids. 
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Table VI.1. Analytical data of the synthetic Id3 polypeptide thioesters. 
Human Id3a 
M1KALSPVRGCYEAVCCLSERSLAIARGRGKGPAAEEPLSL40 
LDDMNHCYSRLRELVP56GVPRGTQLS65QVEILQRVIDYILDLQ81 
VVLAEPAPGPPDGPHLPIQTAELAPELVISNDKRSFCH119 
Synthetic Id3 peptide thioesters 
Method Peptide Sequence MWcalcd. 
(Da) 
MWfound 
(Da) 
tR 
(min)b 
VI.1 H-(1-46)-SPAE 5032.9 5034.3 17.1 
VI.2 H-(1-46)-SBn 5022.9 5022.6 16.6 
VI.3 H-(1-46)-SPAA 5065.9 4895.0c ca. 15 
VI.4 Ac-(41-56)-SPAE 2119.5 2119.0 17.9 
VI.5 Ac-(48-56)-SPAE 1290.6 1290.5 16.4 
a 
VI.6 Ac-(48-56)-SBn 1280.6 1279.7 17.5 
VI.7 Ac-(17-45)-SPAE 3225.7 3225.5 15.2 
VI.8 Ac-(17-45)-SBn 3215.7 3216.0 16.9 
VI.9 Ac-(17-45)-SPAA 3258.8 3256.9 14.8 
VI.10 H-(82-112)-SPAE 3258.8 3256.9 17.7 
VI.11 H-(82-112)-SBn 3248.8 3251.6 19.2 
VI.12 Ac-(41-79)-SBn 4704.5 4702.6 23.4 
b 
VI.13 Ac-[γ-Glu(α-C(O)NH2)-63]-(41-63)-SBn 2805.3 2807.7 16.5 
VI.14 Ac-[Cys(StBu)-47]-(41-61)-SBn 2574.2 2574.8 ndd 
c 
VI.15 Ac-[Cys(StBu)-47]-(38-57)-SBn 2480.0 2479.9 ndd 
a Underlined sequences: helix-1 (41-56) and helix-2 (66-81); double underlined sequence: loop (57-65). The 
positions chosen as the C-terminal thioesters are indicated in bold. 
b  Gradient: 10% ACN for 3 min, 10-70% ACN in 40 min. 
c The peptide corresponds to a mixture of cyclic isomers obtained by aminolysis/thiolysis of the thioester. 
d nd: not determined. 
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To control the quality of the peptide chains after SPPS, a small portion of each peptide 
was cleaved from the resin and simultaneously fully-deprotected. Whereas the short 
sequences 41-56 and 48-56 exhibited good homogeneity, the larger sequence 1-46 was 
contaminated by a conspicuous amount of impurities. As the peptide contains air-sensitive 
amino acids (three Cys and two Met residues), the crude product was treated with DTT to 
reduce potential disulfide bonds; however, the HPLC profile did not change, thus excluding 
the presence of byproducts due to Cys oxidation. By contrast, when the crude product was 
treated with TMSBr/EDT/TFA to reduce potentially oxidized Met residues, one of the two 
major HPLC peaks was significantly reduced, thus confirming the presence of a large amount 
of sequences containing Met(O) (Figure VI.1).  
 
Figure VI.1. HPLC profile of the crude Id3 peptide acid H-(1-46)-OH as obtained after TFA cleavage (A) and 
upon additional treatment with DTT (B) or with TMSBr/EDT/TFA for partial Met(O) reduction (C). The arrows 
indicate the peaks corresponding to the sequences containing oxidized Met. 
It should be pointed out that the poor homogeneity of the fully-deprotected sequence 1-46 
might not reflect the quality of the peptide chain bound to the resin, as a large number of by-
products can be formed during the cleavage step with concentrated TFA. Thus, we decided to 
convert the fully-protected sequence 1-46 into the corresponding thioesters (peptides VI.1-3). 
The peptide acid was activated by DIC/HOBt in DCM and then treated with the thiol. The 
formation of the thioester was monitored by analytical RP-HPLC and MALDI-TOF mass 
spectrometry. It was observed that the rate of the thioesterification increased with the nucleo-
philic character of the thiol: HSPAE < HSBn < HSPAA. When the reaction was completed 
(after 2 days with HSPAA, 4 days with HSBn and 10 days with HSPAE), the side chain pro-
tecting groups were cleaved using TFA with 10% (v/v) scavengers, and the obtained crude 
products were analyzed by RP-HPLC and MALDI-TOF mass spectrometry. In all three cases, 
the desired peptide thioester could be detected, and the crude products were thus subjected to 
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preparative RP-HPLC. The peptide thioesters VI.1 and VI.2 could be obtained with good 
purity, whereas the fraction isolated for the thioester VI.3 showed a complex analytical HPLC 
profile (Figure VI.2). Moreover, mass spectrometry analysis revealed that no peptide thioester 
was present, but rather a mixture of isomers with a molecular mass smaller than the one ex-
pected for the thioester and also for the initial acid. The mass difference was attributed to the 
loss of the SPAA moiety upon intramolecular nucleophilic attack by an amino group (N-
terminus or Lys side chain) or a thiol group from one of the three internal Cys residues. Such 
cyclization must have taken place during the preparative HPLC steps (probably during evap-
oration of acetonitrile from the isolated fractions before freezing and lyophilization).  
 
Figure VI.2. HPLC profiles of the Id3 peptide thioesters H-(1-46)-SPAE (A) and H-(1-46)-SBn (B) after 
preparative RP-HPLC, and of the cyclic isomers of the Id3 sequence 1-46 obtained by aminolysis/thiolysis of the 
corresponding thioester VI.3 during purification by preparative RP-HPLC (C). 
These results have shown that HSPAA has the advantage of forming moderately quickly the 
corresponding thioester, which is however very reactive and highly sensitive to the presence 
of nucleophiles. Therefore, its use should be combined with masked side chains for Cys and 
Lys as well as with a protected N-terminus.  
The preparation of the thioesters VI.4-6 in solution went smoothly, as shown by the HPLC 
profiles of the crude products (the HPLC profile of the crude peptide VI.5 is reported in 
Figure VI.3A as an example), which were then purified by preparative RP-HPLC (Figure 
VI.3B-C).  
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Figure VI.3. HPLC profiles of Ac-(48-56)-SPAE before purification (A), and of Ac-(48-56)-SBn (B) and Ac-
(41-56)-SPAE (C) after purification. 
VI.3.2 Thioester Formation on the Solid Support (Methods b and c) 
The thioester formation on the solid support brings the advantage of avoiding the hand-
ling of fully-protected peptide intermediates in solution. We used two different approaches, 
the first based on the side chain anchoring of the C-terminal amino acid to the resin (method 
b), and the other based on the application of a safety-catch resin linker (method c).  
With the method b, we synthesized the Id3 peptide thioesters VI.7-13. The amino acid se-
quences 17-45 and 82-112 were first assembled on Rink amide resin preloaded with Fmoc-
Asp-OAll, to obtain the native Asn-45 and Asn-112, respectively, after the resin cleavage. 
The sequence 41-79 was assembled on Wang resin preloaded with Fmoc-Asp-OAll, to obtain 
the native Asp-79 after the resin cleavage. Finally, the sequence 41-63 was assembled on 
Rink amide resin preloaded with Fmoc-Glu(OAll)-OH, to obtain an unnatural γ-amino acid 
residue at position 63, in place of Gln, after the resin cleavage (such backbone modification 
might be useful to design an Id3 HLH analogue with an altered loop structure). After the pep-
tide chain assembly was completed, the allyl group was removed by Pd(PPh3)4 and PhSiH3 or 
N-methylmorpholine in DCM. The free acid was then activated with DIC/HOBt and treated 
with the desired thiol. The reaction ran for 18 hours, and the peptide thioester was then 
cleaved from the resin, purified by preparative RP-HPLC and characterized by analytical 
RP-HPLC and MALDI-TOF mass spectrometry. The RP-HPLC and mass spectrometry data 
indicated that the crude products obtained from the syntheses of VI.7-9 were contaminated by 
a large fraction of Met(O)-44-containing chains, and an additional reductive treatment was  
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therefore carried out before purification (Figure VI.4). It is worthwhile to note that the PAA 
thioester of the N-acetylated Id3 sequence 17-45 (peptide VI.9) was found to be stable 
enough during purification, in contrast to the PAA thioester of the Id3 sequence 1-46 (VI.3). 
This confirms the sensitivity of the PAA thioester towards free Cys side chains and the N-
terminus, whereas the unmasked Lys side chain does not seem to cause aminolysis of the 
PAA thioester.  
 
Figure VI.4. HPLC profiles of the crude Id3 peptide thioesters Ac-(17-45)-SR, whit R = PAE (A), Bn (B) and 
PAA (C). (D) HPLC profile of Ac-(17-45)-SPAE after reduction of Met(O)-44. The arrows indicate the peaks 
corresponding to the peptide fraction containing the oxidized Met. 
The other peptide thioesters VI.10-13 were obtained with high homogeneity even as crude 
products (Figure VI.5). Interestingly, Met-44 was not oxidized during the syntheses of pep-
tides VI.12-13, contrarily to the observation during the syntheses of peptides VI.7-9. This 
may be explained by the fact that Met-44 remained exposed to air for much longer time 
during the latter syntheses. 
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Figure VI.5. HPLC profiles of the following Id3 peptides: (A) H-(82-112)-OAll (crude), (B) H-(82-112)-OH 
(crude), (C) H-(82-112)-SPAE (purified), (D) H-(82-112)-SBn (crude), (E) Ac-(41-79)-SBn (purified) and (F) 
Ac-(41-63)-SBn (purified). 
By contrast, the two syntheses carried out with the method c using the safety-catch resin 
linker SAB did not run smoothly. The desired peptide thioesters VI.14-15 were obtained 
as minor products accompanied by abundant and complex byproducts which could not be 
identified by mass spectrometry analysis (Figure VI.6).  
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Figure VI.6. HPLC profiles of the crude products obtained from the syntheses of peptides VI.14 (A) and 
VI.15 (B).  
VI.4 Conclusion  
Thioester formation and subsequent chemical ligation is an alternative method to the 
stepwise SPPS to prepare large Id3 protein fragments or even the full-length protein. Three 
different kinds of peptide thioesters were prepared (R-SPAE, R-SBn and R-SPAA) by three 
different thioesterification routes. The most effective one was the thioesterification on the 
solid support with anchored side chain of the C-terminal residue: indeed, the reaction was fast 
and clean and the work-up was easy.  
It should be kept in mind that sequences containing unmasked thiol and amino groups could 
be critical because of intramolecular transthioesterification or amidation; it would be therefore 
worthwhile to mask these groups with orthogonal protecting groups.  
The synthesized Id3 peptide thioesters may be applied to different types of ligation to form 
large Id3 fragments: for example, Cys-mediated ligation can be used with the thioesters of the 
sequence 1-46. His-mediated ligation can be used with the thioesters of the sequence 17-45, 
whereas thiol-auxiliary-mediated ligation can be used with the remaining thioesters. The 
synthetic study of Id3 peptide thioester was carried out in parallel with the stepwise SPPS of 
the Id3 protein. The latter was successful, as described in Chapter II, and the NCL experi-
ments were therefore not carried out. However, the peptide thioesters presented here provide 
valuable intermediates for the future syntheses of Id3 protein related analogues. 
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VII. Design and Synthesis of Fluorogenic MMP-2 Substrates 
VII.1 Introduction 
A number of biological studies have clearly shown that the Id proteins are required for 
tumor angiogenesis and vascularization. For example, observations made by Benezra and co-
workers suggest that the expression of αvβ3 integrin during tumor-induced angiogenesis and 
the recruitment and/or expression of the matrix metalloproteinase MMP-2 required for tumor 
growth and metastasis may be directly or indirectly controlled by the Id proteins [1]. The 
same research group demonstrated that loss of Id proteins in tumor endothelial cells affects 
the expression of several proangiogenic genes, including α6β4 integrins, MMPs and fibroblast 
growth factor receptor-1 [2]. The Id proteins have been also shown to activate the expression 
of a 120-kDa gelatinase in breast epithelia which enhances the invasiveness of these cells [3]. 
These and other data support the idea that a relationship may exist between the Id proteins and 
the MMPs. Therefore, it would be interesting to see whether the Id protein activity correlates 
with the enzymatic activity of the MMPs. Here, we present the design and synthesis of fluoro-
genic probes for the detection of the MMP activity. Such substrates might be useful tools for 
MMP assays in vitro as well as for in vivo imaging. Beside their fluorescence properties, 
which should reflect the MMP activity, these substrates should also be able to enter the cells 
in order to correlate the fluorescence signal with the MMP localization. Before presenting 
our results, biology of the MMPs and cell-membrane penetration approaches will be briefly 
described 
VII.1.1 The MMP Family 
The MMP family consists of structurally and functionally related zinc-dependent endo-
peptidases which are classified into subfamilies based on their substrate preferences: gelatin-
ases, collagenases, stromelysins, matrilysins, membrane-type MMPs and other MMPs. The 
gelatinase subfamily consists of pro-MMP-2 (gelatinase A, 72 kDa) and pro-MMP-9 (gelatin-
ase B, 92 kDa), and of their active forms which are responsible for physiological degradation 
of basement membrane proteins such as gelatin, collagen, elastin and fibronectin [4]. The 
MMPs are secreted as inactive proenzymes (pro-MMPs) and require extracellular activation 
by protease-catalyzed cleavage of the N-terminal pro-peptide [5]. MMP activity is regulated 
at various levels, including gene expression, spatial localization, activation from the latent 
form and inhibition by tissue inhibitors of MMPs (TIMPs). Whereas MMP-2 appears to be 
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constitutively expressed by many cell types in culture, MMP-9 expression is induced by cyto-
kines, growth factors and cell/stroma interactions [6]. The balance between the levels of acti-
vated MMPs and the free form of TIMPs determines the net MMP activity. The MMPs are 
expressed in low amounts by normal cells. They selectively degrade components of the extra-
cellular matrix and such controlled degradation is essential in many physiological situations, 
including developmental tissue remodeling, angiogenesis, tissue repair (wound healing), and 
normal turnover of extracellular matrix (female reproductive cycle, bone remodeling, nerve 
growth, hair follicle cycling, immune response and apoptosis). 
In pathological conditions, MMPs are overexpressed [7, 8] and involved in inflamma-
tion, degradation of bone, autoimmune disease, gastric ulcer [4, 6], vascular diseases [9] and 
in the invasive migration of cancer cells across the basement membrane, like in tumor meta-
stasis [10]. Malignant tumors use MMPs for tumor growth and spreading. Therefore, MMPs 
present an interesting target not only for anti-tumor therapy but also for tumor diagnostics. 
Synthetic MMP inhibitors and substrates should lead to the development of a new generation 
of anticancer agents [11, 12]. 
VII.1.2 Cell-Penetrating Systems 
The conjugation of a membrane-permeable peptide vector (ca. 10 amino acid residues) 
with cargo molecules enables the transport of various bioactive molecules (oligopeptides, 
oligonucleotides, liposomes, phages, etc.) [13] which would be otherwise unable to trans-
locate into the cells through the membranes and exert their functions [14]. One of the most 
typical peptide vectors is a short Arg-rich peptide segment derived from the human immuno-
deficiency virus (HIV)-1 Tat protein [15]. Various Arg-rich oligopeptides also possess very 
similar characteristics as delivery vectors [16]. No significant damage of the plasma mem-
branes and little toxicity have been observed during the treatment of the cells with Arg-rich 
peptides [14]. Electrostatic interactions with the negatively charged glycosaminoglycans 
supposedly concentrate these peptides on the cell surface, and this would eventually acceler-
ate their cellular uptake [16]. The formation of bivalent hydrogen bonds between the Arg side 
chains and the phosphate groups is also proposed: the guanidinium moiety can form ideal 
hydrogen bonding structures with phospholipids or other bivalent anions present in the 
lipid bilayers [17]. Such hydrogen bonding formation and the highly basic nature of the 
guanidinium function (pKa ~ 12.5) are important factors controlling the translocation of these 
peptides. Whereas the guanidinium head group of Arg is critical for the transport, the chirality 
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of the amino acid [18], the length of the side chain and the spacing and composition of the 
backbone can all be varied [19]. 
VII.2 Design and Synthesis of MMP-2 Substrates 
Targeting of proteases for diagnostics offers some advantages with respect to the targeting 
of other classes of biomolecules like receptors and antigens, the most important one being the 
possibility of the signal amplification due to the fact that one single protease molecule can bind 
and hydrolyze a large number of substrate molecules, thus eliciting the sensitivity of the detect-
ion method. For example, in the case of a substrate bearing a FRET-active donor/acceptor 
(D/A) system which can be deactivated upon protease hydrolysis, the fluorescence signal due 
to the piece of substrate bearing the donor can be amplified by the iterative catalytic cycle, as 
shown in Scheme VII.1. 
Scheme VII.1. Catalytic cycle of the hydrolysis of a FRET-active substrate (top), and schematic view of its 
proteolysis and cellular uptake (bottom). 
 
We were interested in the targeting of MMPs, in particular of MMP-2, which are overexpres-
sed in tumor cells together with the Id proteins. We designed a probe (VII.1) containing the 
D/A FRET pair 5-carboxyfluorescein (FAM)/5-carboxytetramethylrhodamine (TAMRA), the 
consensus sequence for MMP-2 (and, to a minor extent, for MMP-9) Pro-Leu-Gly*Leu-Ala-
Gly (the asterisk represents the cleavage site), and a C-terminal tail with six Arg residues as 
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a peptide carrier to improve the penetration into the cells (Scheme VII.1, bottom). The 
acceptor was attached through an N-terminal Gly residue preceding the MMP-2 consensus 
sequence, whereas the donor was introduced through the side chain of a Lys residue following 
the consensus sequence. MMP-2 (and, to a minor extent, MMP-9) should be able to recognize 
the consensus sequence and cut the substrates in two pieces: the N-terminal part containing 
TAMRA (VII.1-N) and the C-terminal part containing FAM (VII.1-C) (Scheme VII.2). 
Before proteolysis, the presence of the two chromophores in the small peptide should provide 
a FRET-active system which can be “switched off” upon MMP-catalyzed hydrolysis. 
Scheme VII.2. Chemical structure of the MMP-2 substrate VII.1 and MMP-2-catalyzed hydrolysis. 
 
The C-terminally amidated peptide chain of VII.1 was assembled on Rink amide resin using 
the Fmoc chemistry. The side chain of the Lys residue was protected by Mtt group. Before 
removal of the Fmoc group from the N-terminal Gly, the Mtt group was selectively cleaved 
by treating the peptidyl-resin with 1% TFA in DCM in the presence of TIS. The free Lys side 
chain was then coupled to FAM. Fmoc cleavage and coupling of TAMRA followed (route a). 
Alternatively, the coupling of TAMRA to the unprotected N-terminal Gly was performed at 
first, followed by Mtt cleavage and coupling of FAM (route b). However, the route a provided 
a crude product with superior homogeneity, as shown by RP-HPLC profile (Figure VII.1). 
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The double-labeled peptide was cleaved from the resin and the Arg side chain protecting 
groups (Pbf) were simultaneously removed using a TFA cleavage mixture with 10% (v/v) 
scavengers (water/thioanisole/EDT) for three hours. Thioanisole was found to be more 
efficient than TIS in removing all six Pbf groups. The crude product was analyzed by RP-
HPLC and MALDI-TOF mass spectrometry. The desired peptide was found as the major 
product (MScalcd: 2418.8 Da, MSfound: 2419.0 Da). Minor side products were the peptide con-
taining two FAM groups (MScalcd: 2364.6 Da, MSfound: 2364.7 Da) or two TAMRA groups 
(MScalcd: 2473.0 Da, MSfound: 2473.6 Da), and the TAMRA-mono-labeled one (MScalcd: 
2060.5 Da, MSfound: 2060.6 Da). 
 
Figure VII.1. RP-HPLC profiles of the crude peptide VII.1, obtained by route a (A) or route b (B) (see text for 
details). 
VII.3 Spectroscopic Properties of Compound VII.1 
Compound VII.1 was dissolved in Tris-HCl buffer (50 mM, pH 7.25) containing 5 mM 
CaCl2 and 0.01 mM ZnCl2. The UV spectrum of the solution showed two absorption maxima 
at 500 nm for FAM group and 560 nm for TAMRA group (Figure VII.2A). The fluorescence 
spectrum obtained with λexc = 488 nm was characterized by a large peak centered at 520 nm. 
A second peak was expected around 580 nm for the TAMRA emission as a consequence of 
FRET; however, no well-defined emission band was present in this part of the spectrum 
(Figure VII.2B, solid line). This could be due to (a) low intensity of TAMRA emission band 
with respect to that of FAM, (b) the absence of FRET, or (c) significant quenching of the 
TAMRA emission by FAM group. The first hypothesis is supported by the fact that the emis-
sion intensities of the intact probe (before MMP hydrolysis) around 580 nm after excitation at 
550 nm and 488 nm were similar (Figure VII.2C-D, solid line); thus, detection of the TAMRA 
peak is not possible, as the emission band of TAMRA could be hidden under the FAM emis-
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sion band. The second hypothesis can be ruled out: the small dimensions of the probe bring 
the two dyes close enough to allow FRET, unless they are unfavorably oriented. The donor 
and acceptor transition dipoles must be approximately parallel for an efficient FRET. In add-
ition, the emission of FAM increased after proteolysis (Figure VII.2B), thus indicating that 
either FRET or the static fluorescence quenching had occurred. The latter would assume the 
reciprocal quenching of the donor and acceptor due to the fact that the two dyes form an intra-
molecular dimer. This has been reported for other peptide-based molecules bearing FAM and 
TAMRA and exhibiting low fluorescence intensity of both dyes [20-23]. Such dimerization 
leads to a ground-state complex and intramolecular dipole-dipole interaction within the dyes, 
which can be interpreted in terms of the exciton theory [24]. The formation of an intramolecu-
lar dimer between FAM and TAMRA is plausible in the substrate VII.1, as the consensus se-
quence for MMP-2 adopts a hairpin-like structure in solution [25] bringing the fluorescent 
dyes into close proximity. In addition, after MMP-catalyzed hydrolysis of VII.1, not only the 
intensity of FAM emission increased, but also that of TAMRA, as shown in Figure VII.2C-D. 
These results support the idea that a static (ground-state complex) rather than a dynamic 
(FRET) fluorescence quenching occurs in the intact probe VII.1. 
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Figure VII.2. Spectroscopic properties of the substrate VII.1. (A) UV spectrum at two different concentrations; 
(B) emission spectrum at the peptide concentration of 0.69 µM (λexc = 488 nm) before and after MMP-2-
mediated hydrolysis; (C) emission spectrum at the peptide concentration of 0.67 µM (λexc = 488 nm) before and 
after MMP-9-mediated hydrolysis; (D) emission spectrum at the peptide concentration of 0.67 µM 
(λexc = 550 nm) before and after MMP-9-mediated hydrolysis. 
VII.4 Enzymatic Activity of MMP-2/MMP-9 in the Presence of Peptide VII.1 
To investigate the proteolytic function of MMP-2 on compound VII.1, the latter was in-
cubated with the active protease in the ratio 230:1 (VII.1:protease) and the emission spectra 
(λexc = 488 nm) were recorded over three hours (Figure VII.3). The fluorescence intensity at 
520 nm increased until reaching an asymptotic value, indicating that the reaction ran to com-
pletion after about one hour. The hydrolysis products were characterized by MALDI-TOF 
mass spectrometry which confirmed the presence of the expected fragments VII.1-N and 
VII.1-C. 
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Figure VII.3. Enzymatic activity of MMP-2. Emission spectra of peptide VII.1 at the concentration of 0.69 µM 
(λexc = 488 nm) recorded over three hours (left). Fluorescence intensity at 520 nm as a function of time: 
λexc = 488 nm; ∆I = I520(τ) - I520(τ0), (right). 
The same experiment was repeated using MMP-9 instead of MMP-2. However, it was clear 
that this enzymatic reaction was much slower than the one with MMP-2: only after three days, 
the emission curve of FAM at 520 nm reached an asymptote (Figure VII.4). Therefore, probe 
VII.1 is a good MMP-2 substrate, but only a very poor one for MMP-9, as expected. 
 
Figure VII.4. Enzymatic activity of MMP-9. Emission spectra of peptide VII.1 at the concentration of 0.67 µM 
(λexc = 488 nm) recorded over three days (left). Fluorescence intensity at 520 nm as a function of time: 
λexc = 488 nm; ∆I = I520(τ) - I520(τ0), (right). 
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VII.5 Design and Synthesis of MMP-2 Substrates Containing Fibrillogenic 
Domains 
The probe VII.1 described above has been designed to undergo an enzymatic process 
which leads to a change of the fluorescence properties of the conjugated chromophore (in this 
case to an increase in the FAM emission). The possibility to use the enzymatic reaction not 
only to affect the spectroscopic properties of a probe, but also to trigger simultaneously other 
events, such as conformational transitions, aggregation or even precipitation, was also stud-
ied. In the latter case, the enzymatic activity could be detected by the naked eye. An ideal 
probe should aggregate, but it should be possible to reduce or suppress this tendency. Thus, 
we decided to use peptides known for their tendency to form β-sheet aggregates, which can be 
however partially neutralized by the presence of positively charged regions: for example, ag-
gressive precipitation of the Id2 protein fragment 103-124 can be prevented by conjugation 
with an N-terminal Lys-tag [26]. For this reason, we designed the peptide VII.2, in which the 
Id2 fragment 103-124 is linked to an N-terminal Lys-tag through the MMP-2 consensus se-
quence (Figure VII.5). The presence of the Lys-tag should avoid aggressive precipitation of 
the peptide; however, loss of the Lys-tag after MMP-2-catalyzed hydrolysis should cause pep-
tide aggregation with consequent precipitation. We also designed another peptide based on 
the same principle (peptide VII.3). This time, instead of the Id2 fragment, we chose a short 
sequence from the islet amyloid polypeptide (NFGAIL), which was identified as the minimum 
length sequence sufficient to self-associate into β-sheet-containing amyloid fibrils [27, 28]. 
Further, we labeled these peptides with the FRET pair FAM/TAMRA as shown in Figure 
VII.5: if FRET occurs, the emission of FAM should be quenched before, but increased after 
hydrolysis. The FAM group is connected to the C-terminal fragment, which contains the 
fibrillogenic sequence influencing its solubility properties and causing the formation of high-
order oligomers or even insoluble aggregates. This might lead to self-quenching of FAM 
groups located in close proximity due to aggregation. Therefore, a decrease of the FAM 
emission during enzymatic hydrolysis should be related to the association process of the 
fibrillogenic fragments. 
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Figure VII.5. Chemical structure of the MMP-2 substrates VII.2-3. 
Peptides VII.2-3 were prepared as described before for peptide VII.1, using the route a for 
the fluorescent labeling, and were then purified by preparative RP-HPLC (for details see the 
Experimental Part) and analyzed by MALDI-TOF mass spectrometry. 
VII.6 Spectroscopic Properties of Compounds VII.2-3 
Compounds VII.2-3 were dissolved in Tris-HCl buffer (50 mM, pH 7.25) containing 
5 mM CaCl2 and 0.01 mM ZnCl2 (10% DMSO was added to completely dissolve VII.2). The 
UV spectra of the two solutions showed two absorption maxima at 500 nm for FAM and 
560 nm for TAMRA. The fluorescence spectra obtained with λexc = 488 nm were charac-
terized by a large peak centered at 522 nm (Figure VII.6). As already discussed for peptide 
VII.1, the absence of a well-defined peak around 580 nm might be due to (a) low intensity of 
TAMRA emission band with respect to that of FAM, (b) lack of FRET, or (c) significant 
quenching of the TAMRA emission. The first hypothesis is supported as mentioned for sub-
strate VII.1. The second hypothesis can be ruled out because the distance between the two 
dyes should certainly allow FRET in both substrates VII.2 and VII.3. Intensities of the two 
dyes in the intact probe VII.2 did not significantly vary from those found after hydrolysis, 
which excludes both FRET activity and/or reciprocal quenching of FAM and TAMRA groups 
(Figure VII.6A-B). This suggests that the two chromophores are not close enough to form an 
intramolecular dimer as in peptide VII.1, and, moreover, adopt unfavorable orientation for 
dynamic energy transfer. This also implies a reduced flexibility of the dye, which probably 
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reflects an oligomeric state of the probe VII.2, due to the presence of the fibrillogenic C-
terminal domain. This can also explain the poor solubility of this peptide in Tris buffer. By 
contrast, the emissions of both dyes increased after hydrolysis of the probe VII.3, suggesting 
FRET activity and/or intramolecular quenching (Figure VII.6C-D). 
 
Figure VII.6. Emission spectrum of VII.2 at the concentration of 0.7 µM before and after MMP-2-mediated 
hydrolysis: (A) λexc = 488 nm; (B) λexc = 550 nm. Emission spectrum of VII.3 at the concentration of 0.6 µM 
before and after MMP-2-mediated hydrolysis: (C) λexc = 488 nm; (D) λexc = 550 nm. 
VII.7 Enzymatic Activity of MMP-2 in the Presence of Peptides VII.2-3 
To investigate the proteolytic function of MMP-2 on compounds VII.2-3, the latter 
were incubated with the active protease in the ratio 230:1 and 200:1, respectively, and the 
emission spectra (λexc = 488 nm) were recorded over three days (Figure VII.7). Both peptides 
exhibited a slight decrease in the intensity of FAM within the first hour (10% for VII.2 and 
5% for VII.3), followed by a recovery of the initial intensity after ~ 30 hours for VII.2 and 
~ 2 hours for VII.3. Whereas no significant changes were observed for the peptide VII.2 in 
the following hours (Figure VII.7B), the emission of the peptide VII.3 reached a ~ 70% 
increment after ~ 73 hours (Figure VII.7D). 
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Figure VII.7. Enzymatic activity of MMP-2 on peptides VII.2-3. (A) Emission spectra of peptide VII.2 at the 
concentration of 0.7 µM (λexc = 488 nm) recorded over 73 hours. (B) Fluorescence intensity of VII.2 at 520 nm 
as a function of time (λexc = 488 nm; ∆I = I520(τ) - I520(τ0)). (C) Emission spectra of peptide VII.3 at the 
concentration of 0.6 µM (λexc = 488 nm) recorded over 73 hours. (D) Fluorescence intensity of VII.3 at 520 nm 
as a function of time (λexc = 488 nm; ∆I = I520(τ) - I520(τ0)). 
VII.8 Discussion and Conclusion 
We have presented the synthesis of fluorogenic MMP-2 substrates containing the fluor-
escent labels FAM and TAMRA. The enzymatic activity was monitoring by the fluorescence 
of FAM group in Tris-HCl buffer solution containing the substrate VII.1, VII.2 or VII.3 and 
MMP-2 (or, for comparison, MMP-9) in the ratio 230:1 (peptides VII.1 and VII.2) or 200:1 
(peptide VII.3). 
It is known that, when FAM and TAMRA are used together to label a small peptide, not only 
a dynamic (FRET), but also a static (ground-state complex) quenching between FAM and 
TAMRA may occur: in the first case, a decrease in the emission intensity of FAM should be 
accompanied by TAMRA emission, whereas in the second case both fluorophores will be 
quenched. Spectroscopic behavior of peptides VII.1 and VII.3 indicates the formation of 
a ground-state complex between the two dyes. On the other hand, peptide VII.2 exhibited 
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neither a dynamic nor a static quenching of the dyes, probably due to their unfavorable orien-
tation. Peptide VII.1 was found to be a good fluorogenic substrate for MMP-2, and could be 
completely hydrolyzed within 1 hour giving rise to ~ 65% increase in the emission of FAM. 
In contrast, the two peptides containing a C-terminal fibrillogenic domain showed a slight 
decrease in the FAM emission within the first hour, which was after 73 hours accompanied by 
a complete recovery in the case of VII.2 and by a ~ 70% increase of the FAM emission in the 
case of VII.3. An explanation of the behavior of the two peptides is given in Scheme VII.3: 
peptide VII.2 supposedly aggregates under the used conditions, despite the presence of 10% 
DMSO which is necessary to completely dissolve the peptide. Thus, it is likely that the two 
dyes (especially FAM that is closer to the fibrillogenic sequence than TAMRA) suffer from 
reduced spatial freedom with consequent high probability to adopt an orientation unsuitable 
for energy transfer. However, FAM could undergo self-quenching due to aggregation. After 
MMP-2 hydrolysis, the N-terminal domain of VII.2 is removed together with TAMRA group 
and three lysine residues. Therefore, the N-terminally truncated analogue is expected to loose 
some solubility that can cause a conformational change and give rise to more compact and 
larger aggregates, in which the FAM self-quenching could be elicited. These, however, are 
formed only transiently and convert into aggregates similar to those of the intact probe. 
Scheme VII.3. Proposed model of MMP-2 hydrolysis of the fibrillogenic substrates VII.2-3. 
 
By contrast, peptide VII.3 is supposed to be a monomer in which FAM and TAMRA form an 
intramolecular dimer, similarly to peptide VII.1. After MMP-2 hydrolysis, the N-terminally 
truncated analogue probably forms transient oligomers with consequent FAM self-quenching, 
similarly to VII.2. Dissociation follows, leading to monomers characterized by elicited FAM 
emission with respect to the initial intact probe, as neither static nor dynamic quenching can 
take place any longer. 
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VIII. Summary 
The Id3 protein is a member of the Id family of negative regulators of the bHLH tran-
scription factors, especially of the ubiquitous E-proteins and the tissue-specific myogenin-
regulating factor MyoD. By forming heterodimers with the bHLH proteins, Id3 prevents their 
binding to DNA and, consequently, the transcriptional activation. This eventually leads to in-
creased cell proliferation and reduced cell differentiation. E47 and E12 preferentially associ-
ate with Id3 rather than with any other Id protein both in vitro and in vivo. In general, the Id 
proteins are overexpressed in proliferating, undifferentiated normal and cancer cells, while 
their expression level is low or absent in non-proliferating, terminally differentiated cells. The 
expression pattern of Id3 overlaps with that of Id1 during embryogenesis—both proteins are 
required for neurogenesis, angiogenesis and vascularization of tumor. 
With 119 residues (13 kDa), Id3 is the smallest member of the Id protein family. The 
41-residue long HLH motif (spanning the Id3 residues 41-81) is responsible for the interac-
tion with the bHLH proteins. However, the N- and C-termini are also important for the Id3 
function: for example, the N-terminus contains a consensus site for CDK2 which phosphor-
ylates a serine residue at position 5 and thus modulates the Id3 affinity toward the E-proteins. 
Moreover, the N-terminal amino group is important for ubiquitination, whereas the C-
terminal tail is critical for the full inhibitory activity of Id3 on the MCK reporter gene. 
The Id3 protein has been shown to be a valuable target for solid-phase synthesis using 
Fmoc strategy; therefore, preparation of further chemically modified analogues of Id3 which 
enable investigation of its biophysical and conformational features is encouraged. An example 
thereof is the Id3 protein analogue which contains two amino acid substitutions in the loop 
region. Altering the position of a potential proline-induced kink of the backbone within the 
loop does not cause significant structural changes, and shows that this region of the Id3 pro-
tein is flexible enough to tolerate amino acid mutations. The Id3 protein and its analogue—
obtained by chemical methods—spontaneously undergo self-association and form disulfide-
bonded dimers. The value of ∆G0H2O for the unfolding of the Id3 HLH domain was found to 
be smaller than those reported in the literature for the bHLH domains of the Id3 dimerization 
partners E47 and MyoD, which is in agreement with the observation that the Id3 forms less 
stable homodimers then the corresponding binding partners. 
The helical character of the HLH motif of Id3 was found to be sensitive to amino acid 
replacement within the two helices. In particular, mutation of the two tyrosine residues—one 
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in helix-1 and the other in helix-2—which are conserved within the Id family, but not in the 
HLH family, has shown that the hydroxyl group of the tyrosine residue in helix-1 is not im-
portant for the conformation, whereas the tyrosine residue in helix-2 must be involved in 
hydrogen bonds stabilizing the Id3 HLH motif within the dimer. Also the cysteine residue 
in helix-1, which is conserved within the Id family, seems to be important for the helix 
stability, as removal of its side chain led to dramatic helix destabilization.  
Whereas the Id3 HLH motif is highly helical, the regions preceding and following it do 
not adopt any preferred conformation as isolated fragments. However, they influence the α/β 
ratio of the HLH fold in an opposite manner, as the N-terminus favors the formation of β-
sheet strands, while the C-terminus stabilizes the helix component. Phosphorylation of the N-
terminus at position 5 (CDK2 phosphorylation site) is also likely to induce a conformational 
change, as shown by the enhanced β-strand propensity of the N-terminal fragment 1-81 after 
modification. Altogether, these results suggest that the N- and C-domains of the Id3 protein 
are critical for the folding of the central HLH motif and for its dimerization behavior. The in-
trinsic flexibility of the N- and C-tails is probably a structural prerequisite for the modulation of 
the protein fold during the dimerization processes with different bHLH transcription factors. 
To further investigate how the Id3 HLH motif and its flanking regions are spatially 
arranged in solution, large Id3 protein fragments (namely 41-81, 21-81, 17-101, and 41-119) 
were fluorescently labeled by the introduction of the donor/acceptor pair tryptophan/dansyl at 
different positions along the sequence, and the efficiency of FRET which is related to the 
distance between the two fluorophores was examined. It should be pointed out that the Id 
HLH motif exists mostly as a dimer in the solution, similarly to all bHLH domains, in which 
the helix bundle is stabilized by an ideal juxtaposition of the helices. The negative impact of 
the fluorescent labeling of the N- and C-ends of the Id3 HLH peptide on its fold is likely to 
reflect an unfavorable helix packing as resulting from the increased steric hindrance at the 
periphery, which leads to a misfolded state. Interestingly, the labeling of the N-end of the Id3 
HLH motif was tolerated in the case of the larger fragment 41-119, which spans both the 
HLH region and the entire C-terminus. This difference between the short HLH peptide and 
the C-terminally elongated analogue might be explained by the fact that the latter folded into 
a less compact structure, in which the N-terminal Dns groups could be easily accomodated. 
Contrarily to the fragment 41-119, the fragment 21-81 can be considered a misfolded state of 
the Id3 HLH motif, in which the number of α-helical and β-sheet residues was comparable. 
Analysis of the corresponding fluorescent analogues revealed no FRET between Trp-76 and 
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Lys(Dns)-24. This suggests that the N-terminal tail and helix-2 were far away from each other 
as a consequence of the loss of the HLH fold. In contrast to the unlabeled Id3 fragment 17-
101 which displayed a misfolded state rich in β-strands, the corresponding mono- and double-
labeled peptides (Trp-76 and Dns attached to the N-terminal residue Leu-17) were character-
ized by a number of helical residues similar to that found for the Id3 fragments 41-101, 41-119 
and even the full-length Id3 protein, suggesting that the HLH fold was present. Therefore, 
they can be used as fluorescent tools for the study of a “miniaturized” Id3 protein shortened at 
its N- and C-tails. The FRET properties of the Id3 fragment 17-101 suggest that the flanking 
region N-terminal to the HLH motif is not extended but rather folded toward the HLH core. 
In the case of the double-labeled Id3 fragment 41-119 having Trp at position 76 and the Dns 
group at the N-end, the distance between the donor and the acceptor was estimated to 20 Å. 
Considering the crystal structure of the DNA-bound MyoD dimer, this distance is slightly 
smaller than those measured (intra- and intermolecularly) between the N-end of the MyoD 
helix-1 and Tyr-156 of the helix-2 (corresponding to Id3 Tyr-76), which are ~ 26 Å and 
~ 22 Å, respectively. The Id3 HLH dimer probably adopts a more compact structure than the 
DNA-binding MyoD dimer. 
All Id3 polypeptides used for the conformational and fluorescence studies were pre-
pared by stepwise SPPS. An alternative method would consist in the selective ligation of 
C-terminal peptide thioesters with N-terminal thiol-containing peptides. To evaluate the 
synthetic accessibility of peptide thioesters, we prepared a number of Id3 fragments to be 
converted into thioesters either in solution or on the solid support. Short (up to 16 residues), 
medium (up to 29 residues) or large portions (up to 46 residues) of the three Id3 subdomains 
(the HLH motif and the N- and C-termini) were prepared in order to test sequences which 
exhibited various difficulties. Three different thioesterification routes were applied, and the 
one performed on solid support with side chain anchored peptides was the most effective. 
Indeed, the reaction was fast and clean and the work-up was easy. The herein described 
peptide thioesters provide valuable intermediates for the future syntheses of Id3 protein 
related analogues. 
The Id proteins are required for tumor angiogenesis and vascularization. The expression 
of αvβ3 integrin during tumor-induced angiogenesis, and the recruitment and/or expression of 
the matrix metalloproteinase MMP-2 required for tumor growth and metastasis may be dir-
ectly or indirectly controlled by the Id proteins. We were interested in the development of 
fluorescent tools for the detection of the MMPs activity (in particular of MMP-2) which are 
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overexpressed in tumor cells together with the Id proteins. Herein we presented the synthesis 
of a fluorogenic MMP-2 substrate displaying the FRET pair FAM/TAMRA and a C-terminal 
oligo-arginine to favor cell membrane penetration. Additionally, two probes were designed, in 
which a fibrillogenic sequence (from the Id2 protein or the islet amyloid polypeptide) was 
linked to an N-terminal Lys-tag through the MMP-2 consensus sequence in order to use the 
enzymatic process not only to modulate the spectroscopic properties of the probe, but also to 
trigger other events, such as conformational transitions and aggregation. The presence of the 
Lys-tag should avoid aggressive precipitation of the aggregation-prone domain, while loss of 
the Lys-tag after MMP-2–catalyzed hydrolysis should accelerate the aggregation with conse-
quent precipitation of the probe.  
When FAM and TAMRA are used together to label a small peptide, not only a dynamic 
(FRET) but also a static (ground-state complex) quenching due to formation of an intra-
molecular FAM/TAMRA dimer can occur. The spectroscopic properties of the two substrates 
containing the oligo-arginine and the amyloid sequence, respectively, suggested the formation 
of a ground-state complex between the two dyes. In contrast, the substrate containing the Id2 
fragment exhibited neither dynamic nor static quenching of the dyes, presumably due to their 
unfavorable orientation. The oligo-arginine-containing probe was found to be a good fluoro-
genic substrate for MMP-2: its complete hydrolysis within 1 hour was accompanied by ~ 65% 
increase in the FAM emission. In contrast, the two peptides containing a C-terminal fibrillo-
genic domain exhibited a slight decrease in the FAM emission within the first hour, which 
is likely to reflect the triggering of the aggregation process with consequent self-quenching 
of FAM.  
In conclusion, we could show that (i) the SPPS approach using Fmoc chemistry can be 
successfully applied for the synthesis of the full-length Id3 protein as well as of truncated and 
modified analogues. (ii) The conformational properties of all synthesized Id3 polypeptides 
were studied by circular dichroism spectroscopy and revealed a complex interplay between 
the Id3 subdomains; moreover, (iii) the FRET properties of some fluorescence-labeled Id3 
segments suggest that the N-terminus folds back to the compact HLH motif. These results 
contribute to the conformational characterization of this biologically highly relevant biomo-
lecule and build a solid ground for future investigations, which may include the study of the 
structural arrangement of the Id3 C-terminus and of the role of individual Cys residues in the 
Id3 folding and dimerization processes. 
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IX. Experimental Part 
IX.1 Materials 
Nα-Fmoc-protected amino acids were purchased from MultiSynTech (Witten, Ger-
many) and Novabiochem (Merck Biosciences GmbH, Schwalbach/Ts., Germany). Rink 
amide 4-methylbenzhydrylamine (MBHA) resin crosslinked with 1% DVB (loading 
0.6 mmol/g, 100-200 mesh) and HBTU were from MultiSynTech. Wang resin (loading 
1.1 mmol/g, 200-400 mesh), sulfamylbutyryl AM resin crosslinked with 1% DVB (loading 
1.1 mmol/g, 200-400 mesh) were from Novabiochem. 2-Chlorotrityl chloride PS resin cross-
linked with 1% DVB (loading 1.6 mmol/g, 200-400 mesh) was purchased from Senn Chem-
icals (Dielsdorf, Switzerland). HOBt, DIPEA, TFA, trimethylsilyldiazomethane, sodium thio-
phenolate, GnHCl, N-methylmorpholine, dansyl chloride, DCM, tetrakis(triphenylphos-
phine)palladium, phenylsilane, iodoacetonitrile, DMSO, SDS, DTT, α-cyano-4-hydroxy-
cinnamic acid, and sinapinic acid were from Fluka (Taufkirchen, Germany).
The following peptide-synthesis-grade reagents were purchased from Biosolve 
(Valkenswaard, the Netherlands): piperidine, NMP, DMF and diethyl ether. HPLC-grade 
acetonitrile (ACN) and TFA for UV spectroscopy were from Biosolve. DIC, HSPAA and 
TFE were from Acros (Geel, Belgium). Sodium hydrogenphosphate and dihydrogenphos-
phate, acetic anhydride, acetic acid, EDT, TMSBr, HSBn, thioanisole, zinc chloride, THF and 
hexane were obtained from Merck (Darmstadt, Germany). Methanol was purchased from J. T. 
Baker (Deventer, the Netherlands). HSPEA and TIS were from Aldrich (Steinheim, 
Germany). Ammonium carbonate was from AppliChem (Darmstadt, Germany). Tris was 
from USB Corporation (Cleveland, USA). Calcium chloride was obtained from Carl Roth 
(Karlsruhe, Germany). Boc anhydride was from Senn Chemicals. MMP-2 and MMP-9 were 
purchased from Merck Biosciences (Darmstadt, Germany). 5-FAM and 5-TAMRA were ob-
tained from Novabiochem. 
IX.2 Methods
IX.2.1 Solid-Phase Peptide Synthesis (SPPS) 
The SPPS methodology was developed by R. Bruce Merrifield [1] in the early 1960’s, 
and has proven to be a powerful method for the preparation of peptides and small proteins. 
The concept of SPPS is based on the build-up of the peptide backbone from the C-terminal to 
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the N-terminal end, with the C-terminus anchored to a solid support through a linker. The 
chemistry used by Merrifield was based on the Boc strategy. To avoid the repetitive acido-
lysis required in Boc SPPS, new methods were developed. The most successful and exten-
sively explored chemistry for SPPS utilizes the base-labile Fmoc group. In the Fmoc SPPS  
the initial Nα-Fmoc and, if required, side chain protected amino acid is loaded onto the in-
soluble support via an acid-labile linker [2, 3] (Scheme IX.1). The side chain protecting 
groups are also acid-labile, like the trityl, Boc and t-Bu groups. The support-bound Fmoc 
amino acid is deprotected by a base (usually piperidine). The second Nα-Fmoc amino acid is 
activated in situ. Several different activators may be utilized [4, 5]. The most widely used 
coupling method in Fmoc SPPS is the active ester method employing HOBt and its corres-
ponding uronium salt analogue HBTU. The deprotection/coupling cycles are repeated till the 
sequence is complete. Finally, the crude product is cleaved from the solid support and simul-
taneously side chain deprotected by concentrated acid solution (TFA) to obtain the peptide as 
a free acid or amide, depending on the chemical nature of the linker. 
In this work, for the preparation of peptide amides, the Rink amide resin has been used. 
As the MBHA linker of the Rink amide resin is easily acylated, no preloading is necessary 
and the resin can be directly used for the automated synthesis. Instead, the two resins applied 
in the synthesis of peptide acids, the 4-hydroxybenzyl (Wang) and 2-chlorotrityl chloride 
resins, and the resin used for peptide thioester formation, the sulfamylbutyryl resin, must be 
manually preloaded and capped before starting the automated peptide chain assembly. The 
Wang linker is labile in concentrated TFA (> 80%), whereas the trityl linker is labile already 
in the presence of 1% TFA. Therefore, the 2-chlorotrityl chloride resin can be used to prepare 
fully-protected peptide acids which may be further modified at the C-terminus in solution [6]. 
In contrast, the peptidyl-sulfonamide is completely stable in the presence of basic or strongly 
nucleophilic reagents. Alkylation of the sulfonamide by trimethylsilyldiazomethane or iodo-
acetonitrile is therefore required, followed by nucleophilic cleavage. 
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Scheme IX.1. General approach of the Fmoc SPPS. 
 
Fmoc SPPS is primarily designed for acidolysis of the peptide-linker. General side 
chain protection by the t-Bu group (for Asp, Glu, Ser, Thr, and Tyr), Boc group (for Lys and 
Trp), and trityl group (for Arg, Asn, Gln, Cys, and His) allows simultaneous deprotection and 
peptide-linker cleavage by TFA. The cleavage of the t-Bu and Boc groups in TFA results in t-
Bu cation and t-Bu-trifluoroacetate formation, which can lead to tert-butylation of Trp, Tyr 
and Met residues. These undesired modifications can be minimized by utilizing effective 
combinations of scavengers (including thiol compounds, water, phenol, TIS) [7]. 
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Figure IX.1. Chemical structures of the four different resin linkers used in this work for SPPS (the Rink amide 
MBHA resin was purchased as Fmoc-protected). 
The Fmoc protecting group is highly labile to bases, especially to secondary amines 
(e.g. piperidine), which can remove the acidic proton of the fluorene ring system and cause 
the formation of a reactive dibenzofulvene. This reacts with the used secondary amine to form 
a stable adduct (e.g. fluorenylmethyl-piperidine). 
IX.2.2 Circular Dichroism Spectroscopy 
Circular dichroism [8] (CD) is the most widely used form of chiroptical spectroscopy 
which relies on different absorption of left- and right-circularly polarized light by chiral chro-
mophores which either possess intrinsic chirality or are placed in a chiral environment. In 
practice, the plane-polarized radiation is split into two (left and right) circularly polarized 
components. If one of the components is absorbed by the sample to a greater extent than the 
other, the resultant radiation will be elliptically polarized. Dichroism is expressed as the dif-
ference in absorbance of the two components as a function of wavelength: 
 
lclclcAAA RLRL ××∆=××−××=−=∆ εεε Eq. IX.1
 
where AL and AR are the absorbances for the left- and right-circularly polarized light, respect-
ively, εL and εR are the molar extinction coefficients for the left- and right-circularly polarized 
light, respectively, ∆ε is the differential molar extinction coefficient (M-1cm-1), c is concentra-
tion (M) and l is the path length (cm). 
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The CD signal is also expressed as the ellipticity (Θ) in degrees. The numerical relationship 
between ∆A and Θ is: 
 
A∆×=Θ 98.32 Eq. IX.2
 
For peptides and proteins, it is helpful to convert the ellipticity Θ to the mean-residue molar 
ellipticity [Θ]R (deg cm2 dmol-1): 
 
[ ]
nclR ××
Θ×=Θ 100 Eq. IX.3
 
where n is the number of amino acid residues. A CD spectrum is obtained when the dichroism 
is recorded as a function of wavelength. 
The CD spectroscopy is a valuable technique to study protein structure in solution [9]. 
In the far UV region (190-240 nm), the peptide bond is the main absorbing group, which can 
be used to estimate the content of secondary structural motifs including α-helix, β-sheet, un-
ordered structure, PPII helix, and turns (Figure IX.2). The α-helix displays intensive CD 
amide bands attributed to the n→π* (negative ellipticity at 222 nm) and π→π* transitions,  
the latter is split into two bands of opposite sign (negative at 208 nm and positive at 193 nm) 
because of exciton coupling. The β-sheet exhibits a broad negative band near 218 nm (attri-
buted to the n→π* transition) and a positive band near 195 nm (attributed to the π→π* tran-
sition). Unordered structure and the PPII helix, which is a component of unordered struc- 
tures, have an intensive negative band near 200 nm (attributed to the π→π* transition) and the 
PPII helix has also an additional weak positive band near 225 nm (attributed to the n→π* 
transition). 
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Figure IX.2. Characteristic CD spectra of polypeptides in the α-helical (●), β-sheet (▲), β-turn (■), and 
unordered conformation (►) [10]. 
The CD spectrum is a sum of the characteristic individual spectra arising from each type 
of secondary structure present in a protein sample. Typically, empirical analysis methods  
utilize a reference database [10-13]comprising spectra of proteins whose crystal structure 
(and therefore their secondary structures) are known and can provide an estimate of α-helix, 
β-sheet, β-turn and unordered structure content. In addition, the CD spectrum in the near UV 
(250-300 nm) reflects the environments of the aromatic amino acid side chains (Phe, Tyr, and 
Trp) and thus gives information about the tertiary structure. 
Protein Folding 
The CD spectroscopy can be used to monitor protein denaturation because it is a quanti-
tative technique [8, 9]. Like other optical measurements, CD measurements obey the Beer’s 
Law: the intensity of the CD signal of each component in the solution is directly proportional 
to its concentration, and the total spectrum represents the sum of all the contributing spectra. 
Thus, the change in the CD spectrum of a protein upon addition of a denaturant, ligand, heat, 
or pH change is directly proportional to the amount of protein changed by the perturbation. 
Following changes in the optical activity of a protein as a function of temperature or denatur-
ant is a very convenient method to study the thermodynamics of folding. Indeed, the major 
contemporary application of CD is the determination of the thermodynamics of protein fold-
ing and the effects of mutations on protein stability. 
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IX.2.3 Fluorescence Steady-State Spectroscopy 
Fluorescence energy transfer measurements [14] are used to estimate the average dis-
tances between sites on macromolecules. Measurements of the effects of conformational 
changes on these distances yield important structural information about the molecule. 
Fluorescence resonance energy transfer (FRET) is the transfer of energy from an 
electronically-excited donor chromophore (D) to an acceptor chromophore (A) in the ground 
state through long-range dipole-dipole interactions without emission of a photon [15]. The 
acceptor absorbs energy at the emission wavelength of the donor, and if fluorescent, emission 
will be observed when the donor is excited (sensitized emission). The theory of energy 
transfer is based on the concept of fluorophore as an oscillating dipole, which can exchange 
energy with a second dipole having a similar resonance frequency [16]. In 1948, Förster 
proposed a theory for long-range molecular interactions by resonance energy transfer, which 
postulated that the rate of transfer depends on the inverse sixth power of the distance between 
the donor and the acceptor. Förster theory is based on very weak interactions between donor 
and acceptor, which should be in the distance range of 10 to 100 Å. The average D-A distance 
can be determined from the efficiency of energy transfer according to the following formula: 
 
6
0 1
1 −×=
E
RRDA Eq. V.2
 
where RDA is the distance between the donor and the acceptor, and R0 is the critical distance 
between the two fluorophores, called the Förster radius, at which the energy transfer effi-
ciency (E) is 50%. E can be determined by steady-state measurements of the extent of donor 
quenching due to the acceptor 
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where FD and FDA are relative average donor fluorescence intensities in the absence and pres-
ence of the acceptor, respectively. Typical R0 values for different D-A pairs are reported in the 
literature [17]. Calculation of the Förster distance within a D-A pair depends upon the spec-
troscopic properties of D and A, including the transition dipole orientation factor κ2 between 
D and A, the overlap integral between D emission and A absorption spectra J(λ) (Figure 
IX.3), the refractive index of the medium n, and the quantum yield of the D (QD) in the 
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absence of A [18]. The greater the overlap of emission spectrum of D with the absorption 
spectrum of the A, the higher is the value of R0. 
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Since the timescale of resonance energy transfer is in the order of nanoseconds, many 
processes that are time-averaged in other techniques can be resolved [17]. 
 
Figure IX.3. The spectral overlap between donor emission and acceptor absorption, defined as J(λ). 
IX.3 Standard Procedure for Polypeptide Synthesis 
Peptide chain synthesis was performed at 0.018 mmol scale in 2 mL vessels using 
a Syro-I batchwise synthesizer (MultiSynTech, Witten, Germany), and applying Fmoc 
chemistry. The following side chain protecting groups were used: t-Bu for Asp, Glu, Ser, Thr, 
and Tyr; trityl for Cys, His, Asn, and Gln; Boc for Lys and Trp; 2,2,4,6,7-pentamethyl-di-
hydrobenzofurane-5-sulfonyl (Pbf) for Arg. The peptide amides were assembled on Rink 
amide MBHA resin (loading 0.6 mmol/g), whereas peptide acids were synthesized on Fmoc-
His(trityl)-Wang resin (loading 0.6 mmol/g). Double couplings (40 min each) were per-
formed by in situ activation of Nα-Fmoc-amino acids (5 eq) by HBTU/HOBt/DIPEA 
(5:5:10 eq) in DMF/NMP (70:30, v/v). Fmoc-Aib-OH, Fmoc-Lys(Mtt)-OH and Fmoc-O-
benzylphosphoserine were also inserted into the sequence by these standard coupling con-
ditions. The Fmoc group was cleaved by 40% piperidine (v/v) in a mixture of DMF/NMP 
(4:1, v/v) for 3 min, and then again with 20% piperidine for 10 min. 
The N-terminally truncated analogues were acetylated at the N-terminus with acetic an-
hydride (10 eq) in the presence of DIPEA (10 eq) in DMF for 15 min. Finally, cleavage of the 
polypeptides from the resin with concomitant side chain deprotection was performed with 
TFA in the presence of 10% (v/v) scavengers (water/TIS/EDT 3:4:3, v/v). After 2.5 h, the 
IX.3 Standard Procedure for Polypeptide Synthesis 123 
 
resin was filtered off and the crude products were precipitated with ice-cold diethyl ether and 
recovered by centrifugation at 3 °C for 8 min. Several ether washes/centrifugation cycles were 
carried out to efficiently remove the scavengers. When Met oxidation occurred, a reductive 
treatment by TFA/EDT/TMSBr solution (95:3:2, v/v) followed the cleavage of the Id3 poly-
peptides or whole proteins from the resin. After 1 hour, the reduced peptides were precipitated 
by ice-cold diethyl ether and recovered by centrifugation as mentioned above. The benzyl 
protecting group was cleaved from the side chain of the Ser residue simultaneously with the 
reduction of oxidized Met residues. The crude peptides were purified and analyzed by RP-
HPLC (Figures IX.4-7) and mass spectrometry. 
 
Figure IX.4. Analytical RP-HPLC profiles of crude (top) and purified (bottom) Id3 peptides III.1-4. 
 
Figure IX.5. Analytical RP-HPLC profiles of purified peptides III.5-7, helix-1 (III.8) and crude helix-2 (III.9). 
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Figure IX.6. Analytical RP-HPLC profiles of purified Id3 peptides IV.3-5 and IV.7 and crude peptide IV.6. 
 
Figure IX.7. Analytical RP-HPLC profiles of purified Id3 peptides IV.8-12. 
IX.3.1 Synthesis of the Full-Length Id3 Protein 
Fmoc-His(trityl)-preloaded Wang resin (0.6 mmol/g) was prepared by treatment of pre-
swelled Wang resin with Fmoc-His(trityl)-OH/HOBt/DIC (4 eq each) in DMF. After 30 min, 
DIPEA (4 eq) was added and the reaction was let run overnight. The resulting loading was 
determined by Fmoc cleavage with piperidine in DMF and UV measurement of the fluorenyl-
methyl-piperidine adduct at 300 nm (ε = 7800 M−1 cm−1) [19]. The remaining free hydroxyl 
groups of the Wang linker were acetylated with acetic anhydride (10 eq) in the presence of 
DIPEA (10 eq) in DMF. 
Due to the increased swelling volume during the synthesis, the peptidyl-resins for II.4, II.5 
and II.6 were split into two reactor vessels after about 60 acylation steps. The acylations after 
the resin splitting were accomplished by doubling the reagent excess. The HPLC profiles 
of the crude products of the native (II.5) and double mutated Id3 protein II.6 were compared 
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(Figure IX.8A), both proteins were purified and characterized by MALDI-TOF mass 
spectrometry before (Figures IX.9-10) and after trypsin digestion. The ESI-MS method was 
used for the characterization of the four intermediate products II.1-4 (Figures IX.11-14). 
 
Figure IX.8. Analytical RP-HPLC profile of the Id3 double mutant II.6. (A) Comparison of the crude products 
of II.6 (solid line) and II.5 (dashed line). (B) Product II.6 after preparative RP-HPLC purification. 
 
Figure IX.9. MALDI-TOF-MS spectra of two samples (A and B) of product II.5 (average MWfound: 12971.1 ± 
1.8 Da). The matrix α-cyano-4-hydroxycinnamic acid was used. The spectra were recorded on a mass 
spectrometer from GSG (Bruchsal, Germany). 
 
Figure IX.10. MALDI-TOF-MS spectra of two samples (A and B) of product II.6 (average MWfound: 12971.1 ± 
1.6 Da). The spectra were recorded on a mass spectrometer from Applied Biosystems. 
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Figure IX.11. ESI-MS spectrum of peptide II.1 (MWfound 5999.6 ± 0.6 Da was obtained from all the observed 
charge states). An impurity with molecular mass of 5870.6 ± 0.3 Da (129 Da, probably due to the absence of one 
glutamic acid residue) could be detected (*). 
 
Figure IX.12. ESI-MS spectrum of peptide II.2 (MWfound was obtained from all the observed charge states). An 
impurity with molecular mass of 6765.6 ± 0.5 Da (129 Da, probably due to the absence of one glutamic acid 
residue) could be detected (*). 
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Figure IX.13. ESI-MS spectrum of peptide II.3 (MWfound was obtained from all the observed charge states). An 
impurity with molecular mass of 8708.8 ± 1.6 Da (130 Da, probably due to the absence of one glutamic acid 
residue) could be detected (*). 
 
Figure IX.14. ESI-MS spectrum of peptide II.4 (MWfound was obtained from all the observed charge states). 
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IX.3.2 Dansyl-Labeled Peptides 
The dansyl group was connected either to the free N-terminus (V.1, V.1b, V.3, V.4, 
V.5, and V.6) or to the side chain of a Lys residue (V.2). In peptide V.2, the orthogonally 
protected lysine, (Fmoc-Lys(Mtt)-OH), was inserted instead of the natural Ile-24. When the 
synthesis of V.2 was complete, the N-terminus was acetylated with acetic anhydride (10 eq) 
in the presence of DIPEA (10 eq) in DMF for 15 min, and the Nε-4-methyltrityl (Mtt) protect-
ing group was cleaved from the Lys-24 side chain by 1% TFA in dry DCM in the presence of 
5% TIS in ten repetitive cycles (1 min each). After Mtt deprotection, the resin was washed 
with DIPEA to neutralize the Lys side chain group. The free amino group of the Lys side 
chain (peptide V.2) or of the N-terminus (V.1, V.1b, V.3, V.4, V.5, and V.6) was derivatized 
with dansyl chloride (5 eq) in the presence of DIPEA (5 eq) in DMF overnight. The reaction 
was checked in small scale by MALDI-TOF mass spectrometry. The labeled peptides were 
then cleaved from the resin and analyzed by RP-HPLC (Figure IX.15) and MALDI-TOF mass 
spectrometry. 
IX.3.3 Labeling of MMP-2 Substrates 
The Mtt-group was cleaved from the Lys side chain by 1% TFA in DCM in the pre-
sence of 5% TIS [20] in ten repetitive cycles (1 min each) before removal of the Fmoc group 
from the N-terminal Gly in peptide VII.1. The free amino group was then acylated with 5-
FAM (5 eq) activated with DIC/HOBt (5 eq each) in DMF. The reaction ran for 30 min and 
its completion was checked qualitatively by the ninhydrin test, and quantitatively by per-
forming a small scale TFA cleavage of the peptide from the resin and by HPLC and MALDI-
TOF mass spectrometry analysis. Afterwards, the N-terminal Fmoc group was removed and 
the resulting free amino group of Gly was acylated with 5-TAMRA (3 eq) activated with 
DIC/HOBt (3 eq each) in DMF. The reaction was stopped after 40 min and the peptide was 
cleaved from the resin with concomitant side chain deprotection with the mixture of TFA and 
10% (v/v) scavengers (water/thioanisole/EDT 2:4:4, v/v) for 3 hours. The crude peptide was 
precipitated from ice-cold diethyl ether and recovered by centrifugation at 3 °C for 8 min. 
Alternatively, the TAMRA group was first coupled to the unprotected N-terminus, followed 
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by Mtt cleavage from the Lys side chain and acylation by 5-FAM. However, the former strat-
egy provided a crude product with superior homogeneity, as shown by the better HPLC 
profile. Labeled peptides VII.2 and VII.3 were thus prepared by the former strategy (Figures 
IX.16-17). The major products resulted to be the desired peptides with the expected molecular 
mass (MScalcd for II.2: 4311.9 Da, MSfound: 4338.2 Da (M+Na)+; MScalcd for II.3: 2552.9 Da 
and MSfound: 2557.9 Da). 
 
Figure IX.15. Analytical RP-HPLC profiles of dansyl-labeled purified peptides. 
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Figure IX.16. Peptide VII.2 crude (left) and after preparative RP-HPLC (right). 
 
Figure IX.17. Peptide VII.3: unprotected and unlabeled (A), FAM mono-labeled crude (B), FAM/TAMRA 
double-labeled crude (C) and purified peptide VII.3 (D). 
IX.3.4 Synthesis of Id3 Peptide Thioesters 
Thioester Formation in Solution 
Fmoc-His(trityl)- and Fmoc-Pro-preloaded 2-chlorotrityl chloride resins (both 
0.32 mmol/g) were prepared by treatment of the pre-swelled resin with Fmoc-His(Trt)-OH or 
Fmoc-Pro-OH (1 eq) and DIPEA (2 eq) in DMF for 2.5 hours. The resulting loading was 
determined by Fmoc cleavage with piperidine in DMF and UV measurement of the fluorenyl-
methyl-piperidine adduct at 300 nm (ε = 7800 M−1 cm−1) [19]. The remaining chloride groups 
of the trityl linker were capped with the mixture DCM/MeOH/DIPEA 17:2:1 (v/v) in three 
repetitive cycles (10 min each). 
When the synthesis was complete, the cleavage of the peptide from the resin was per-
formed by 1% TFA with 1% TIS in dry DCM in approximately ten cycles (1 min each) to 
obtain the fully-protected peptide with the free C-terminal carboxylic acid. The presence of 
the peptide in the filtrates was checked by UV. The peptide-containing fractions were pooled 
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and the solvent was evaporated. The peptide was re-dissolved in a small amount of MeOH 
and precipitated by cold water. Thioesterification with HOBt/DIC/thiol (1.5:1.5:15 eq) in 
DCM followed. Three different thiols were used for the thioesterification: HSPAE, HSBn and 
HSPAA. The reaction was monitored by analytical RP-HPLC and MALDI-TOF mass spec-
trometry of the fully-deprotected product which was obtained by treating small portions of the 
reaction mixture with TFA containing 10% (v/v) scavengers (water/TIS/EDT 3:4:3, v/v. 
When Cys and Met were absent in the sequence, EDT was omitted). After 2.5 h, the crude 
peptides were precipitated from ice-cold diethyl ether and recovered by centrifugation at 3 °C 
for 8 min. When the reaction was complete (after 2 days when HSPAA was used, after 4 days 
when HSBn was used and after 10 days when HSPAE was used), DCM was evaporated, the 
peptides were re-dissolved in a small amount of MeOH and precipitated by cold water. The 
side chains were deprotected by TFA containing 10% (v/v) scavengers (water/TIS/EDT 3:4:3, 
v/v. When Cys and Met were absent in the sequence, EDT was omitted). After 2.5 h, the 
crude peptides were precipitated from ice-cold diethyl ether and recovered by centrifugation 
at 3 °C for 8 min. As the peptides VI.1-3 contain air-sensitive amino acids (three Cys and two 
Met residues), they were further treated with TMSBr (TFA/EDT/TMSBr 95:3:2, v/v) and 
DTT (sulfhydryl reducing agent). The latter treatment proceeded with 15 eq of DTT in am-
monium carbonate buffer (pH 8) at room temperature overnight.  
Thioester Formation on Solid Support 
Fmoc-Asp-OAll-preloaded Wang resin (0.55 mmol/g) was prepared by treatment of the 
pre-swelled Wang resin with Fmoc-Asp-OAll/HOBt/DIC (5 eq each) in DMF. After 30 min, 
DIPEA (5 eq) was added and the reaction was let run at room temperature overnight. The 
resulting loading was determined by Fmoc cleavage with piperidine in DMF and UV meas-
urement of the fluorenylmethyl-piperidine adduct at 300 nm (ε = 7800 M−1 cm−1) [19]. The 
remaining free hydroxyl groups of the Wang linker were acetylated with acetic anhydride 
(10 eq) in the presence of DIPEA (10 eq) in DMF. When the synthesis was complete the free 
N-terminal amino group was acetylated (peptides VI.7-9 and VI.12-13) or Boc-protected 
(VI.10-11) by Boc anhydride (5 eq) in the presence of DIPEA (5 eq) in DCM. The reaction 
proceeded for 1 hour at room temperature. 
The allyl group was deprotected by Pd(PPh3)4 (0.5 eq) with PhSiH3 (20 eq) or N-methyl-
morpholine (20 eq) in DCM in five repetitive cycles (10 min each). The efficiency of the 
deprotection was analyzed by MALDI-TOF mass spectrometry using small scale TFA 
cleavage from the resin. The unprotected acid underwent thioesterification in a mixture of 
132 IX. EXPERIMENTAL PART 
 
HOBt/DIC/thiol (1.5:1.5:15 eq) in DCM on solid support. Three different thiols (HSPAE, HSBn 
and HSPAA) were used for the thioesterification. After 18 hours, the polypeptides were cleaved 
from the resin with concomitant side chain deprotection by TFA containing 10% (v/v) scaven-
gers (water/TIS/EDT 3:4:3, v/v). The Cys- and Met-free peptide thioesters were cleaved from 
the resin by an EDT-free TFA cleavage mixture containing 10% (v/v) scavengers (water/TIS 
5:5, v/v). After 2.5 h, the crude peptides were precipitated from ice-cold diethyl ether and re-
covered by centrifugation at 3 °C for 8 min. 
Thioester Formation Using Sulfamylbutyryl Resin 
Fmoc-Gly-preloaded sulfamylbutyryl resin (0.5 mmol/g) was prepared by the treatment 
of pre-swelled sulfamylbutyryl resin with Fmoc-Gly-OH/PYBOP (4 eq each) and DIPEA 
(8 eq) in DMF overnight at room temperature. The resulting loading was determined by Fmoc 
cleavage with piperidine in DMF and UV measurement of the fluorenylmethyl-piperidine ad-
duct at 300 nm (ε = 7800 M−1 cm−1) [19]. The remaining free sulfonamide groups of the linker 
were acetylated with acetic anhydride (10 eq) in the presence of DIPEA (10 eq) in DMF. 
The Cys-47 residue was inserted into the sequence in the form of Fmoc-Cys(t-Buthio)-
OH. The double coupling (2 h each) was performed using Fmoc-Cys(t-Buthio)-OH/HOBt/ 
DIC (5 eq each) in DMF at room temperature. To check the quality of the growing chain, 
a small peptide portion was cleaved from the resin after the coupling of Tyr-48. Before cleav-
age, the N-terminus of Tyr-48 was acetylated by acetic anhydride (10 eq) in the presence of 
DIPEA (10 eq) in DMF, then the resin linker was alkylated by trimethylsilyldiazomethane 
(10 eq) in THF/hexane (1:1, v/v) for 2 h, and, finally, the peptide was cleaved from the resin 
by nuclephile (MeOH) in the presence of 10% (v/v) DIPEA at room temperature overnight. 
The solvent was evaporated by a stream of nitrogen and then the peptide methylester was de-
protected by TFA containing 10% (v/v) scavengers (water/TIS 5:5, v/v). After 2.5 h, the crude 
peptide was precipitated from ice-cold diethyl ether and recovered by centrifugation at 3 °C 
for 8 min. The corresponding peptide methylesters were characterized by analytical RP-HPLC 
an MALDI-TOF mass spectrometry. 
Once the synthesis was complete, the N-terminus of the peptidyl-resin was acetylated 
by acetic anhydride (10 eq) in the presence of DIPEA (10 eq) in DMF for 15 min and the 
resin was activated by ICH2CN (35 eq) in the presence of DIPEA (15 eq) in 1 mL NMP. The 
reaction mixture was shaken in dark for 18 hours. The activated N-alkyl-N-acyl sulfonamide 
was cleaved by HSBn (50 eq) in the presence of NaSPh in 700 µl of THF for 24 h, leading to 
the formation of the corresponding peptide benzylthioesters. The solvent was evaporated by 
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a stream of nitrogen, and then the peptide side chains were deprotected by TFA (1.5 mL) with 
10% (v/v) scavengers (water/TIS/EDT 3:4:3, v/v). After 2.5 h, the crude peptides were pre-
cipitated from ice-cold diethyl ether and recovered by centrifugation at 3 °C for 8 min. 
IX.4 Analytical and Preparative RP-HPLC 
For purification, the crude products were dissolved in aqueous acetic acid (30%, v/v) or 
in the mixture with 50% (v/v) DMSO (peptide VII.2), and separated by preparative RP-HPLC 
using the Luna C18(2) column, 10 µm particle size, 250 × 21.2 mm (Phenomenex, Aschaffen-
burg, Germany). The binary gradient elution system was: (A) TFA (0.004%, v/v) in water, 
and (B) ACN. The following gradient was used: 15-65% B over 66.7 min at a flow rate of 
21 mL/min. UV detection at 220 nm was used. Purity of the products after lyophilization was 
checked by analytical RP-HPLC using the Luna C18(2) column, 90 Å pore size, 3 µm particle 
size, 150 × 4.60 mm (Phenomenex). The samples were dissolved in 0.1% TFA (v/v) or in 
MeOH (peptide VII.2). The binary gradient elution system was (A) TFA (0.012%, v/v) in 
water and (B) TFA (0.01%, v/v) in ACN. The following gradient was used: 10% B for 3 min, 
then up to 70% B in 40 min at a flow rate of 1 mL/min. UV detection at 220 nm was used, 
except for the double-labeled, dark-red colored, peptide VII.1, which was analyzed by analyt-
ical RP-HPLC using the following gradient: 10-40% B over 30 min, with detection at 220 nm 
(peptide bond absorption), 480 nm (FAM absorption) and 550 nm (TAMRA absorption). The 
gradient 10-70% B over 30 min was used in RP-HPLC analysis for the labeled peptides VII.2 
and VII.3. 
All purified peptides were obtained with purity higher than 90% (based on their analytical 
RP-HPLC profiles) and the overall yields were 8 to 16% (Chapter II). 
IX.5 Mass Spectrometry 
Molecular masses were recorded on a Future GSG spectrometer (Bruchsal, Germany) or 
on a mass spectrometer from Applied Biosystems for matrix-assisted laser desorption time-of-
flight (MALDI-TOF) analysis, and on a ThermoQuest spectrometer (Finnigan) for electro-
spray ionization (ESI). MALDI-TOF mass spectrometry samples were dissolved in 0.1% 
(v/v) TFA in water and mixed 1:1 (v/v) with a solution of α-cyano-4-hydroxycinnamic acid in 
MeOH/ACN (1:1, v/v). 
Tryptic digestion of the full-length Id3 protein and its mutant was carried out overnight 
at 38 °C in ammonium carbonate buffer (50 mM, pH 8). After acidification by 0.1% (v/v) 
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TFA in water and mixing with the matrix solution, the resulting protein fragments were ana-
lyzed by MALDI-TOF mass spectrometry. 
IX.6 SDS-PAGE 
Id3 protein samples II.5 and II.6 (fresh, incubated overnight, air-oxidized, or cross-
linked with glutaraldehyde) were diluted to a final concentration of 15 µM with Tris buffer 
(70 mM, pH 6.8) containing SDS (3%) with or without DTT (10 mM) (Figure IX.18). The 
solutions were heated to 95 °C for 3 min and loaded on a SDS-polyacrylamide gel (12.5%) 
with a stacking gel (4%). Staining was performed by Coomassie brilliant blue. The molecular 
weight marker was the peqGOLD Protein Marker 1. 
 
Figure IX.18. SDS-PAGE characterization of the homodimers formed by the Id3 protein II.5. The loaded 
samples correspond to the protein incubated overnight and then denatured in the presence (lane a) or in the 
absence (lane b) of DTT, and to the protein incubated overnight, air-oxidized and denatured in the absence of 
DTT (lanes c and d, with and without boiling, respectively). Lanes e-g correspond to the protein incubated 
overnight, crosslinked with glutaraldehyde, and then denatured in the presence (lane e) and in the absence (lanes 
f and g – the sample in g was not boiled) of DTT. The molecular weight marker was loaded in lane h.  
IX.7 UV and CD Spectroscopy 
All CD spectra were recorded on a Jasco J-710 CD spectropolarimeter (Groß-Umstadt, 
Germany) using a quartz cell of 0.02 cm path length (Hellma, Mühlheim, Germany). The pep-
tides were dissolved in phosphate buffer (0.1 M; pH 7.25), in the mixture with TFE (15 or 
30%), or in water, centrifuged, and the supernatant was analyzed by UV spectroscopy for the 
determination of the concentration on the basis of the absorption of the Tyr and/or Trp resi-
dues at 280 nm (ε = 1480 M-1 cm-1 for each Tyr [21], ε = 5540 M-1 cm-1 for each Trp [22]) on 
a Cary 100 Conc from Varian GmbH (Darmstadt, Germany). The UV cuvettes (1 mL and 
0.5 mL with 1 cm path length) were purchased from Hellma. For the peptides III.5 and III.6 
which did not contain any Tyr or Trp residue in the sequence, the concentration was 
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determined by weight considering a 70% peptide content. The CD samples were obtained by 
dilution of freshly prepared stock solutions of the peptides. For each spectrum, eight scans 
were accumulated using a step resolution of 0.2 nm, a bandwidth of 2 nm, a response time of 
2 s, and a scan speed of 20 nm/min. The spectrum of the buffer was subtracted from that of 
the peptide to eliminate interferences from cell, solvent, and optical equipment. Noise re-
duction was obtained by a Fourier transform filter with the program Origin (OriginLab Cor-
poration, Northampton, MA, USA). The ellipticity was expressed as mean-residue molar 
ellipticity. The helix percentage was estimated using the measured ellipticity at 222 nm and 
the predicted value for a 100% helix of n residues, which was calculated using the following 
equation [23, 24]: 
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In addition, composition of secondary structure elements was obtained by submitting the CD 
data to the Dichroweb online server [11, 25]. The best fit, characterized by the lowest RMSD 
value between the calculated and the experimental CD curves was given by the 
CONTIN algorithm [13, 26]. 
IX.7.1 Denaturation with Guanidinium Chloride  
The experimental data obtained from the guanidinium chloride-induced unfolding, as 
monitored by CD at 222 nm, were fitted by a two-state model with Eq. IX.6, as described by 
Santoro and Bolen [27]: 
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where Θ0N and Θ0U are the values extrapolated to zero denaturant concentration [D] for the 
pre- and post-transitional baselines, respectively, mN and mU are the slopes of the baselines. 
∆G0H2O (free energy of unfolding in aqueous solution in the absence of denaturant) and mG are 
the intercept and the slope, respectively, of the linear fit of the ∆G vs. [D]. Non-linear least-
squares fitting of the experimental data was performed by MS Excel. 
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IX.7.2 Temperature-Dependent CD measurement 
The CD spectra of peptide IV.6 were collected from 5 to 45 °C with steps of 5 or 10 °C. 
For each spectrum, eight scans were accumulated using a step resolution of 0.2 nm, a band-
width of 2 nm, a response time of 2 s, and a scan speed of 20 nm/min. 
IX.8 Fluorescence Spectroscopy 
IX.8.1 Fluorescence Spectroscopy of the Trp/Dns Id3 Peptides 
The labeled polypeptides were dissolved in 0.1 M phosphate buffer (pH 7.25) or in the 
mixture thereof with 15% TFE, and the peptide concentration was determined from the UV 
absorbance of Trp and Tyr at 280 nm, as mentioned above. The 5 µM samples were obtained 
by dilution of the CD stock solutions prepared the same day. The emission spectra were re-
corded at 25 °C by excitation at 295 nm (λexc of Trp) on a Varian Cary Eclipse Fluorimeter. 
The efficiency of FRET and distances between Trp and Dns were calculated using Eq. V.1-2. 
IX.8.2 Fluorescence Spectroscopy of the MMP-2 Substrates VII.1, VII.2 and VII.3 
Compounds VII.1 (dark-red colored), VII.2 (dark-red colored) and VII.3 (bright-orange 
colored) were dissolved in Tris-HCl buffer (50 mM, pH 7.25) containing 5 mM CaCl2 and 0.01 
mM ZnCl2 (10% DMSO was added to completely dissolve VII.2) and the peptide concentra-
tion was determined from the UV absorbance of FAM at 495 nm (ε = 83000 M-1 cm-1 [28]) at 
27 °C. The enzymatic activity was monitored by incubating the substrates VII.1-3 and MMP-
2 (or, for comparison, MMP-9) in the ratio 230:1 (peptides VII.1 and VII.2) or 200:1 (peptide 
VII.3). The emission spectra were recorded at 27 °C by excitation at 488 nm (λexc of FAM) or 
550 nm (λexc of TAMRA) in the absence and then in the presence of active MMP-2 (or, for 
comparison, MMP-9). The reaction was monitored for 3 hours (VII.1 with MMP-2) or 3 days 
(VII.1 with MMP-9, VII.2 and VII.3 with MMP-2) and the fluorescence emission spectra 
were collected every 5 min during the first hour, every 30 min during the next two hours, and 
then once a day (VII.1 with MMP-9, VII.2 and VII.3 with MMP-2). 
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